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ABSTRACT
The highly sulphated glycosaminoglycan (GAS) heparin is 
widely used clinically as an anticoagulant and antithrcmbotic. 
However, parenteral heparin, and also other anionic polysaccharides 
currently of interest as antithrcmbotics, release lipases fran the 
capillary endothelium, resulting in clearing of circulating lipo­
proteins. These enzymes, lipoprotein lipase (LPL) and hepatic tri­
glyceride lipase (HTGL) are released from the extra-hepatic and 
hepatic circulations respectively.
A number of recognised lipase assay systems were compared 
and shown to vary considerably in their effectiveness and selec­
tivity in measuring LPL and HTGL in post-heparin plasma (PHP). In 
an effort to determine what differences in polysaccharide structure 
influence lipase release, heparin and other GA3s and sulphated 
polysaccharides have been cotpared for their ability to release 
lipase after intravenous injection into rats. Molecular weight and 
charge density (degree of sulphation) were shown to be important, 
as well as some unknown factor associated with the heparin-heparan 
family of GAGs. Heparin was able to release approximately 50% more 
LPL than the other polysaccharides tested, but was only moderately 
mere effective at releasing HTGL. No major differences could be 
found in the time courses of lipase release and clearance for the 
different polysaccharides.
Purified LPL and HTGL were used to test the hypothesis that 
lipase release has a role in changing blood coagulability after 
injection of sulphated polysaccharides. HTGL was shown to have a 
significant effect on plasma anti-Xa clotting activities (by tests 
in vitro), to lengthen clotting times in the absence of heparin and
to shorten them in its presence. The change induced by HTGL in the 
absence of heparin could be related positively to the lipoprotein 
content of the test plasmas, which is consistent with the proposed 
action of HTGL via lipoproteins. LPL had only a minimal effect, 
increasing clotting times slightly in both the presence and absence 
of heparin, and this may be due to the presence of contaminatory 
antithrombin III.
OÎAPTER 1
INTRODUCTION
The transport of lipids is of vital importance to the body, 
which relies largely on lipids for an energy source and as struc­
tural components for membranes and hormones. Due to their hydro- 
phobic nature, only very small amounts of free lipids are present 
in the blood, but instead they exist in conjunction with specific 
proteins to form lipoproteins. Triglyceride-rich lipoproteins 
derived from the liver and intestine are acted upon in the peri­
pheral circulation by the endothelial-bound enzyme lipoprotein 
lipase* to release free fatty acids and glycerol which can then be 
taken up by the surrounding tissue. Another triglyceride lipase, 
located on the hepatic endothelium, is thought to act further on 
the lipoproteins, and to also be involved in ranoving phospholipid 
and cholesterol. This enzyme is known as hepatic triglyceride 
lipase. When certain polyanions are introduced into the circu­
lation, both these lipases are released into the blood stream.
1.1 TEÎE PLASMA TRIGLYCERIDE LIPASES
1.1.1 Source of enzyme
Lipoprotein lipase (LPL) (E.G.3.1.1.34) is present on the 
capillary endothelium of many tissues and organs including the 
heart, lungs, adipose tissue, skeletal muscle (Krauss et al..
* In this thesis, LPL and HTGL will either be referred to
specifically or as triglyceride lipase which will be used as a 
general term for both enzymes.
** This enzyme does not have a separate E.G. coding.
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1973), kidney and spleen (Korn, 1955). The closely related enzyiæ 
hepatic triglyceride lipase (HTGL**) is similarly located on endo­
thelial cells (Kuusi et al., 1979), but in the hepatic sinosoidal 
circulation (not on Kupffer cells). There have also been reports 
of HTGL-like activity in the adrenal glands and the ovaries (Cordle 
et al., 1983). For both cases, the enzyme is synthesized by the 
parenchymal cells of the various tissues and subjected to alter­
ation there, possibly de-phosphorylation, before being transported 
by a vesicular system to the cell surface (Ghiselli and Catapano, 
1979; Nilsson-Ehle et al., 1980). Evidence for this oomes frcm 
comparing lipase activity of cultured endothelial and parenchyma 
cells, the activity being only produced and secreted by cells of 
the latter type (Wang-Iverson et al., 1980). It is thought that 
both enzymes are bound to the luminal surface via electrostatic 
interactions to glycosaminoglycans (GAGs). These anionic molecules 
are thought to be present at the endothelium as proteoglycans, where 
one or more GAG chains are bound to a protein core. Tlie protein 
moiety may itself be a membrane protein (see Fig. I) (Olivecrona et 
al., 1977) or be part of a discrete proteoglycan cell surface 
(Williams et al., 1983). The GAG heparan sulphate is found at the 
surface of endothelial cells (Olivecrona et al., 1977) and binding 
and other studies suggest that this is the molecule responsible for 
attachment of LPL (Williams et al., 1983; Shimada et al., 1981).
It was first noted by Hahn in 1943 that injection of heparin 
led to the release of a 'factor' which cleared lipaemic plasma (in 
vivo and in vitro). Other workers established this factor as an 
enzyræ which acts in vivo and in vitro against triglycerides. Much 
of the early work was done using heart and adipose tissue extracts
ot
lOa
Fig 1 Proposed model for the binding of LPL 
at the endothelium
(From Olivecrona et al., 1977)
LPL
HS-proteoglycan
V
Membrane proteins
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(Korn, 1955; Korn and Quigley, 1957), post-heparin plasma (Korn and 
Quigley, 1957) and milk which is also a good source of a possibly 
identical enzyire (Olivecrona et al., 1982; Hernall et al., 1975).
It was not at the time realized that at least two enzymes are present 
in post-heparin plasma (PHP), so varying results were obtained (La 
Rosa et al., 1972; Augustin and Greten, 1979a) in testing the effect 
of certain inhibitors such as sodium chloride and protamine (which 
inhibit LPL but not HTCX). It was also observed that patients with 
type 1 hyperlipoproteinaemia (genetic LPL deficiency) still have 
lipase activity against glycerides in their PHP (Augustin and Greten, 
1979a), and this was ascribed to HTGL.
Evidence for the existence of two heparin-releasable enzymes 
caiæ initially from work by La Rosa et al. (1972) and Krauss et al. 
(1973), who studied the effects of inhibitors and serum activators 
on lipases from different sources. They reported that the effect 
of salt on normal PHP activity resembles that on the activity of 
the enzyræ from the liver rather than that from adipose tissue.
Also the activity from the hepatectomized rat is, like adipose 
tissue LPL, inhibited by salt above 0.5 M. The difference in 
overall substrate specificity (using purified glycerides and phos­
pholipids) of the lipases present in PHP of control and hepatec- 
tomized rats had also previously been noted (Augustin and Greten, 
1979a). Also, heparin-Sepharose chromatography of the latter PHP 
gave only one peak on elution, whereas the PHP from the control 
animal gave two peaks, corresponding to the enzymes of hepatic and 
extra-hepatic origins. The enzymes have different antigenic 
determinants to which specific antisera can be raised (Augustin and 
Greten, 1979a; Huttenen et al., 1975).
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1.1.2 Molecular properties
The active form of LPL is believed to be a dimer (Iverius and 
Ostlund-Lindqvist, 1976) and that of HTGL to be a monomer (Ehnholm 
et al., 1974) and possibly also a tetramer (Twu et al., 1984). Pub­
lished values for the molecular weight (MW*) of the monomer LPL 
from different sources have ranged between 34,000-73,000 daltons 
(Smith et al., 1978; Augustin and Greten, 1979b), although most 
have been within 50,000-60,000. Among the latest figures available 
for the monomer of bovine milk LPL is 42,000 determined by gel 
filtration in 6 M guandinium chloride and sedimentation equilibrium 
(Olivecrona et al., 1982). Results from SDS-PAGE (sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis) give 55,000-63,000 for 
milk LPL (Olivecrona et al., 1982) and 56,000 for the rat adipose 
tissue enzyme (Parkin et al., 1982). LPL is a glycoprotein, and it 
is thought that the high carbohydrate content affects its electro­
phoretic mobility, which would explain why generally higher figures 
are obtained by this means than by other methods (Nilsson-Ehle et 
al., 1980). The active enzyme is believed to be a dimer (Iverius 
and Üstlund-Lindqvist, 1976).
It has been suggested (Fielding et al., 1977) that there are 
two LPL enzymes in PHP: one from adipose tissue which has a monomer 
MW of 69,000 and low affinity for triglyceride (TG) and a separate 
enzyme from heart tissue with a lower NW of 37,500, but with high 
TG affinity. This has not been verified by other workers.
The IVW of HTGL purified from human PHP has been determined by
* MW in this text corresponds to the relative molecular mass (Mj-) 
of the iTonoTiers which combine to form the active enzyme dimer.
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SDS-PAGE and gel filtration as 69,000 OEhmolm ot al#,"19760. The 
value for the enzyme from other species appears to be lower (Frost
et al., 1982; Twu et al., 1984), the latest figure obtained by SDS-
PAGE analyses of the enzyme purified from rat liver homogenate
being 53,000 (Twu et al., 1984).
1.1.3 Amino acid analysis
Early work suggested that the amino acid composition of LPL, 
and HTGL are very similar, if not identical, and led to the sug­
gestion that the enzymes could be interconverted by cleavage of 
short peptide sequences or by glycosylation (Augustin and Greten, 
1979a). However, these results were criticized by Üstlund- 
Lindqvist (1979), who attributed the observed similarities to heavy 
contamination of both preparations with anti thrombin III (At III). 
At III is a glycoprotein of similar MW to LPL and HTGL, which also 
binds strongly to the heparin-Sepharose columns used in purifica­
tion of the enzymes from PHP. Indeed, it was found that removal of 
this contaminant using a second heparin-Sepharose column modified 
so as to have low affinity for At III, resulted in significant 
differences being found in the amino acid composition of the two 
enzymes (Üstlund-Lindqvist, 1979). In particular, LPL was shown to 
contain proportionally more threonine, methionine, isoleucine and 
leucine, but less tyrosine. Minor differences between species 
(bovine and human) were also noted.
Both enzyme monomers consist of a single polypeptide chain, 
with identical glycine N-terminals and serine C-terminals (Augustin 
et al., 1978). Amino acid analysis showed that each chain contains 
an equal proportion of hydrophilic and hydrophobic amino acid resi­
dues (Augustin et al., 1978). Evidence suggests that the polar
14
residues serine and histidine are present in the active site of 
both enzymes (Twu et al., 1984; Vainio et al., 1982).
1.1.4 Carbohydrate analysis
It has been suggested (Augustin et al., 1976) that there 
exists microheterogeneity of the enzymes (especially LPL) via the 
carbohydrate chain, and this may explain in part the wide variation 
in results obtained by different workers for the amount of carbo­
hydrate present. For example the carbohydrate value for LPL varies 
from 3.3% for the enzyme from rat heart (Chung and Scanu, 1977) to 
18% for the human PHP enzyme (Augustin and Greten, 1979b). The 
figures generally quoted are given in Table 1.
The absence of fucose is surprising since it is usually a com­
ponent of circulating plasma glycoproteins (Augustin et al., 1976). 
It has been suggested that heparin is part of the enzyme structure 
but since neither iduronic acid nor glucuronic acid can be detec­
ted, this is not likely (Augustin et al., 1976). It has been sug­
gested that the greater carbohydrate content of HTGL stabilizes its 
tertiary structure (Augustin et al., 1976), since it is detectable 
in the circulation for longer than is LPL after they are both 
released by heparin.
1.1.5 Lipid analysis
Although early reports indicated small amounts (1.8% w/w) of 
phospholipid present in LPL, (Fielding et al., 1974), no lipid is 
detectable in the more highly purified LPL or HTGL (Augustin et 
al., 1976).
1.2 LIPOPROTEIN METABOLISM
All the major plasma lipids are insoluble in water, so exist 
as lipoproteins - 'macromolecular complexes of lipids bound to a
14a
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variety of polypeptides' (Owen and McIntyre, 1982) - to allow trans­
portation to cells and tissues. All lipoproteins are basically 
composed of a hydrophobic core containing neutral lipids (mainly 
triglycerides and cholesterol esters), enclosed in a monomolecular 
surface film of apoproteins and polar lipid (phospholipid and 
cholesterol) (Nilsson-Ehle et al., 1980). They exist in the circu­
lation as distinct, spherical particles with diameters ranging from 
4-600 rm, depending on the lipoprotein class; the classes differ in 
lipid and apoprotein content, physical properties and function.
1.2.1 Classification of lipoproteins
There are four major classes of lipoprotein defined by the 
density range at which they float after density gradient ultracen­
trifugation, dependent on the proportions of lipid and protein 
(although there is heterogeneity within each group). The lipopro­
tein groups can also be separated by electrophoresis, gel filtra­
tion and affinity chromatography (using differences in the major 
protein content). The four groups in order of decreasing particle 
size are chylomicrons (CMs), very low density lipoproteins ( \7LDL), 
low density lipoproteins (LDL) and high density lipoproteins (HDD. 
A summary of their composition and physical characteristics is 
given in Table 2.
1.2.2 Apoproteins
There are eight major polypeptides/proteins present in lipo­
proteins of the different classes (see Table 3) which, as well as 
playing a structural role, may act as enzyme co-factors in lipo­
protein metabolism. They also interact with liver receptors with 
consequent removal from the circulation (Owen and McIntyre, 1982). 
They are present in varying amounts in the different classes, bound
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non-œvalently to the lipid which allows their exchange and trans­
fer during metabolism (Owen and McIntyre, 1982).
1.2.3 Origin of lipoproteins
The liver and intestinal mucosa are the sites of synthesis of 
VLDL and HDL. VLDL carries endogenous triglycerides into the circu­
lation, along with dietary and newly-synthesized cholesterol (Smith 
et al., 1978; Lewis, 1977). HDL transports most of the cholesterol 
(HDL is thought to be important here (Owen and McIntyre, 1982)).
The mucosal cells of the small intestine also produce Œs, and LDL 
is formed from enzymic degradation of VLDL as shown in Figure 2.
Lecithin cholesterol acyltransferase (LCAT) is another impor­
tant enzyme in lipoprotein metabolism. It is present on the HDL 
surface where it catalyses the following reaction in HDL;-
lecithin + cholesterol -► choiesteryl ester + lysolecithin 
Fatty acids are transferred from lecithin to the hydroxy group of 
cholesterol (Nilsson-Ehle et al., 1980). Cholesterol is passed to
HDL from VLDL and CMs, esterified by LCAT in HDL, then either re-
o( to
transferred back to CM- VLDL-remnants via the cholesterol ester
transfer protein (CETP) (Owen and McIntyre, 1982). LPL has been 
reported to enhance the CETP-mediated transfer of cholesterol 
ester from HDL to VLDL during its action against TG of VLDL in 
vitro (Tall et al., 1984). The physiological significance of this 
finding is not known.
1.2.4 Lipoprotein catabolism
CM and VLDL carry TG from the liver and intestine into the 
circulation, and in man about 70-150 g TG would be given up to the 
tissues in a 24-hour period (Nilsson-Ehle et al., 1980). CM and 
VLDL TG are acted upon very quickly by LPL; the half-life of CM in
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the circulation is less than 5 mins. and that of VLDL about two 
hours (Nilsson-Ehle et al., 1980).
Cholesterol and the apoproteins C and E are transferred from 
HDL (produced by the liver) to newly-synthesised VLDL and CM, with 
concomitant transfer of phospholipid and apo A to HDL. Apoprotein 
CII (apo CXI) acts as a LPL oo-factor, and its presence on VLDL and 
CM allows efficient action by LPL. Subsequent hydrolysis of the TG 
core leads to a decrease in the volume of the particle, with an 
increase in the protein:lipid ratio and so of the density. At the 
same time, excess surface components cholesterol, phospholipid and 
apo C are transferred non-enzymically back to HDL^(to produce HDL2 ) 
and the 'remnants' receive esterified cholesterol from HDL (Owen 
and McIntyre, 1982) (see Fig. 3).
During the conversion of VLDL and CM to IDL (VLDL remnants) 
and CM remnants, the lipoproteins become poorer substrates for LPL 
but better ones for HT(3Li, so it is thought that it is mainly HTGL 
that acts on VLDL remnants to produce LDL (Olivecrona et al.,
1977). LDL are taken up either by peripheral cells or, together 
with CM remnants, by the liver (Ghiselli and Catapano, 1979). The 
removal by the liver partly depends on a specific receptor which 
recognises the apo E ('receptor mediated endocytosis').
The above applies to man, but it should be noted that in rats 
and rabbits, very little LDL is formed and it is mainly IDL which 
is removed by the liver (Faegerman et al., 1975). This may be due 
to a different apo E/apo C ratio present in the lipoproteins, which 
is reported to be how the liver receptor recognises the particles 
ready for rénovai (Owen and McIntyre, 1982).
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Fig 3 Transfer of lipoprotein components 
during iipase action
phospholipid
VLDL/
CMs HDL
apo C & E 
cholesterol
LPL action
apo 0
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remnants IDL CETP action
Cholesterol
esterHTGL action
©
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1.2.5 Lipase specificity
Both LPL and HTGL can hydrolyse acylglycerides, phospholipids 
and fatty acid Co.A esters (Olivecrona et al., 1977), but differ in 
their Kms towards the various substrates. LPL has a low substrate 
specificity ccxrpared with most enzymes, both with respect to the 
chanical substrate and physicochemical nature of the substrate 
(Nilsson-Ehle et al., 1980). LPL has been reported to act against 
tri-, di- and monoglycerides, and that all three reactions are 
stimulated by apo C II (Bengtsson and Olivecrona, 1979) although 
this has been disputed (Nilsson-Ehle et al., 1980). The enzyiæ's 
activity against natural substrates was compared and in vitro VLDL- 
TG was hydrolyzed preferentially to CM-TG (possibly because of the 
relatively greater amount of apo C II in the former) (Dolphin and 
Rubinstein, 1974), but both of these were better substrates than 
LDL or HDL (Eisenberg et al., 1981).
LPL has been shown in vitro to have total specificity for the 
1 (or 3) ester bonds with partial stereospecificity for the 1 posi­
tion (Nilsson-Ehle et al., 1980), so that preferential cleavage of 
a TG is as shown in Figure 4.
Action against 2,3-diglycerides is slower than against TGs 
(Smith et al., 1978). Before the 2-monoglyceride can be hydrolysed 
by LPL, it has to be isomerized to the 1-position (Bengtsson and 
Olivecrona, 1980a) This appears in vitro to be non-enzymic and 
rate-limiting but, as it does not accumulate in vivo, there may be 
an alternative mechanism for 2-MG hydrolysis - a platelet mono- 
glyceride hydrolase has been irrplicated here, as has HTGL 
(Nilsson-Ehle et al., 1980).
HTGL has high phospholipase activity and is thought to be
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responsible for most of the phospholipase A]^ activity (see Fig. 5) 
which is present in PHP (Augustin and Greten, 1979a). This acti­
vity has been noted especially against the HDL2 sub-group of HDL, 
to convert it to HDL3 (Frost et al., 1982) (see next section).
HTGL is more active against monoglycerides than against di­
glycerides or TGs (Jansen et al., 1977) and its stereospecificity 
is apparently similar to that of LPL (Huttenen et al., 1975). TG 
hydrolysis in CM and VLDL by HTGL is low compared with LPL, 
although as LPL action progresses - to produce IDL and CM-remnants 
- hydrolysis is much more effective (Nicoll and Lewis, 1980).
1.2.6 Role of the heparin-releasable enzymes
The primary role of LPL in TG hydrolysis of CM and VLDL has 
been shown by using LPL anti-sera in chickens and isolated rat 
hearts, where there was in both cases a total block on TG removal/ 
uptake from the TG-rich lipoproteins (Nilsson-Ehle et al., 1980). 
Patients with LPL deficiency suffer severe hypertriglyceridaemia 
(termed Type 1), manifested by excess plasma CMs, although VLDL 
levels are normal (Haberbosch et al.,1984). It has also been 
suggested (Wallinder et al., 1979) that LPL, when bound to CM 
remnants, acts as a signal for uptake by the liver, although the 
involvement of an apo E receptor has since been demonstrated by 
Mahley and Innerarity (1983).
The role of HTGL in lipoprotein metabolism is still a matter 
of debate. The accumulation of TGs in the LDL and HDL of patients 
with a familial deficiency of HTGL (Breckenridge et al., 1982) 
gives added support to the now generally accepted view that HIGL is 
important in the clearance of CM and VLDL remnants (Olivecrona et 
al., 1977; Frost et al., 1982). However, recent studies have also
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suggested a role in hydrolysis of phospholipids in LDL and HDL2 . 
This is followed in the latter by non-enzymic removal of choles­
terol (to produce HDLg) which is taken up by hepatocytes (Nilsson- 
Ehle et al., 1980) (see Fig. 6 ). Bengtsson and Olivecrona (1980b) 
have shown that HDL does bind strongly to HTGL and that this 
markedly inhibits the enzyme's action against TG emulsions.
Care must be taken in interpreting results in this field 
because of species differences. The main effect of an anti^TTGL 
serum injected into rats was enrichment of IDL and HDL phospholipid 
and cholesterol and subsequent accumulation of the HDL2 subfraction 
(Nikkila et al., 1980; Kinnunen and Virtanen, 1980), without major 
TG accumulation in VLDL and IDL (Groot et al., 1983). It was sug­
gested that the phospholipase activity of HTC3L is more important 
than its action against TGs (Groot et al., 1983). However, it has 
been disputed that this is true in man too ((Soldberg et al., 1983) 
since rats (and rabbits) are unusual in that little of their VLDL 
is metabolized in the circulation further than IDL, so only a small 
amount of LDL is formed.
Goldberg and coworkers (1983) chose the cynomolgus monkey as a 
better human model (though there are doubts to its suitability 
(Jansen, 1984)), and showed that inhibition of HTGL by anti-serum 
in this species induced significant accumulation of an abnormally 
large, less dense form LDL sub-group (sometimes referred to as 
p-VLDL) and of IDL, as well as an increase in the HDL2 concentra­
tion. Ihey suggested the following: HTGL acts on TG-rich lipopro­
teins which are low in apo C II and following transfer of surface 
components, these lipoproteins are taken up directly by the liver. 
In other tissues, however, where LPL also degrades TG-rich lipo-
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proteins, the surface components are transferred instead to HDL. 
This would mean that, on HTGL inhibition, proportionally more VLDL 
is hydrolysed by LPL, which would result in an increase in HDL2 r 
without it being due to the HTGL conversion of HDLg to HDL3 .
Further work by Rao et al. (1982), testing the PHP of patients 
with LPL deficiency, suggests that both roles of HTGL are iiipor- 
tant, viz. catabolism of VLDL and phospholipid hydrolysis in HDL. 
The decrease in HDL2 concentration occurring as a result of HTGL 
release was accompanied by a reciprocal increase in HDL3 . In the 
PHP of normal subjects, however, there were not significant changes 
in HDL subfractions, which supports their theory that the two 
lipase enzymes effect opposite changes in HDL in the course of 
their action (see Fig. 6 ).
HTGL has also been assigned a role in actual removal of 
CM-remnants and HDL2 from the circulation by uptake by the liver 
(Nilsson-Ehle et al., 1980; Nikkila et al., 1980). This could be 
either by being the receptor, as has been suggested for LPL, or by 
hydrolysis, in uncovering ccxnponents on the lipoprotein particle, 
which are then recognized by the liver.
1.2.7 The effect of serum factors on LPL and HTGL activity
Korn first observed in 1955 that LPL from rat heart is 
activated by serum and this has been found to be true for the 
enzyme from all major sources (Havel et al., 1973). This was shown 
in vitro to be due to apo C II (La Rosa et al., 1972), also called 
apo LP-glu to indicate its C-terminal amino acid. Hypertriglyceri­
daemia in humans due to its deficiency has been described 
(Haberbosch et al., 1984). The enzyme is reported to be inhibited 
by high apo C II concentrations (Haberbosch et al., 1984),
22
Early work on the other C-apoproteins suggested that they also 
stimulated LPL (La Rosa et al., 1972), but this was due probably to 
contamination by apo C II. Both apo Cl (apo LP-ser) and apo C III 
(apo LP-Ala) inhibit LPL increasingly with concentration (Chung and 
Scanu, 1977; 0\æn and McIntyre, 1982), but the degree of response 
depends on the assay conditions used (Ôstlund-Lindqvist, 1979).
This effect may be just an artefact of the in vitro system without 
any physiological significance (Nilsson-Ehle et al., 1980). The 
other apoproteins are generally reported not to affect the LPL 
reaction (Smith et al., 1978; Owen and McIntyre, 1982).
However, it has been recently shown (Mackinnon and Cryer, 1984) 
that the rate of TG-VIJDL hydrolysis by LPL may be affected by 
the apo E content of the lipoprotein.
There have been many reports on the inhibitory effect of serum 
on HTGL activity from many different species Cki^ ius and 
ëefeluRdwL infijgriTiot Huttenen et al., 1975; Fells te et al.,
1982; Cordle et al., 1982) both as the purified enzyme and as PHP. 
HDL was found to be responsible for this inhibition in vitro (La 
Rosa et al., 1972; Bengtsson and Olivecrona, 1980b) due to the 
action of both apo A I and A II (Haberbosch et al., 1984) (the 
major components of HDLs). Recent work on the action of C-apo- 
proteins on HTGL from rat liver showed no effect by C I and C II, 
but that apo C III produced a 90% inhibition of TG-hydrolysis, 
v^ilst having no effect on its action against monoglyceride or phos­
pholipid (Twu et al., 1984). This suggests that C III interacts 
with the substrate, rather than by a direct effect on the enzyme.
Other workers, however, have found a threefold activation of 
HTGL by low serum concentrations (optimal at concentrations of 10%
23
(v/v) in the reaction mixture), with inhibition only occurring at 
high serum levels (Jahn et al., 1983). They further attributed 
this activation to the apo A II component of HDL and inhibition to 
the C-apoproteins. It was suggested that the wide variation in the 
effects found by different workers is due to the specific assay con­
ditions used (Nilsson-Ehle et al., 1980).
1.3 ENZYMIC ACTIVITY - Mode of action in vivo
1.3.1 ^
The conversion of CM and VLDL to remnants and IDL is accom­
plished by LPL in its position at the capillary endothelium. As 
mentioned earlier, it is bound to the membrane via heparan sulphate 
proteoglycans which extend 20-50 nm from the surface and so would 
allow interaction of the lipoprotein substrates with the enzyme 
molecule, as shown in Figure 7 (Olivecrona et al., 1977). This is 
supported by electron microscope studies (Nilsson-Ehle et al., 1980)
Certain conclusions have been reached on the mode of action of 
LPL against CM and VLDL, based on clearance times and turnover 
numbers of the enzyme against these substrates. A 'typical' CM of 
diaiæter 150 nm would contain approximately 3 x 10^ TG molecules, 
so 6 X 1 0  ^hydrolytic events would have to occur within five 
minutes (its normal clearance time) (Olivecrona et al., 1977). 
Working on a turnover number of 650 molecules second (40,000 
minute"^) approximately 30 LPL molecules would be needed to act 
simultaneously to accomplish this. According to the fluid mosaic 
model of membrane structure, LPL molecules anchored by a membrane 
protein would be able to move to bind the substrate. The VLDL par­
ticle, however, has approximately 15,000 TG molecules which could 
be hydrolysed by a single LPL molecule in one minute (Olivecrona,
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1983), whereas they are present in the circulation for at least 2 
hours. This suggests that VLDL is bound and released during the 
course of degradation at different sites in the circulation 
(Nilsson-Ehle et al., 1980).
Bengtsson and Olivecrona (1982a) have divided the action of 
LPL into five steps
1. Binding of substrate
2. Positioning in active site
3. Interaction with and stimulation by apo C II
4. Chemical steps of hydrolysis
5. Dissociation of products
LPL has a domain structure and, as well as the active site, has 
three other functional sites - the lipid-binding region (interface 
recognition site), a region for interacting with apo CII, and a 
region for interaction with heparin and other polyanions (Bengtsson 
and Olivecrona, 1981a). Although the relative positions of these 
regions are not known, binding may be aided by interaction with apo 
C II of CM and VLDL (although this is not essential) (Bengtsson and 
Olivecrona, 1983) and/or through binding of the GAG to the lipopro­
tein (through apo B) (Bengtsson and Olivecrona, 1982a). Approxi­
mately 10% of the TG is present in the VLDL surface layer, so LPL 
could act on this (continually being replaced from the 'core' TG). 
It has also been suggested that LPL may use its phospholipase acti­
vity to 'eat its way' through the membrane to reach the TG core 
(Nilsson-Ehle et al., 1980).
The amino acid sequence of apo C II has been worked out and, 
using fragments and synthetic sequences, the relative efficiency of 
varying lengths of the activator has been investigated (Smith et
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al., 1978). Initially it was thought that the lipid-binding region 
(N-terminal residues 1-49) mediated the activation effect, but full 
activation may be achieved by residues 55-78 (Bengtsson and 
Olivecrona, 1980c). Residues 55-78 have been reported to contain a 
6-pleated sheet structure which for activation interacts with a 
B-pleated sheet section of LPL and the inportance of an arginine-49 
residue, which in the native molecule lies adjacent to this area, 
has recently been implicated (Holdsworth et al., 1984).
It has now been claimed that as good binding of substrate 
can (under optimal conditions) be achieved in the absence as in the 
presence of apo C II (Bengtsson and Olivecrona, 1983; Haberbosch 
et al., 1984) and that under some conditions there may even be com­
petitive binding for CM and VLDL sites between LPL and apo C II 
(Haberbosch et al., 1984). One theory of apo C II action is that, 
by interacting with the lipid, it aids either the actual entry of 
the substrate molecule into the active site or the removal of pro­
ducts (Bengtsson and Olivecrona, 1980c). This is unlikely since 
activation is seen with many different substrates and so is unspeci­
fic. It is generally accepted that apo C II does not modify the 
stereospecificity of the enzyme (Ghiselli and Catapano, 1979;
Vainio et al., 1982). A current view is that apo C II binds pre­
ferentially to a more catalytically effective conformation of the 
enzyme, so pushing the equilibrium in its favour (Bengtsson and 
Olivecrona, 1980c).
E ^ -------- E*
less more
effective effective (removed by apo
C II binding)
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Since LPL assay conditions can be adjusted to give very high 
hydrolysis rates in the absence of apo C II (Bengtsson and 
Olivecrona, 1980c), apo C II is not a true cofactor by the defi­
nition of being 'directly involved in catalysis'. By the above 
theory it acts more like a positive effector on an allosteric 
enzyme (Olivecrona and Bengtsson, 1980). Some workers have sug­
gested that apo C II actually effects a conformational change in 
the enzyme which aids binding (Shirai et al., 1982). Kinetic 
studies show that a 1:1 molecular conplex of apo C II and LPL forms 
during activation, which supports either of the last two theories.
The detailed mechanism of LPL action is as yet unresolved, 
although, in common with other enzymes with histidine and serine at 
the active site, it is likely that a tetrahedral intermediate is 
formed (Vainio et al., 1982).
The dissociation of products from the active site is often the 
rate-limiting step of enzyme action, and apo C II has also been 
implicated, since it has been shown to aid displacement of benzene 
boronic acid, an inhibitor of LPL, possibly by esterase-type acti­
vity which has been observed in apo C II (Vainio et al., 1982).
Once the products of hydrolysis are removed from the active site, 
sorte FFA goes into the circulation, but most will be taken up by 
surrounding tissue cells, where it is either oxidized or re-esteri- 
fied for storage (Nilsson-Ehle et al., 1980). In vitro studies 
(Nilsson-Ehle et al., 1980) have shown that lipolytic products (FFA 
and glycerol) would be able to move via lateral diffusion in the 
cell itembrane and so get across the capillary endothelium.
The mechanism for removal of TGs from the plasma is not satu­
rated under normal conditions, so that when TG plasma concentra-
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tions (in CM and VLDL) increase after a meal, this can be easily 
dealt with by the LPL (Nilsson-Ehle et al., 1980). Fielding et al. 
(1977) thought that LPL enzymes differ according to their tissue of 
origin in their affinity for triglyceride. The heart enzyme was 
reported to have a higher affinity for TG than the enzyme fron 
adipose tissue, to ensure that it was saturated even when plasma TG 
levels are lew. However, the validity of this finding seems doubt­
ful as it could not be reproduced by other workers (Olivecrona, 
personal communication).
1.3.2 HTGL
HTGL is generally assumed to have an extra-cellular location 
in the liver, similar to that of LPL in other tissues (Nilsson-Ehle 
et al., 1980). Most of the general aspects of action described for 
LPL will probably apply also to HTGL, but different lipoprotein 
classes are involved and there is no activating effect by apo C II. 
As mentioned earlier, there have been suggestions that apo A II 
present on HDL is an activator for HTGL (Jahn et al., 1983).
Kinnunen and Virtunen (1980) have proposed that HTGL works, at 
least against some of its substrates (possibly LDL and HDL2 ) by 
receptor-mediated endocytosis via coated pits. In this model, endo­
thelial-bound HTGL enzymes(s) bind the substrate, the cell membrane 
invaginates and both are internalized to form coated vesicles. The 
enzyiæ could then act on the lipoprotein in the cell, with or 
without the aid of lysosomes, and the modified lipoprotein re- 
released into the circulation.
1.3.3 Hormonal regulation of lipolytic activity
As well as the passive regulation of enzymic activity descri­
bed earlier, both enzymes are under hormonal control. There are
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significant, longer term effects on activity brought about by the 
nutritional state - for exartple, LPL activity in adipose tissue is 
low in fasting but high in fed animals, vhereas the reverse is true 
for the enzyme in heart and skeletal muscle (Nilsson-Ehle et al., 
1980). These changes are thought to be controlled by hormones such 
as adrenaline, insulin, ACTTH* and prolactin in the case of LPL 
(Nilsson-Ehle et al., 1980), by oestrogens in the case of HTGL 
(Augustin and Greten, 1979a). HTGL and LPL are both made in cells 
different fron those in vhich they are ' displayed ' and it seems 
that as well as regulation at the transcription level (via rate of 
mRNA formation), there is control on transport from parenchymal 
cells and uptake by the endothelial cells (Schoonderwoerd et al.,
1983). Peptide hormones such as AdH, for exanple appear to 
decrease both the amount of enzyme secreted from the synthesising 
cells and the amount bound by the non-parenchymal cells, by dec­
reasing the number of enzyme-binding sites on the membrane 
(Schoonderwoerd et al., 1983).
1.4 RELEASE OF TRIGLYCERIDE LIPASES BY HEPARIN AND OTHER GLYCO- 
SAMINOGLYCANS
The release of LPL and HTGL into the circulation on injection 
of heparin is now a well-established phenomenon. However, under 
normal conditions some chondroitin sulphate circulates, but there 
is little or no heparin in the blood (< 2 ng/ml (Lindahl and Hook, 
1978). The presence of > 1 yg/ml as is usual in anticoagulant and 
antithrombotic therapy, should be seen therefore as a highly arti­
ficial situation.
* ACTH - adrenocorticotrophic hormone
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1.4.1 The GA3 group
Glycosaminoglycans (GAGs, formerly known as acid mucopoly­
saccharides) are widespread in animal tissues. They consist of 
chains of alternating monosaccharide units or uronic acids 
(L-iduronic acid or D-glucuronic acid) and amino sugars, the latter 
being either D-glucosamine (in the case of heparin, heparan sul­
phate (HS) and hyaluronic acid) or D-galactosamine (in chondroitin, 
chondroitin sulphate and dermatan sulphate (DeS)). Their acid can- 
ponents enable them to interact with proteins and other biomole­
cules, to perform several important structural and controlling 
functions (Lindahl and Hook, 1978). Only heparin, HS and DeS have, 
as far as is known, biological relevance to this project.
Heparin, which is a salt of the strongest organic acid 
isolated from maitmalian tissues, is synthesized and stored in mast 
cell granules, from which it is released under certain physio­
logical conditions. Mast cells are present in connective tissue, 
such as that in mucosa, around venules and in the bronchial lumen. 
HS is a common cell surface membrane conponent of arterial walls, 
organ cell surfaces and connective tissue, and is also present in 
the cytoplasm and to a lesser extent in the nucleus (Coiper, 1981). 
DeS is also a ubiquitous GPG, present in skin, tendons and heart 
valves, but its function is not known. It has previously been 
called 6-heparin because of its weak anticoagulant activity 
(Comper, 1981).
1.4.2 Primary structure of heparin, HS and DeS
The structure of the disaccharide units of these three GPG 
groups is given in Figure 8 ; the polysaccharides are linear poly-
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mers of alternating A and B monosaccharide units. Whereas there is 
almost total consistency of the structure of the chondroitins (not 
shown) and of the DeS structure (90% consists of disaccharide units 
of a non-sulphated iduronic acid and 4 -sulphated acetyl galacto- 
samine ), there is wide heterogeneity within the heparin and HS 
classes. This variation can be in the nature, number and distri­
bution of the various substituents (e.g. acetyl and sulphate 
groups) along the carbohydrate chain. Other possible differences 
are the configuration and position of the intermonosaccharide glyco- 
sidic linkages (Jeanloz, 1974).
Heparin is distinguished from other (SAGs both by its more pro­
nounced biological activity (anticoagulant and antilipaemic) and by 
its high degree of sulphation. More than 70% of most commercial 
heparins consist of repeating tri-sulphated disaccharide units of 
0-sulphated iduronic acid and 0-and N-sulphated glycosamine joined 
by 1 to 4 glycosidic linkages (Casu, 1979), as shown in Figure 9.
The latter stages of the biosynthesis of heparin involve the 
enzymic modification of a non-sulphated chain made up of disac­
charide units of D-glucuronic acid and N-acetyl-D-glucosamine 
(Jacobsson et al., 1984). These steps are suirmarized in Table 4 
for a representative section of chain. Each of these steps is 
dependant on the extent of the previous reaction because of the 
substrate specificity of the enzyme. For example, glucuronic acid 
(G) can only be epimerized to iduronic acid (I) i^ it is located 
between two N-sulphated glucosamine residues (Jacobsson et al.,
1984). The biosynthesis of HS is by the same pathway, but none of 
these enzymic conversions goes as far, resulting in more N-acetyl 
groups and glucosamine residues and so less overall sulphation.
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TABLE 4: Steps of enzymic modification of N-acetyl glucuronic 
acid-glucosamine polymer to fonn heparin
■ - G - A ^  - G - A[^ - G - A[^ - G - Aj^ - G -
partial deacetylation 
- A|^ - G - AfQH2 “ G-A[QH2 - G - A;^ - G - A,^2 ' G -
epimerization and N-sulphation 
- A|^ - G - Afgs - 1 - Aj^ - I - A|XIA ” G - A(^ - I -
0 -sulphation
^NA - G - Aws - l2s - Aws - 1 - A ^  ' G - A^g - I2S - 
6 S 6 S 6 S
G = glucuronic acid 
^NA “ N-acetyl glucosamine 
I = iduronic acid
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The existence of discrete molecular species has been postu­
lated on the basis of electrophoretic studies with the use of ampho­
lytes, but this has been challenged, and it seems more likely that 
the heterogeneity is due to randomness in biosynthesis (Barrowcliffe 
et al., 1978). As stated by Barroweliffe et al. (1978),* A conse­
quence of the heterogeneity is that there is no sharp boundary 
between purification and fractionation. "
1.4.3 Protein moiety of heparin
Native GAGs exist in a macromolecular form, with several carbo­
hydrate chains bound covalently to a protein core (Lindahl and 
Hook, 1978). However, commercial heparins are single chains and 
contain only very small amounts of amino acids (Johnson et al., 
1983).
1.4.4 Molecular shape of heparin
X-ray crystallography and NMR data have suggested that heparin 
exists in a helical form (Casu, 1979); however, there is very 
little evidence that this can be related to how it exists in solu­
tion. Since there is rotational freedom between monosaccharide 
units of the GAG it is flexible and so could assume any of a range 
of conformations.
1.4.5 Anticoagulant activity of heparin
The anticoagulant action of heparin is usually regarded as 
based mainly on its binding to At III, the serine protease inhi­
bitor for which it acts as a co-factor in the inactivation of 
several clotting factors in the 'coagulation cascade'. The 
presence of a specific pentasaccharide At Ill-binding sequence is 
important, but other parameters are also involved. This will be 
further discussed in Section 6 of this Chapter.
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1.4.6 Mechanism of lipase release by GAGs
The release of LPL and HTGL by heparin from their position 
bound to the capillary endothelium is thought to be through the 
formation of a heparin-enzyme complex (Olivecrona et al., 1977).
The dissociation from cell surface HS may be either a result of a 
conformational change induced by the binding of heparin, or by 
actual competition for the same GAG-binding site on the enzyme 
(Olivecrona et al., 1977).
1.4.7 Structural recpjirements for lipase release
The structural requirements for the lipase-releasing activity 
of GAGs do not appear to be as specific as those for At III 
binding. Binding seems to be largely dependent on charge density, 
resulting in an ability to form electrostatic interactions with 
lipases. In vivo work has been done mainly in rats and humans 
(Jansen and Hülsmann, 1974; Ganesan and Bass, 1976; Krauss et al., 
1974; Casu et al., 1983) and the affinity of different (3A3s for the 
lipases has also been studied in vitro using affinity chromato­
graphy (Bengtsson et al., 1980).
Casu et al. (1983) studied a large range of fractionated 
heparins and HS from different sources on total lipase release when 
injected into rats. Their results showed the importance of the 
degree of sulphation, and they concluded that a GAG must have > 50% 
trisulphated disaccharide units to have significant releasing 
ability. However, since activity does not rise linearly with the 
sulphation level, other factors must be involved, for example, the 
length of the sulpha ted sequences along the chain. The in vitro 
work by Bengtsson and co-workers (1980) using Sepharose columns sub­
stituted with a range of GAGs measured the affinity for lipase in
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terms of the salt concentration needed to displace the bound 
enzyme. The order of affinity for both LPL and HTGL - heparin > HS 
- DeS > chondroitin - was confirmed (Bengtsson et al., 1980) by in 
vivo studies in the rat, vAere only iduronic acid-containing GASs 
released lipase (none with chondroitin sulphate). The HS they 
used, however, was of low sulphation and gave lipase levels less 
than 10% of those achieved with heparin, whereas Casu et al. (1983) 
have shown that more highly sulphated HS may be a good releaser.
It should also be noted that artificially sulphated chondroitin 
(SSHA, sani-synthetic heparin analogue) (Thomas et al., 1980) and a 
heavily sulphated synthetic polypentosan (Fischer et al., 1982) 
have also been shown to release lipase in in vivo studies, so that 
iduronic acid groups are not essential. Heparin loses most of its 
affinity for lipase (as measured using substituted gels) on partial 
N-desulphation, but this can be largely restored by N-substitution 
with either acetyl or sulphate groups (Bengtsson et al., 1980).
This could mean that the reduction in binding ability on desulpha- 
tion is due in part to the presence of free amino groups and that 
the nature of the substituted group is not all-important. However, 
reacetylation of completely N-desulphated heparin does not restore 
affinity for the enzyme (measured by the same method).
Various heparin fragments were compared for their ability to 
release LPL from immobilized, unmodified heparin (Bengtsson et al., 
1980). Their affinity for LPL was shown to decrease with molecular 
weight, with no releasing ability present below the hexasaccharide. 
The effect of heparin molecular weight has also been studied by 
fluorescence polarization spectroscopy (Clarke et al., 1983). The 
results suggest that the length of the heparin chain determines the
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type of complex formed with the enzyme. The strong binding 
achieved with heparins of > 10,000 MW could be due to their ability 
to interact with sites on both LPL subunits, whereas lower MW 
molecules are not sufficiently long to bind both, so have lower 
affinity. These results are supported by the molecular dimensions 
and results of crystallographic studies. They also find that the 
LPL dissociation constant with HS is much greater than with 
heparin. No data are available on the effect of MW on the inter­
action of heparin with HTGL, but I24W heparins have been reported to 
be low releasers of the enzyme in vivo (de Swart et al., 1980).
1.4.8 Plasma lipase levels after polyanion injection
The levels of lipase activity and the proportion of the two 
enzymes after injection of heparin and other polysaccharides may 
depend on the time after injection, the dose and type of polysac­
charide used (Jansen and Hülsmann, 1974; Ganesan and Bass, 1976).
It has also been shown in the human that lipase activity depends on 
sex, age and nutritional state and is also altered in certain 
disease conditions (Krauss et al., 1974: Huttenen et al., 1976).
All these factors, in addition to differences in measuranents 
achieved using different assay conditions, make comparison of 
results by different workers difficult (especially as full details 
are not always given).
As an example of this, significant differences have been 
reported on the effect of sex and age on human LPL levels.
Huttenen et al. (1976) report that LPL in PHP is higher in females 
than males at all age groups, and that it decreases with age in 
both sexes. Krauss et al. (1974), however, report that LPL levels 
are the same in adult men and wcxnen, but lower in adolescent girls
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than boys. This would mean that LPL increases with age in females, 
but stays constant in males. There is more agreement between these 
two sets of workers on HTGL levels: HTGL is higher in males than 
females, ranging from 49-95% of total lipase activity (Krauss et 
al., 1974) and does not change with age in either sex.
Low heparin doses are reported (Jansen and Hülsmann, 1974) to 
release mainly LPL into the circulation, but as dose is increased 
so does the contribution of HTGL to total lipolytic activity. The 
peak of HTGL release has been found to be reached at lower heparin 
doses than that required for LPL (Huttenen et al., 1975).
1.4.9 Time course of lipase in plasma after heparin injection
The time course of release and clearance of LPL and HTGL after 
heparin injection has been studied in man. HTGL is released first 
of the two enzymes, to reach peak activity at 2-5 mins. after injec­
tion, and is reported to remain at this level for at least 15 mins. 
(Huttenen et al., 1975) after which it is slowly removed (half-life 
in the plasma of approximately 4 hours) (Krauss et al., 1974; de 
Swart et al., 1980). LPL is released more slowly than HTGL, and is 
at a maximum 15-30 mins. after injection, after which it declines 
quickly to be completely removed by 2-4 hours (Huttenen et al.,
1975; de Swart et al., 1980). Figure 10 shows a representative 
time course after 100 u/kg heparin (Huttenen et al., 1975). The 
removal of HTGL especially has been reported to be slower at higher 
heparin doses (Krauss et al., 1975). Use of radiolabelled LPL 
(Wallinder et al., 1979) has shown that this enzyme is taken up 
fron the blood and degraded by the liver. The liver receptor res­
ponsible has not yet been identified, but it is not among the known 
galactose- or mannose-binding protein receptors which ranove other
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Fig 10 Time course of iipase in piasma 
after reiease by heparin
(From Huttenen et al., 1975)
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glycoproteins (Wallinder et al., 1979). Other workers (de Swart et 
al., 1980) followed the disappearance from plasma of both 358- 
heparin (used for injection) and the HTGL released by it, and the 
similar curves achieved suggested that they both exist in the 
blood, and are taken up, as a ccxtplex. The lipase-bound heparin 
may influence removal of the ccxrplex (de Swart et al., 1980). 
Clearance of purified LPL injected into rats was greatly slowed 
down by prior administration of heparin (Wallinder et al., 1979) 
and high heparin doses give more sustained levels of both enzymes 
(Krauss et al., 1974).
The type of heparin injected may also affect the time of 
clearance. It has been reported that heparins separated by their 
affinity for At III gave similar maximum levels of release, but 
that lipase released with low-affinity heparin was cleared faster 
than that with high-affinity heparin (de Swart et al., 1975).
1.4.10 Heparin and atherosclerosis
The clinical use of heparin for the prophylaxis and therapy of 
atherosclerosis has been suggested. The rationale behind this is 
the beneficial action of heparin in two areas - by its effect at 
the vascular endothelium and by general effects within the circula­
ting blood (Engelberg, 1980). At the endothelium, heparin may 
reduce platelet adhesion and the formation of thrombi, and also 
slow down the uptake of serum lipoproteins, possibly by maintaining 
the negativity of the cell surface. The effects in the bloodstream 
are considered to be mediated mainly through the action of released 
lipolytic enzymes.
It has been repeatedly noted (see Mahley and Innerarity, 1983) 
that there is a positive correlation between blood LDL levels and
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the incidence of coronary heart disease. On the other hand, the 
reverse is true of HDL levels (Twu et al., 1984) and above normal 
levels in individuals appear to be associated with longevity 
(Engelberg, 1984). For this reason HDL has been termed a 'protec­
tive factor' against atherosclerosis. The difference between the 
lipoproteins is due to differences in their roles in cholesterol 
transport. Whereas cholesterol-rich LDL delivers cholesterol to 
tissues, which may lead to overloading of cells with the LDL (apo 
B, E) receptor, HDL acts in 'reverse cholesterol transport' by 
accepting excess cholesterol from peripheral tissues and trans­
porting it to the liver for removal (Mahley and Innerarity, 1983). 
It has been known for some time that heparin injection leads to an 
increase in blood HDL levels and that this is accompanied by an 
increase in cholesterol excretion (Engelberg, 1984). These changes 
can be attributed to the release of LPL and HTGL by heparin, 
leading to an increase in TG and phospholipid hydrolysis and 
cholesterol estérification and transfer (see Fig. 3).
A second beneficial effect of the lipases would be via their 
action against the fatty lesions which develop on vessel cell walls 
and which interfere with the blood supply of these cells, since 
there are several lines of evidence which suggest that hypoxia 
accelerates the atherosclerotic process (Engelberg, 1984).
Only a small number of clinical trials of heparin against 
atherosclerosis have as yet been conducted (see Engelberg, 1980), 
possibly because of the risk of haemorrhage and osteoporosis in 
heparin therapy. The results of the majority of these trials 
however, did suggest that use of heparin can cut down the number of 
deaths in patients with established coronary heart disease
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(Engelberg, 1980). It has also been shown that some heparans, as 
well as heparin, slow down the development of atherosclerosis in 
cholesterol-rich animals (Grossman et al., 1971). However, as in 
the case of the human studies, there have also been negative 
results (Engelberg, 1980), so that more study into this is needed.
1.5 LIPASE ASSAY METHODS
1.5.1 Development of Lipase Assays
From the time of the early work by Korn on 'clearing factor' 
(Kom, 1955), many different means of measurement of lipase acti­
vity in HiP and tissue extracts have been used. These can be 
divided into different groups depending on the nature of the sub­
strate and the method employed to measure product release. Physio­
logical substrates such as CM or VLDL preparations, have been used, 
as well as artificial triglyceride emulsions, which can be radio­
labelled. Enzymic activity is measured by the release of glycerol 
or FFA, either by chemical means or by scintillation counting when 
radiolabelled TGs have been used.
The assay substrates used by Korn and co-workers (1955; 1957) 
were CM suspensions or coconut oil emulsions, with quantitation of 
activity by converting the glycerol released into formaldehyde 
which was then measured spectrophotometrically. Other early work 
by Angervall and Hood (1957) followed the decrease in the optical 
density at 570 nm on addition of enzyme to lipaemic plasma or homo­
genized cow's milk cream/saline mixtures. There are problems in 
using natural substrates, among them the instability of the lipo­
protein suspensions, and the difficulty in standardization of both 
these and the lipaemic plasma used for the turbidity measurements. 
CM or VLDL suspensions are now used mainly for specificity tests.
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or for studies of kinetics or mechanism (Eisenberg et al., 1981). 
Despite the problems of using these substrates, Korn (1955) did 
show some important properties of post-heparin lipase activity, 
although it was not realized at this time that there are two 
enzymes of different specificities and properties present in FHP. 
These findings included the inhibition of activity by incubating 
the enzyme mixture with salt or protamine, the need for fatty acid 
acceptors (such as albumin) and also for serum components when arti­
ficial substrates are used.
Due to the drawbacks of using natural substrates, later 
workers have mainly used commercial emulsions, such as Intralipid 
(made from soya bean triglycerides emulsified with phosphatidyl­
choline (PC)) and 'Ediol' (coconut oil in a detergent mixture), or 
purified triglycerides prepared for use daily in the laboratory. 
Intralipid, because of its structural similarity to the surface 
layer of native lipoproteins for which the LPL binding site is 
adapted (Bengtsson and Olivecrona, 1981b), has been shown to com­
pare favourably with CMs or VLDL as a substrate when testing LPL 
both in adipose tissue extracts (Lithell and Boberg, 1977) and PHP 
(Riley and Robinson, 1974). HTGL, however, does not bind well to 
either, and Intralipid has been used by some workers to separate 
LPL and HTGL on the basis of their different affinities (Ehnholm et 
al., 1975).
The predominantly non-polar nature of lipids means that emulsi­
fiers/stabilizers have to be employed in making up TG substrates 
(except when short chain TGs such as tributyrin are used (Rapp and 
Olivecrona, 1978)). A range of these has been used in different 
laboratories (Riley and Robinson, 1974). Phosphatidylcholine (PC)
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and its derivatives have been a common choice, but other agents 
used include Triton X-100, gum arabic or acacia, Tveen 60 and bulk 
egg yolk lipids. These emulsions are prepared by sonication immedi­
ately before use. The Nilsson-Ehle and Schotz assay (1976) (see 
Ch. 2), however, uses a substrate onulsified with PC and stabilized 
with glycerol. This allows its use for several weeks after a 
single sonication which is an obvious advantage.
For measurement of enzymic activity, glycerol or more 
commonly, FFA are extracted from the incubation mixture and quan­
ti tized. The early methods for FFA extraction based on those of 
Dole (1956) or Kelley (see Iverius and Ostlund-Lindqvist, 1976) are 
time-consuming and require large enzyme volumes for accuracy.
Assay improvements were male by the adoption of methods such as 
that of Belfrage and Vaughn (Nilsson-Ehle and Schotz, 1976), v^ich 
is a one-stage, liquid-liquid partition method using organic 
solvents. Once extracted, the FFA can be titrated (Havel et al., 
1973). Measurements were made quicker and easier by the use of 
radiolabelled substrates; the products once extracted can be 
measured directly by scintillation counting (Nilsson-Ehle and 
Schotz, 1976).
There have also been reports of determination of FFA by fluor­
escence with the use of a coumarin derivative (Curzon and 
Kantamanteni, 1977) and by enzymic means (Woollett et al., 1984).
In this latter method, aliquots of the incubated enzyire-substrate
enzymes
mixture are added to a series of purified^and cofactors, and the 
eventual oxidation of NADH to NAD"*" is measured spectrophotometri - 
cally. It should be noted, however, that these FFA measurements 
are carried out, without their prior extraction, on reaction
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mixtures containing albumin which as it binds FFA may interfere 
with the quantitation.
Since the work of La Rosa et al. (1972) and Krauss et al. 
(1973) led to the understanding that there are at least two lipase 
enzymes in PHP, assays have been developed which purport to measure 
them selectively. These may use conditions that i) inhibit LPL or 
HTGL, ii) involve the precipitation of one of the enzymes by speci­
fic antibodies or iii) separate the enzymes by the difference in 
their affinity for heparin.
1.5.2 Methods of Selective Measuranent
i) Inhibition of LPL or HT(3L activity
a) Use of salt to inhibit LPL It is v^ll documented 
(Nilsson-Ehle et al., 1980) that the two PHP lipases are affected 
differently by high salt concentrations. LPL is increasingly inhi­
bited by NaCl, up to > 90% at 1.0 M, whereas HTGL is resistant to, 
and perhaps stimulated by, this high ionic strength (Krauss et al., 
1973; Augustin and Greten, 1979a). The basis of the effect on HTGL 
is not known, although it has been suggested that high salt dis­
rupts a high MW complex of HTGL into more active subunits (Ehnholm 
et al., 1974). The mechanism of LPL inhibition by high salt has 
been well investigated. Fielding and Fielding (1976) found it to 
be fully reversible and to be mediated to the same extent by dif­
ferent cations (tested with the same anion), but to significantly 
different extents by a range of salts which varied in their anionic 
component (with reactivity following the Hofmeister series). Since 
they also found a relationship between activation by apo CEI and 
the extent of inhibition by salt, they concluded that salt acts 
through a reaction with a positively charged site on the apo CII.
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Other workers (Bengtsson and Olivecrona, 1983) suggest that the 
salt acts either by reducing the degree of binding of the enzyme to 
the substrate, or through a direct effect on the enzyme.
The differential action of salt on the enzymes has been used 
to estimate the proportions of the two in PHP. Total lipase acti­
vity can be assayed at physiological salt concentrations in the 
presence of serum (to provide apo CII for full LPL activity), and 
HTCSL activity under high salt conditions in the absence of serum, 
where there should be very little LPL activity (Huttenen et al., 
1975; Ostlund-Lindqvist and Boberg, 1977). The degree of salt inhi­
bition has been reported to vary between substrates (La Rosa et 
al., 1972; Bengtsson and Olivecrona, 1983). Notable is the limited 
salt inhibition achieved vhen Intralipid is used, and this is 
thought to be due to the strong binding of LPL to this substrate 
(Bengtsson and Olivecrona, 1983). Other workers (Fielding and 
Fielding, 1976) find no difference between Intralipid and other 
substrates. Conflicting reports like this seem to be commonly 
encountered in this field.
b) Use of protamine sulphate to inhibit LPL Protamines are 
siitple LMW proteins which are rich in arginine and strongly basic 
((Goodman and Gilooft, 1970). They inhibit heparin through binding 
to acid groups, and have been found (like other polycations) also 
to inhibit PHP lipases (Korn, 1955). LPL is more sensitive to pro­
tamine inactivation than HTGL, and under carefully specified con­
ditions, this can be exploited to achieve maximum inhibition of LPL 
(90%) with minimum inhibition of HTC5L (10%) (Krauss et al., 1973). 
It is not possible to inhibit all the LPL without some effect on 
HTGL. Protamine is thought to act by decreasing enzyrte stability
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(although there have been reports that purified LPL is not affec­
ted), but it may also act by decreasing binding to substrates 
(Augustin and Greten, 1979b).
c) Use of sodium dodecyl sulphate to inhibit HTCL A chemical 
method for the removal of HTCL activity in PHP has been described 
(Baginsky, 1981). Baginsky and Brown (1979) report that the two 
lipases differ markedly in their response to SDS over a limited 
concentration range, and this can be used for selective measure­
ment. They preincubated the enzyme sample with 35-50 mM SDS in 
buffer before testing with a gum arabic-stabilized triolein sub­
strate, and under these conditions they report that 80-90% of the 
HTGL is inhibited whereas the LPL is unaffected.
ii) Precipitation of lipase by specific antibodies
LPL and HTGL possess different antigenic determinants, so that 
specific antibodies to each can be raised (Huttenen et al., 1975; 
Augustin et al., 1978). Removal of one then allows measuronent of 
the remaining lipase under its optimal conditions. These anti­
bodies are not available commercially.
iii) Separation by heparin-Sepharose chromatography
The assay method of Boberg et al. (1977) makes use of the dif­
ferent affinity of the two PHP lipases for heparin. Each sample is 
loaded on to a small column of heparin-Sepharose, washed, then HTGL 
and LPL are eluted stepwise with increasing salt concentrations. 
Fractions at each salt concentration are assayed under the condi­
tions optimal for the two enzymes. This method was devised to 
overcome possible interference by lipoproteins present in PHP. 
However, it is a time-consuming method and there are extensive 
losses during chromatography.
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1.5.3 Miscellaneous Points on Assay Conditions
i) Product inhibition and the use of albumin
Both LPL and HTGL are subject to product inhibition by FFA 
(Bengtsson and Olivecrona, 1980a). In vivo FFA move by lateral dif­
fusion into surrounding tissues where they are utilized, but in 
vitro a FFA-acceptor has to be present. Normally serum albumin is 
used in assays (Eisenberg et al., 1981), although calcium ions are 
as effective (Kom, 1955). Several factors appear to contribute to 
the inhibitory effect of FFA (Olivecrona and Bengtsson, 1980). FFA 
are more surface-active than TGs, so may displace TGs from the 
lipid-water interface and coirpete for the active site. The enzyme 
would then form di- and triglycerides from FFA and partial gly­
cerides. It is also thought that the lipase forms complexes with 
FFA vhich prevent binding of the enzyme to emulsion surfaces. In 
the case of LPL, it has been shown (Bengtsson and Olivecrona,
1980a) that there is no activation by apo CII in the absence of 
albumin, so it is also possible that FFA hinder the enzyme-acti- 
vator interaction. The relieving of product inhibition by albumin 
is due to the latter binding FFA stronger than do the lipases 
(Bengtsson and Olivecrona, 1980a), via ç 7 high affinity binding 
sites.
ii) Effect of heparin
There have been many reports on the in vitro effect of heparin 
on lipase activity (Bengtsson and Olivecrona, 1981a). Early work 
(Korn, 1955) showed that heparin stimulated the activity of crude 
enzyme preparations, and that the presence of bacterial heparinase 
led to a decrease in enzyme activity. Heparin was thus thought to 
be a lipase co-factor. However, tests of highly purified enzyme
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have shown that stimulation occurs only under sub-optimal condi­
tions, and it has been suggested that heparin acts to stabilize the 
enzyme and keep it in solution (Bengtsson and Olivecrona, 1981a).
1.6 THE ANTICOAGULANT ACTION OF HEPAEtCN
The action of heparin as an anticoagulant is now widely 
exploited clinically both in the control of thromboanbolism and 
in maintaining blood fluidity outside the body (such as with 
dialysis machines) (Barrowcliffe et al., 1978). Use of heparin
heightens the risk of haemorrhage, so different heparin types are
continually being assessed for effectiveness and reduced risk.
As mentioned in Section 4 of this Chapter, the anticoagulant 
activity of heparin and HS spears to be dependent on the presence 
of a number of physicochemical parameters, which affects their 
interaction with At III (the major plasma serine protease inhibi­
tor), and in some cases with the serine protease itself, for 
example thrombin.
1.6.1 Blood Coagulation
The physiological formation of a thrombus is a result of a 
series or cascade of linked reactions involving the conversion of 
enzyme zymogens into active serine proteases (for reviews see 
Esnouf, 1977; Jackson and Nemerson, 1980). The initial signal is 
the contact of blood either with a foreign surface (to start the 
intrinsic pathway) or with damaged tissues (the extrinsic pathway).
These two pathways converge at the activation of Factor X (see Fig.
1 1 ) into a conmon pathway, and at each step there is an amplifi­
cation of the signal. The conversion of Factor X and prothrombin 
to active serine pro teas es are both key steps in the coagulation 
sequence. The activation of prothrombin (Factor II) by Factor Xa
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to form thrombin (Factor IIa) is the best characterized stage 
(Jackson and Nenerson, 1980); it takes place on a gtiospholipid jwrÇ^ cc 
(such as that of a platelet membrane) in the presence of Factor V 
and calcium ions, as shown diagranmatically in Figure 12. Thrombin 
in turn converts fibrinogen to fibrin and activates Factor XIII.
These two products finally interact to give a crosslinked clot of 
stable fibrin (Fig. 11).
1.6.2 Inhibition of Clotting Factors and the Role of Heparin
There are three inhibitors present in normal plasma which are 
largely responsible for control of activated clotting factors 
(Barrowcliffe et al., 1978). Of these, alpha2-macroglobulin and 
alpha^-antitrypsin are general protease inhibitors, whilst At III, 
a glycoprotein of MW 58,000-65,000 (Messmore, 1982) has more speci­
fic activity against clotting factors, and is thought to be respon­
sible for 50-75% of the total inhibitory action present in plasma.
The main action of At III is against Factor Xa and thrombin, but it 
also inhibits Factors IXa, XIa and Xlla (Lindahl and Hook, 1980) in 
earlier stages of the intrinsic pathway. At III binds irreversibly 
in a stoichoiætric ratio of 1 : 1  with all these factors to form an 
inactive complex (with the possible exception of Factor IXa, which 
is thought to be At III:FactorIX a, 2:1) (Messmore, 1982). (It 
should also be noted that At III also has action against plasmin, 
which is involved in fibrinolysis, and so regulation by At III of 
normal conditions of both coagulation and fibrinolytic mechanisms 
has been suggested (Rosenberg, 1975)).
At III binds more rapidly to Factor Xa than to thrombin, but 
in mixtures of the two binds preferentially to thrombin 
(Barrowcliffe et al., 1978). In normal coagulation there is 100
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times more thrcmbin present than Factor Xa, since the latter is 
'one step up' in the enzyme cascade, but because of the At III 
affinity difference both are neutralized within 15 minutes of 
clotting. There appears to be only little activity against the 
other serine proteases (Wessler and Gitel, 1979). However, heparin 
acts as a potent catalyst for all these reactions; in the case of 
thrcmbin, the rate of neutralization is increased 1 ,0 0 0 -fold 
(Messmore, 1982). The mechanism or stoichiometric ratio is not 
altered (Messmore, 1982).
It is thought that heparin binds to lysyl groups of At III via 
specific At Ill-binding sequences. This causes a conformational 
change in the making a specific arginine residue more acces­
sible to fit into the active site serine pocket of the clotting 
factor (Lindahl and Hook, 1980). A suggested scheme is shown in 
Figure 13. Heparin dissociates after formation of the At III- 
serine protease complex, since its affinity for this is less than 
for At III alone. Potentiation of At III action can be achieved at 
very low heparin concentrations (At Illrheparin, 150:1), which 
further supports its catalytic function (Barrowcliffe et al.,
1978).
Heparin can also bind directly to thrombin, although less 
strongly than to At III alone, and also very weakly to Factor Xa 
(Barrowcliffe et al., 1978). It is now thought (Thomas et al.,
1982) that for effective neutralization of thrombin. Factor IX and 
and Factor XIa, heparin has to be bound to both At III and the 
clotting factor, whilst binding of At III alone is sufficient for 
inhibition of Factor Xa.
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1.6.3 Heparin Assays
There are many clotting assays that may be used to assess the 
anticoagulant effect of a GtC (Barrowcliffe et al., 1978; Wessler 
and Gitel, 1979). These assays may be divided into two major 
groups; those which test the effect of heparin on one particular 
purified clotting factor (for instance, the anti-Xa assay) and 
those which show an effect on overall clotting - for exanple whole 
blood clotting time and activated partial thrcxnboplastin time 
(APTT).
There are also synthetic substrates ( chratiogenic ) assays 
v^ich measure the effect of heparin on thrcmbin or Factor Xa by the 
use of artificial substrates for the amidolytic functions of these 
factors (Wessler and Gitel, 1979). The release of a chromogenic 
product (which is measured spectrophotometrically) is related to 
the degree of neutralization of thrcmbin or Factor Xa by At III.
In both clotting and amidolytic assays, the action of the test GA3 
may be compared to that of a standard heparin.
A more physiological measure of the anti-clotting activity 
induced by a particular batch of heparin can be achieved by test of 
blood samples taken after injection (i.e. ex vivo plasmas) (Thomas 
et al., 1980).
1.6.4 Effect of GA3 Structure on its Anticoagulant Activity
In addition to heparin, the two other iduronic acid-containing 
GA3s, HS and DeS, also have a certain amount of anticoagulant acti­
vity. It seems that HS has a similar mechanism of action to 
heparin, but there is no evidence that DeS acts through At III 
(Lindahl and Hook, 1980).
The effect of MW of heparin on its activity was studied by
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separation on gel filtration followed by AETT and anti-Xa assays 
(Andersson et al,, 1979). The different values achieved in these 
two assays can be expressed in terms of the anti-Xa/APTT ratio, 
which for unfractionated heparin is generally around 1 (Thcxnas et 
al., 1982). By definition the activity of the standard heparin 
gives the same value by anti-Xa and APTT assays, so any heparins 
which are similar will have a ratio close to unity. It was found 
that for heparins of MWs below 15,000 dal tons, the relative value 
by APTT decreases ccxipared to that by anti-Xa assay, giving a ratio 
of > 1 (Andersson et al., 1979). Low MW (IMW) heparins with high 
anti-Xa/APTT ratios have been investigated for possible clinical 
use (Thomas et al., 1982). It was thought that such heparin frac­
tions, whilst having the desired therapeutic effect, would be less 
likely to cause haemorrhage since they have less effect on overall 
clotting. (Conparison of the use in animals of and BMW heparin 
has also shown that only in the latter is there evidence of osteo­
porosis (thinning of bones) (Murray, 1984)). However, this has 
been shown to be an over-simplification which is not supported by 
in vivo work (Thomas et al., 1982). Thomas and co-workers (1982) 
found that whilst heparin fragments of both 1 0 and 16-18 monosac­
charide units long have potent anti-Xa activity in vitro, only the 
latter has some antithrombotic effect. One factor in this may be 
the need for the GAG to bind thrcmbin as well as At III for neutra­
lization.
It is now known that the binding of At III by heparin is accom­
plished most effectively via a specific pentasaccharide sequence in 
the heparin molecule (Lindahl et al., 1983). This sequence is 
present in approximately 30% of heparin molecules of an unfrac­
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tionated samples, as determined by their affinity for At III- 
Sepharose (Lindahl and Hook, 1980). This is the only specific 
action of heparin that is known at present, in that it d^jends on a 
defined molecular sequence for maximum effectiveness. However, 
recent work (Merton et al., 1984) has indicated that heparin which 
has little At Ill-binding ability (low affinity (LA) heparin) acts 
synergistically with the heparin containing the specific At Ill- 
binding sequence (high affinity (HA) heparin). A mixture of HA and 
LA heparin was found to be more effective in preventing stasis 
thrombosis than HA heparin alone, although the mechanism for this 
is not yet known.
Work by Thomas et al. (1980) on heparin analogues further 
emphasized that in vitro assays alone cannot be relied upon in 
assessment for clinical use. They compared the in vitro and in 
vivo effects of SSHA (Thcxnas et al., 1980) and SP54 (Fischer et 
al., 1982) and found that although they were virtually inactive by 
in vitro assays, post-injection plasmas had enhanced anti-Xa 
activity. These results are cxxrpared in Table 5 to that using an 
unfractionated heparin. This suggests that some factor has been 
released into the blcxxi by the heparin analogues which has, or 
induces anti-Xa activity. One of the suggestions given (Thomas et 
al., 1980) was that endogenous GAGs (possibly HS) with anti-Xa 
activity had been released. However, the activity could not, 
unlike heparin in ex vivo plasmas, be neutralized by platelet 
factor 4 (a heparin inhibitor occurring naturally in plasma) or by 
protamine sulphate. Yin and co-workers (1979) have noted the 
presence of factors in pre-injection plasma which protect Factor Xa 
from neutralization, and it has been suggested that these factors
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TABLE 5: Comparison of the anti-Xa clotting 
activity of heparin, SSHA and SP54 by in vitro 
assay and that measured in plasma 2 hours 
following subcutaneous injection
Anti-Xa clotting activity
In vitro Ex vivo 
iu/mg iu/ml
Heparin* 180 0.05
SSHAt < 5 0.06
SP54* 6 0 . 0 2
* Fischer et al. , 1982
t Thomas et al.. 1980
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are lipoproteins (Thomas et al., 1980). In addition to this, it 
has been reported (Barrowcliffe et al., 1982) that certain lipo­
protein classes (particularly LDL and HDL) have anti-Xa activity. 
Since triglyceride lipases are released into the^  circulation after 
injection of SP54 and SSHA, it is possible that these enzymes are 
responsible for the additional anti-Xa activity, by an effect on 
plasma lipoproteins.
1.7 WORK COVERED AND AIMS
The primary aim of this project was to coirpare various assay 
methods for ease and reliability in measurement of PHP lipase acti­
vity, including, if possible, selective measurement of LPL and 
HTGL. Literature surveys show the danger of directly relating 
results from different assays. For exairple, as described in 
Sections 5.2 and 2.7 of this chapter, descriptions of the effect of 
salt and of various serum components on the enzymes' activity have 
varied widely depending on the assay conditions used by the 
separate groups of workers.
Three lipase assays have been compared for reliability and 
reproducibility. Possible iirprovanents of one assay in particular 
were studied. This assay purports to allow selective measurement 
of the two lipase enzymes. The effect of dilution of PHP by either 
buffer or pre-injection plasmas were also studied - results from 
preliminary experiments suggested that LPL and HTGL were differ­
ently affected by these two diluents.
A series of sulphated polysaccharides was selected to cover 
a range of MWs, sulphate content and sulphate/carboxyl ratios.
This included several heparins and HS, a DeS, a non-GAG polysac­
charide (SP54) and an over-sulphated chondroitin (SSHA). These
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were used to investigate further possible correlations between poly­
saccharide structure and the ability to release lipase on injec­
tion, and also to see if there were differences in the proportions 
of LPL and HTGL released. Most of these in vivo studies were 
carried out in the rat; a range of doses of each polysaccharide 
(with blood sanpled a set time after injection), and time courses 
of lipase release and clearance (at one dose per polysaccharide) 
were investigated. A limited amount of work was carried out using 
human subjects.
Various methods of inducing lipase release in vitro were also 
investigated using preparations of rat adipose tissue. This was 
tried as a potential alternative, or support, to the in vivo work, 
which is subject to animal variation. This would also have the 
advantage of reducing the number of experimental animals required.
LPL and HTGL were purified by affinity chronatography fran 
bovine milk and both rat and human PHPs. These enzyme preparations 
were used in clotting tests to investigate whether their presence 
contributes to the anti-Xa clotting activity present in post­
injection plasmas. These tests were carried out both in the 
absence and presence of heparin.
Heparin is widely used clinically as a drug for the control 
and treatment of thrcmboembolism, although other polysaccharides 
and heparin fractions are continuing being assessed for anticoagu­
lant action with reduced risk of haenorrhage. It was hoped that 
this work would contribute to the overall knowledge of the various 
effects of injection of heparin and heparin 'analogues' in vivo.
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CHAPTER 2
MEASUREMENT OF LIPASES IN POST-HEPARIN PLASMA
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2.1 INTRODUCTION
In order to study in detail the effectiveness of various 
polyanions in releasing lipase into the circulation, it is 
desirable to have a reliable, sensitive and convenient assay of 
the lipase in post-injection plasmas. The assay used by Crinos SpA 
(see Appendix I) uses Intralipid as substrate, fron which FFA are 
extracted by Dole's method after incubation with the enzyrre, and 
titrated for quantitation (Casu et al., 1983). It has the dis­
advantage of requiring relatively large volumes of plasma for 
accuracy (0 .5-1.0 ml) and being fairly lengthy to perform, thus 
limiting the number of samples which can be assayed at one time. 
"Riis method does not differentiate between the two lipolytic 
enzymes released into plasma.
An improved procedure was desirable, and so possible alter­
native assays were investigated. Most of the work was done on the 
assay of Nilsson-Ehle and Schotz (1976) (the 'Modified NES Assay'), 
using a glycerol-stabilized radiolabelled TG substrate, with adap­
tations to allow selective measurenents of HTGL and LPL. In 
addition, two other assays involving radiolabelled substrates were 
tried, one using a TG emulsion stabilized with gum arabic (the 'Gum 
Arabic Assay') and the other using the commercial TG emulsion. 
Intralipid (the 'Intralipid Assay').
2.2 Assay No. 1: the Modified Nilsson-Ehle and Schotz-Assay
The Nilsson-Ehle and Schotz assay was selected for initial
investigation since, according to the authors, it offered iirprove- 
nent in the 'sensitivity, precision and practicality' of lipase 
measurements (Nilsson-Ehle and Schotz, 1976). The advantages of 
the assay include the use of a stable emulsion which can be used
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for at least six weeks, the radiolabelled tracer which allows 
sensitive determinations on small enzyme volumes and the quick and 
easy extraction and quantitation of FFA's. An adaptation was made, 
due to Dr. J. Stocks (Lipid Research Laboratory, St. Bartholomew's 
Hospital, London), which was described as permitting the distinc­
tion of the two PHP lipases by using of different substrates.
2.2.1 Materials
Glycerol tri [9,10-%] oleate (triolein) (5 mCi/ml) Ihe Radio­
chemical Centre Ltd., Annersham, Bucks., U.K.
Unlabelled triolein (made from technical grade oleic acid). BDH 
Chemicals Ltd., Poole, Dorset, U.K.
Glycerol (Analar grade). BDH (Zhanicals Ltd.
Phosphatidyl choline ( 10 mg/ml in chloroform and 10% methanol )
Type V-E from egg yolk. Sigma, Poole, Dorset, U.K.
Bovine serum albumin, fraction V. BDH Chemicals Ltd..
Tris (Tris (hydroxymethyl)^aminoiæthane). BDH Chemicals Ltd.
Sodium chloride (Analar grade). BDH Chemicals Ltd.
Human serum prepared from a six-donor pool, heated for 60 mins. at 
56°C to remove any endogenous lipase activity.
Chloroform Analar used in ratios 141 ) Belfrage
Methanol Analar 125 ) reagent
n-Heptane GPR 100 )
Potassium carbonate BDH Chemicals Ltd.
Cocktail T 'Scintran' BCH Chemicals Ltd.
Assay tubes; Sterilin screw-cap, glass 10 ml.
2.2.2 Methods
i) Preparation of stock substrate
Labelled triolein was diluted to 20 yCi/ml with hexane
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(Analar) and stored at 4°C. Counts were checked each time 
before use by ccnparison with a %  Packard standard and by 
adjusting if necessary for radioactive decay. 1 ml of this diluted 
triolein was mixed in a sonication vial (glass, round-bottomed) 
with 0.7 ml phosphatidylcholine (10 mg/raL) and the solvents 
blown off under nitrogen. 1 2 0 mg of unlabelled triolein and 
2.52 g glycerol were then added and the mixture sonicated for 
5 mins. in 30 second bursts. This was done using a 3/8 inch 
titanium probe (with the tip placed 2 mm below the surface) 
set at amplitude 18 microns of a MSE 150 watt Ultrasonic 
Disintegrator. The vial was placed in an ice/water mixture 
during sonication to prevent overheating, 
ii ) Preparation of working substrate 
Made on day of use
a) For measurement of both enzymes 
0.625 g stock substrate
2.0 ml of 0 .2 M Tris/HCl buffer, pH 8.5 containing 30 mg
albumin/ml (= 'low salt buffer')
0 . 5 ml human serum
b) For measuranent of HTGL only 
0.625 g stock substrate
2.0 ml of 0.2 M Tris/HCl buffer, pH 8.5, 30 mg albumin/ml,
1 M NaCl (= 'high salt buffer')
0.5 ml 1 M NaCl (in distilled water)
These mixtures were v^ll vortexed.
Final substrate concentration
The working substrate concentrations and that in the assay 
based on a 30 yl enzyme volume are given in Table 1.
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TABLE 1: Final substrate concentrations of the NES assay
Working substrate
In assay 
(30 yl 
sample volume)
Unlabelled
triolein
10.7 mmoles/ml 
(9.5 mg/ml)
9.3 mmoles/ml 
(8.3 mg/ml)
Labelled
triolein
3.4 nmoles/ml 
(1.7 yCi/ml)
3.0 nmoles/ml 
(1.5 yCi/ml)
Glycerol 0 . 2 1 g/ml 0.19 g/ml
Phosphatidyl­
choline 0.58 mg/ml 0.5 mg/ml
Tris 0.13 M 0.11 M
Albumin 2 0 mg/ml 17.4 mg/ml
Low salt High salt Low salt High salt
Serum 0.17 y1/ml 0.15 yl/ml
Sodium chloride 0.83 M 0.77 M
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iii) Assay procedure
200 yl of working substrate were dispensed with Finn automatic 
pipettes into glass tubes, and pre-incubated for 1 0 mins. in a 
water-bath at 37°C. All sanples were tested in duplicate. The 
assay was started by the addition of 30 y 1 of enzyme, or buffer 
(for blank) with mixing at staggered intervals. The reaction was 
stopped after 10 mins. by the addition of 3.25 ml of Belfrage 
reagent, and 1.0 ml of 1.0 M potassium carbonate (pH 10.5) using 
'Zippette' autonatic dispensers (Jencons). The contents of the 
tubes were well-mixed on a vortex mixer then centrifuged at 3,000 g 
for 15 mins. 1 ml of the upper methanol/water phase was aliquoted 
into scintillation vials, and 1 0 ml of scintillation fluid added. 
The radioactivity was counted on a Packard Tri-Carb Liquid Scintil­
lation Counter 3255 for 10 mins. Aliquots (50 yl) of each of the 
working substrates were also counted for radioactivity to enable 
calculation of specific activities. To copy the quenching charac­
teristics of the counted samples, these were added with 0.95 ml of 
!
blank upper layer (no enzyme, no substrate) of Belfrage reagent 
(3.25 ml) and potassium carbonate (1.0 ml).
Calculation of enzymic activity
The following have to be taken into account:
1. Blank values
2. Enzyme volume (x yl)
3. Adjustment for % extraction of FFA (76%)
4. Total volume of upper layer (2.45 ml)
5. Incubation time (minutes)
6 . Conversion to nanomoles
7. Specific activity of working substrate (y = cpm in 50 yl)
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8 . Molar ratio of triglyceride to FFA 
mU/ml = net cpm X lOQOyl x x 2.45 x 1 x 1000 x 1.617ymol FFA x3
X yl 76 n mins y
= nanomoles oleic acid released minute"^ ml”^
2.2.3 Results and Comments
Test of assay parameters and possible improvanents 
i ) Linearity of the NES assay with incubation time 
Nilsson-Ehle and Schotz report the measured enzyme activity 
to be linear with time for up to 120 mins. However, their tests 
were done on enzyme extracts of acetone powders frcxn rat adipose 
tissue, and the authors suggest that shorter incubation times are 
used when PHPs of higher activity are assayed.
Tests of linearity were carried out on human PHP using both 
low and high salt substrates. A rabbit anti-human HTGL serum which 
binds and inactivates the HTGL was also used (kindly donated by Dr. 
Bengtsson, University of Umeâ, Sweden). PHP and anti-serum were 
mixed in a ratio of 4:1 and left for two hours at 4°C before 
assaying.
Linearity of activity was measured under four sets of con­
ditions: with or without anti-HTGL serum, and with using low or 
high salt substrates. The results in Figure 1  show that whilst 
'total' and 'LPL only' activities are linear up to 4 0  mins., the 
'HTGL' is l i n e a r  only up to 1 0 - 1 5  mins. Possible reasons for the 
non-linearity were tested by the addition after 4 5  mins. of further 
enzyme, albumin (to bind FFA which may be causing product inhibi­
tion) or substrate. None of these additions led to the resumption 
of a l i n e a r  reaction rate. Subsequent assays were run for 1 0  mins.
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Fig 1 Time course of the NES assay
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These results also show that there is not ccwplete inhibition 
of LPL activity by high salt and lack of serum, since there is some 
residual activity under these conditions (salt-resistant lipase 
activity - HTGL activity).
There was no appreciable difference in linearity when tested at 
25°C or 37°C.
ii) Linearity of the NES assay enzyme volume
To see whether the enzyme activity is proportional to the 
volume added, a range from 5 yl to 50 yl was compared in the assay 
of total and 'HTGL only' measurements at 37°C. Varying amounts of 
PHP were added to the substrates and the volume was made up to 50 yl 
with serum after the reaction had been stopped with Belfrage 
reagent.
Figure 2 shows that, whilst total activity is linear up to 50 
yl, the high salt activity slope levels off after 30 yl. This 
effect was also reported by Huttenen et al. (1975), but the reason 
for this is unclear.
iii) Albumin in the NES assay
The presence of albumin or calcium ions in incubation mixtures 
is necessary as acceptor for FFA produced by the lipase from tri­
glyceride (Korn, 1955). Fraction V and 'essentially fatty acid- 
free' grades of albumin (both from BDH Chemicals Ltd.) were compared 
for use in the assay, but no differences were found, either in the 
blank volume of the substrates or in the enzyme activities achieved. 
(Results not shown).
Eisenberg et al. (1981) have reported differences in lipase 
activities measured when albumins fran different suppliers (of the 
same grade) are used in lipase assays. They explain the discrepancy
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Fig 2 Effect of enzyme volume 
in the NES assay
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as being due to the presence of contaminants such as apo A-I (which 
inhibits LPL) in one of the preparations. Olivecrona (personal 
CŒTinunication) has found the BDH product to be satisfactory.
Some albumin preparations have been reported to contain lipase 
contaminants (Benson and Clayton-Love, 1982), but these can be des­
troyed by heating at 50°C for one hour before use, without affecting 
their ability to act as FFA acceptors,
iv) Use of Serum in the NES Assay
a) Effect of time of pre-incubation of substrate with serum on 
the lipase activity measured Baginsky and Brown (1979) found that 
highest LPL activities are measured in PHP when the serum- 
containing substrates have been pre-incubated for at least 80 mins. 
at 37°C. Their substrate was also triolein, but stabilized in gum 
arabic instead of phospholipid and glycerol. Serum made up 16-25% 
of the total incubation volume in their assay.
Tests were done to see whether pre-incubation of the glycerol- 
stabilized triolein substrate increased the enzyme activity 
measured. Rat PHPs of a range of lipase activities were used, and 
also human PHPs pre-incubated with anti-human HTGL in order to see 
the effect on LPL alone. Substrates were incubated at 37°C for 0, 
15, 40 and 60 minutes.
The results demonstrated that the time of substrate pre­
incubation has no effect on the LPL activities measured in this 
assay (results not shown).
b) Test of optimal amount of serum to be used in the 
substrate Baginsky (1981) reports that the level of serum needed in 
the low salt substrate for maximal stimulation of LPL varies with 
the serum batch. To test this two PHPs were assayed in substrates
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with three serum batches at four different concentrations.
Figure 3 shows that the pattern of lipase stimulation by serum 
can vary with serum batch and with the PHP assayed.
Comparison of the use of rat and human serum in assays of 
LPL in rat and human PHP Rat and human serum as source of apopro­
tein C-II were compared in assays of both rat and human PHPs.
In testing rat PHPs, substrates containing human serum gave 
higher lipase activities at all serum concentrations. With human 
FHPs the trend was less clear. One PHP tested showed no difference 
between rat and human serum, whereas another showed a 2 0 % increase 
when using rat serum (at all concentrations of serum),
v) The Effect of Salt on NES Lipase Assay Measurements
a) Use of physiological salt concentrations Several methods 
suggest the use of physiological (0.145 M) salt concentrations in 
the serum-containing substrate for maximal activity of LPL (Krauss 
et al., 1973; Baginsky and Brown, 1977). Measurements at this con­
centration were compared with those using no added salt other than 
that of the 0.2 M Tris-HCl buffer used to make up the substrate.
The results in Table 2 show that in this emulsion, increase of salt 
concentration with NaCl to 0.145 M leads to a slight inhibition of 
'total' activity of PHP sanples.
b) Use of high salt concentrations
Purified lipases LPL and HTGL purified by heparin-Sepharose 
chromatografùy (see Chapter 3) were assayed in 'low salt' (0.1 M 
Tris-HCl buffer) and 'high salt' (1.0 M NaCl in 0.2 M Tris-HCl 
buffer) substrates, both in the presence and absence of serum.
The results in Table 3 clearly show the inhibitory effect of 
high salt on s e r u m — stimulated LPL, although there is little effect
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Fig 3 Effect of serum batch and volume 
on the enzymic activity measured 
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TABLE 2: Effect of physiological salt con­
centration on the enzymic activity of PHP
Total enzymic activity 
mU/ml
No sale 0.145 M
PHP 1 51 44
49 44
PHP 2 186 164
186 171
PHP 3 234 225
231 214
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TABLE 3: Efrect of sait concentration on the enzymic activity 
of LPL and HTGL in the presence and absence of serum using the 
NES assay
Enzymic activity (mU/mi)
Low
No
serum
salt
With
serum
High :
No
serum
salt
With
serum
LPL
HTGL
42.3
83.3
126.1
67.7
46.3
133.6
39.8
27.9
62
in the absence of serum. HTGL is inhibited by serum, especially at
1.0 M NaCl. HTGL has the highest activity at high salt in the 
absence of serum, and LPL at low salt in the presence of serum.
HiP A range of salt concentrations (0 - 1.2 M NaCl) was used to 
make up the substrates, and to assay whole PHP lipase activity in 
the absence and presence of serum. The results (see Table 4) show 
that at salt concentrations below 1.0 M there is little effect of 
added serum on the enzymic activity measured of PHP. At higher 
concentrations where the LPL would be inhibited the activity is 
generally higher in the absence of added serum.
Comparison of the results of Tables 3 and 4 emphasizes that the 
effect of conditions observed with purified enzymes does not neces­
sarily apply also for HiP samples.
vi) Use of Sodium Dodecyl Sulphate in Selective Measurement of 
Lipase Enzymes
The method reported by Baginsky (1981) aims to selectively 
inhibit HTGL activity in PHP with SDS, to allow direct measurement 
of LPL alone. A one-step adaptation (i.e. without pre-incubation of 
the enzyme sample with SDS) was tried. This involved the use of 
buffers containing a range of SDS (BDH Chemicals Ltd.) concentra­
tions to make up a series of substrates.
The results in Figure 4 show the action of SDS on three PHPs in
low salt substrates containing serum. The results seem to suggest 
that the higher the activity of the PHP the more SDS is needed to 
inhibit the HTGL, and that going much above this level leads to
inhibition of the LPL also. This means that the approximate level
of activity would have to be known before selecting the SDS concen­
tration to use.
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TABLE 4; Effect of salt concentration on lipase activities measured liy the 
NES assay in the presence and absence of serum
0 0 . 2
NaCl concentration (M) 
0.5 0.75 1 . 0 1 . 2
PHP 1 + serum 240 215 181 73 6 6 6 6
- serum 226 209 173 73 85 94
PHP 2 f serum 31.1 25.7 21.7 13.5 13.0 15.7
- serum 27.5 30.9 17.0 11.4 15.2 15.6
PHP 3 + serum 181 39
- serum 177 50
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Fig 4 Effect of SDS on lipase measurement
of PHP by the NES assay
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Better results were not achieved by pre-incubation of the PHP 
sample with SDS (results not shown).
vii) Test of Variability of the NES Assay
This was based on the test of 30 y 1 aliquots of FHP incubated
for 10-15 mins. at 37°C.
a) Intra-assay variability The average difference between 
duplicates was 3.5% for both total and HTGL activities (n = 20).
b) Inter-assay variability A single PHP batch was tested in 
the assay on different days using different stock substrate batches.
The variability was 12% for total lipase activity and 23% for HTGL
(n = 15).
Using a single substrate batch on different days the variation 
for both total and HTGL activities was approximately 10% (n = 10).
viii) Standardization of the NES Assay
The need for standardization between assay runs was recognised 
and three different sources of lipase activity were tried out for 
use as internal standards.
a) Milk LPL Skimmed milk was prepared from fresh bovine unpas­
teurized milk by centrifugation for 20 mins. at 3,000 g and 4°C and 
stored in aliquots at -2 0 °C.
b) Pancreatic lipase Pancreatic lipase is commercially avail­
able as a stable pancreas extract in powder form which can be stored 
for long periods with minimal loss of activity (for several years 
when stored at < 15°C in a closed container). It has been reported 
to have certain similarities to LPL, being a glycoprotein with com­
parable substrate specificity (Baginsky and Brown, 1977). NaCl is 
also reported to affect pancreatic lipase similarly to LPL (Baginsky 
and Brown, 1977), but this is true only in the presence of its acti-
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vator 'co-lipase', a low MW polypeptide thought to be analagous to 
the apo ClI of LPL (Bengtsson and Olivecrona, 1982b).
Solutions of Pancreatin (Pancrex V Powder, Paines & Byrne Ltd., 
Greenford, England) were prepared in 0.2 M Tris/HCl buffer (pH 8.2), 
of a concentration range 0.01 - 0.5 mg/ml. Initial dispersion of 
the powder was aided by sonication in an ultrasonic bath for 2 - 3  
mins. Solutions could be made up with reasonable reproducibility (± 
4.6%, n = 4 assayed on the same day).
c) Human PHP A human volunteer was injected i.v. with 1,000 
u heparin (Pularin, Evans Medical), blood taken after 10 mins. and 
mixed 9:1 with 3.8% trisodium citrate. Plasma was prepared by cen­
trifugation at 38,000 g for 10 mins. at 4°C, snap-frozen in aliquots 
and thawed immediately before assaying.
Skimmed milk lipase could generally be used to correct total 
lipase values between assays with good agreanent (± 15%). However, 
since milk contains no HTGL it could not be used for adjustment of 
the levels of this enzyme. There is no firm evidence on the simi­
larity under assay conditions of LPL preparations from PHP and milk 
and this leads to doubts on the reliability of using the milk enzyite 
as a standard for the PHP activity.
There is an obvious advantage of using aliquots from a single 
pooled batch (as in milk and PHP) where the enzyme is stored fresh 
and thawed just before use. The enzymes have been reported to be 
stable for at least six months v^ e^n stored at -20°C (Krauss et al., 
1973; Huttenen et al., 1975). Although pancreatic lipase is very 
stable in powder form, the manufacturers recommend that fresh 
solutions be made up every day. The stability of frozen aliquots 
was not investigated. A linear relationship was found to exist
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between the concentration and lipase activity of Pancreatin within 
the range 0.025 - 0.25 mg/ml, which would cover the range of lipase 
activities found in PHP samples (this could not be done with skinmed 
milk or PHP where dilution led to significant non-linearity as des­
cribed in Ch. 5). However, despite this advantage of Pancreatin, it 
was not found to be as reliable as a standard normal pooled PHP, pre­
sumably because the enzymes were not affected in the same way by 
variations in conditions.
An average value for the control PHP used was obtained by 
repeat assays in low and high salt substrates. It was found suit­
able for correcting lipase levels of the experimental PHP samples to 
within 10%. Subsequent to this, a PHP was used as an internal 
standard in all assays.
ix) Effect of Purity of Substrate on the Enzymic Activity Measured
a) Test of substrate purity
The purities of the radiolabelled and unlabelled triolein used 
to make up the substrate for the assay were checked using GC (gas 
chromatography) and reverse phase HPLC (high pressure liquid chratia- 
tography). This was done primarily as a check of the radioactive 
triolein, which by this time had been stored for two years, and may 
have contained significant amounts of impurities not present in the 
unlabelled triolein (which is used greatly in excess for the sub­
strate) with possible effects on the enzyme activity. (3C is a 
standard method of separating fatty acid mixtures. It is sensitive 
and allows the separation of a small amount of material with good 
accuracy. This was done with the help of Dr. C. Jones and Mrs. A. 
Wilson (Chemistry Section, NIBSC). HPLC is a rapid separation 
method and has the advantage that, as in conventional chromato-
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graphy, fractions can be easily collected.
The system used was suggested by Dr. P. Corran (Chemistry 
Section, NIBSC) and run with his help. The methods of GC and HPLC 
used are given in Appendix II.
The unlabelled triolein had two main peaks by HPLC (see Fig. 5) 
and these were shown by GC to be the oleic (80%) and the palmitic 
(12%) glycerol esters (see Table 5). More than 95% of the radio­
activity of the labelled triolein was associated with a peak that 
coincided with the major peak of the 'cold' triolein by HPLC (see 
Fig. 5). This suggests that there had not been a substantial amount 
of deterioration in the labelled substrate in terms of the position 
of the radiolabel (Table 5).
b) Comparison of the use of '99% pure' and technical grade 
triolein in the NES assay 
Substrate batches were prepared using '99% pure' triolein 
(Sigma) and the values measured in the assay compared with those 
using technical grade substrate, testing the same PHP under the same 
conditions.
The levels achieved with the pure triolein were about twice as 
high as those using technical grade substrate for total lipase, and 
three times higher for HTGL (Table 6 ). In the original report on 
this assay (Nilsson-Ehle and Schotz, 1976), technical grade was 
used, but some other workers since have used purer substrates.
Further work could be done to compare the composition of 
various TG preparations and the activity measured with their use.
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Fig 5 HPLC of technical grade triolein
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TABLE 5: Fatty acia composition of technical grade 
triolein determined by gas chromatography
Palmitate 12%
Oleate 80%
Arachidonate 5%
66c
TABLE 6: Effect of triolein parity on enzymic activity measured 
in the NES assay
Triolein used Enzymic activity (mU/ml)
in substrate Total
lipase HTGL only
% HTGL 
of total
Technical
substrate
Batch I 237 124 55%
Batch II 223 1 2 1 54%
99% pure 521 462 89%
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2.3 ASSAY NO. 2; The Gum-Arabic Assay
Gum arabic-stabilized TG emulsions have been used in lipase 
assays by many groups of workers (Huttenen et al., 1975; Baginsky 
and Brown, 1977; Havel et al., 1973; Hernail et al., 1975). Like 
the NES assay, the incorporation of radioactive triolein allows many 
samples to be tested in one run making it a convenient assay, and 
differential use of salt and serum in the substrates may allow selec­
tive measurements of LPL and HTGL in PHP samples (Havel et al.,
1975). However, some non-linearity with respect to time and volume 
has been found (Huttenen et al., 1975; Goldberg et al., 1983) and it 
is reported to be a poor substrate for purified LPL (Havel et al., 
1973), although it is a good one for HTGL and it is less sensitive 
to other plasma proteins (especially lipoproteins) (Olivecrona, 
personal comnunication ). Preliminary tests were done using this 
assay to investigate its usefulness in testing PHP as a possible 
replacement for the NES assay. The particular assay method used 
was suggested by Dr. Olivecrona (Umeâ, Sweden).
2.3.1 Materials
Glycerol tri [9, lO-^H] oleate 
Bovine serum albumin, fraction V 
Tris
Human serum 
Sodium chloride 
Gum arabic, BDH Chemicals Ltd.
Olive oil, local supplier
2.3.2 Methods
i) Preparation of substrate
The QTiulsion has to be prepared daily with sonication using
As for NES assay
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fresh gum arabic solutions. A batch of albumin solution is made up 
and frozen in aliquots.
25 mg olive oil 
100 yl 2 X 1 0  ^cpm %-GTO
solvent blown off under Nn
'I
Add 1 ml gum arabic (10% in water)
1.25 ml 1 M Tris-HCl (pH 8.5)
2 . 0  ml distilled water 
Sonicate for 8 mins. in ice/water 
Low salt High salt
substrate substrate
Add 1.75 ml serum Add 3.12 ml 4 M  NaCl
1.5 ml 1 M NaCl 2.5 ml 10% albumin
2.5 ml 10% albumin (pH 8.0) 2.625 ml distilled
2.5 ml distilled water water 
Substrate concentrations The working substrate concentrations
and assay concentrations based on a 50 yl enzyme volume are given in 
Table 7.
ii) Assay procedure
150 yl of the appropriate substrate were dispensed per tube, 
and preincubated at 25°C or 37°C for 15 mins. 15 yl enzyme were 
added at zero time and the reaction stopped, the FFA extracted and 
the radioactivity counted as in the NES assay.
Calculation of enzymic activity The olive oil used as source 
of triglyceride in the substrate contains mixed triglycerides, the 
fatty acids of which are mainly oleic acid (approx. 85%) (Merkx 
Index, 1976), but for the purposes of calculation (relating labelled
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TABLE 7: Substrate concentrations of the gum arabic assay
Working
substrate
In assay 
(50 pil sample volume)
Olive Oil 2.26 mmoles/ml (2 mg/ml) 1.7 mmoles/ml (1.5 mg/ml)
Gum arabic 8 mg/ml 6 mg/ml
Tris 0.1 M 0.075 M
Albumin 2 0 mg/ml 15 mg/ml
Low salt High salt Low salt High salt
Serum 0.14 ml/ml 0 . 1 1  ml/ml
Sodium chloride 0.12 M 1.0 M 0.09 M 0.75 M
69
to unlabelled IG) 100% oleic acid was assumed. On this basis, 50 yl 
of working substrate contains 0.33 ymoles of oleic acid. Further 
factors which must be taken into account, such as the % FFA extrac­
tion by Belfrage reagent and the total upper layer volume, are 
adjusted for as in the NES assay.
2.3.3 Results
i ) Linearity of enzyme activity measurements with time 
Human PHP samples were assayed in 'low salt' (0.15 M) and high 
salt (1.0 M) substrates for incubation times ranging fran 10 - 80 
mins. at 25°C and 37°C. Anti-serum to HTGL was also used in tests 
to allow measurement of LPL only after incubation with PHP for 2 
hours (anti-serum: PHP, 1:8).
The non-linearity of the HTGL (high salt) measurements is 
immediately obvious from Figures 6 and 7, especially at 37°C. The 
FFA released by HTGL after 10 mins. incubation are lower at 37°C 
than at 25°C, and this suggests that the inability of the enzyme to 
work on the substrate (whatever the cause) develops progressively.
It would not appear to be due solely to inactivation of the enzyme, 
since further addition of fresh enzyme after 40 mins. incubation did 
not result in further hydrolysis. This would suggest that the 
active enzyme is in some way prevented from interacting with the 
substrate.
Total and LPL activities (measured in low salt substrates) were 
generally linear with time at least up to 40 mins. at 25°C and to 20 
mins. at 37°C (Figs. 6 and 7). No LPL is measurable in the high 
salt substrate as shown by the use of anti-HTGL serum.
The difference in suitability of the two substrates for LPL and 
HTGL is shown most clearly at 25°C (Fig. 7) where HTGL activity is
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Fig 6 Time course of the gum arabic assay 
at 37°C
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Fig 7 Time Course of the gum arabic assay 
at 25°C
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greater than total, up to incubation times of 40 mins.
The overall level of PHP activities measured by this assay was 
of the same order as those calculated frcm use of the NES assay.
2.4 ASSAY NO. 3; The Intralipid Assay
Intralipid is a commercial preparation of soya bean oils, 
emulsified with, and stabilized by, phosphatidylcholine. Because of 
its similarity to LPL’s natural substrates, it is readily hydrolyzed 
by this enzyme (Bengtsson and Olivecrona, 1981) although it is not 
by HTGL (Üstlund-Lindqvist and Boberg, 1977). The assay described 
here uses the Intralipid emulsion prepared with radiolabelled 
triolein, to permit quick and reproducible tests.
The use of this assay was suggested by Dr. T. Olivecrona, Umeâ, 
Sv^en. Heparin is included in the substrate to prevent destabili­
zation of purified LPL, for which this assay was originally 
designed.
2.4.1 Materials
Intralipid (10%) containing -triolein (produced by AB Vitrum, 
Stockholm, kindly donated by Dr. Olivecrona, ütteâ).
Heparin (5,000 iu/ml) (Leo Laboratories Ltd., Princes 
Ris borough, Bucks., U.K.)
Tris )
Human serum ) As for NES assay 
Sodium chloride )
Bovine serum albumin )
2.4.2 Methods
i) Preparation of substrate
The substrate is prepared by thorough vortex mixing of the 
following:
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160 yl % -Intralipid
100 yl heparin (5,000 iu/ml)
100 yl 1 M Tris/HCl buffer pH 8.5 
400 yl 1 M NaCl 
40 yl distilled water 
1 0 0 0  yl serum 
ii) Assay procedure
90 yl of the above substrate per tube are pre-incubated at 25°C 
or 37°C for 10 mins. and 60 yl of 20% albumin (w/v in 0.5 M Tris- 
HCl buffer, pH 8.5) added immediately prior to the addition of 50 yl 
enzyme at zero time. The reaction is stopped, the FFA extracted and 
the radioactivity counted as described for the NES assay.
Substrate concentrations The final concentrations in the assay 
substrate using an enzyme volume of 50 yl are given in Table 8 .
Calculation of results Soya bean oil used in the Intralipid 
substrate contains a mixture of saturated and unsaturated fatty 
acids, the major ones of which are given as linolenic acid (51%), 
oleic acid (29%) and palmitic acid (10%) (Merkx Index, 1976). A 
weighted average triglyceride MW was calculated on the basis of 
these figures, and used in the conversion of radioactive counts to 
mU/ml as in the NES assay.
2.4.3 Results
Linearity of the assay The assay was linear for incubation 
times at least up to 60 mins. and with a volume range up to 50 yl 
(results not shown).
Calculated values of PHP activities using this assay were 3 - 4  
times higher than those from the NES or gum arabic assays.
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TABLE 8 : Final substrate concentrations of the Intralipid
assay
Intralipid
Soya bean oils 4 mg/ml
Fractionated egg phospholipids 0.48 mg/ml
Glycerol 0. 8 8 mg/ml
Tris 0.17 M
Albumin 60 mg/ml
Serum 0.25 ml/ml
Sodium chloride 0.1 M
Heparin 125 u/mL
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2.5 DISCUSSION
The range and variety of the lipase assays used by different 
workers suggest the difficulties in finding a satisfactory method. 
The work described in this Chapter has mainly been concerned with 
ways of improving the reliability and reproducibility of a modified 
NES assay. An adaptation to allow selective measuranent of LPL and 
HTGL was incorporated, using substrate preparations containing 
either serum or a high concentration of salt. Another assay investi­
gated used a gum arabic-stabilized TG emulsion and the same method 
of distinguishing between the two enzymes. With a third assay using 
the commercial substrate, Intralipid, no such differentation was 
employed, since inclusion of salt produces only little inhibition of 
LPL activity with this substrate (Bengtsson and Olivecrona, 1983), 
and it was reported to be hydrolysed much more readily by LPL than 
by HTGL (Olivecrona, personal communication).
Measurements of 'total' or 'LPL only' activities did not 
deviate from linearity with respect to both time and sample volume 
in all three assays (up to 40 mins. and 50 yl of PHP (300 mU/ml) ). 
However, results for 'HTGL activity' (in high salt and the absence 
of serum) in both the NES and gum arabic assays were significantly 
non-linear with respect to incubation time and sample volume, espe­
cially the gum arabic assay. Various means of overcoming the reduc­
tion in enzymic activity were not successful, so the assay incuba­
tion time and enzyme volume were reduced to within the linear range 
in the NES assay, and tests on other parameters of this assay were 
continued. However, linearity of response was so poor in the gum 
arabic assay that its use was discontinued. The Intralipid assay 
gave measured activities 3 - 4  times higher than those from the
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other assays tried, as was found by Riley and Robinson (1974) but, 
as stated, it cannot be reliably used for assessment of the propor­
tion of LPL and HTGL in PHP samples.
The variability between NES assay runs was reduced by use of a 
pooled PHP as an internal standard. Assays of this nature are sensi­
tive to slight variations in procedure, especially in the prepara­
tion of the substrate emulsion. The degree of sonication used has 
to be constant since in altering the emulsion particle size, binding 
of the enzymes (and apo CII) and so the measured activity are also 
altered. LPL measurement is reported to be especially sensitive to 
sonication changes (Huttenen et al., 1975).
The scatter of 'total lipase' values obtained using varying 
amounts of different serum batches in the low salt substrate, gives 
an indication of the complicated activation/inhibition effects 
operating on the enzymes in this measuronsnt. This is obviously a 
source of inter-assay variability, especially of higher activity 
PHPs (see Section 2.2.3, iv), b) of this Chapter). Even greater 
differences were found however, by Baginsky (1981) using a gum 
arabic-stabilized substrate. As a consequence, fresh serum batches 
were compared with the current batch to check for major variations.
Pre-incubation (other than for temperature equilibration) was 
found to be unnecessary for the serum-containing substrate of the 
NES assay. In other assay systems (Korn and Quigley, 1957; Baginsky 
and Brown, 1979) it was necessary to pre-incubate the substrate with 
the serum prior to addition of the enzyme, to allow incorporation of 
apo CII into the emulsion. Apo CII is reported to be taken up 
readily by phospholipid-containing emulsion since these resemble 
VLDL and Ols in structure (Bengtsson and Olivecrona, 1981b).
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Different workers have used substrates of different grades of 
purity - ranging from chromatographically pure TGs (for example 
Baginsky, 1981) to relatively crude mixtures such as olive oil and 
soya bean oils. Results given in 2.2.3, ix) of this Chapter com­
paring the use of substrates prepared with '99% pure' and technical 
grade triolein show the great effect this can have on the activity 
measured. There have been reports that the chain length and degree 
of saturation of the fatty acid acyl chains affect the hydrolysis of 
TGs by both LPL (Demel et al., 1984) and HTGL (Hülsmann et al.,
1980). Since oleic acid and its main contaminant in technical grade 
triolein, palmitic acid, differ only by two carbons in chain length 
the effect may perhaps be explained in terms of the degree of satura­
tion. Packing of TG emulsions are 'looser' with unsaturated fatty 
acid chains than with saturated chains, so hydrolysis by lipase of 
the former is quicker since the lipid is more accessible (Demel et 
al., 1984). This could account for the lower values obtained with 
the technical grade triolein, although the presence of inhibitory 
contaminants cannot be discounted.
The differential use of serum and salt in the two substrates to 
distinguish LPL from HTGL is not totally reliable. This was shown 
by assaying both purified enzymes and PHP before and after anti-HTGL 
treatment; in both systems the figures were not additive (i.e. 'LPL 
only' and 'HTGL only' / total). This was also found by Hernall et 
al. (1975) using a gum arabic-stabilized substrate, where the 
activity of purified HTGL against the serum-stimulated substrate was 
only 40% of that in the high salt substrate.
Other chemical methods of inhibiting one or other of the 
lipases also have proved not to be totally selective. Pre-
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incubation with SDS has been used (Baginsky and Brown, 1971) at con­
centrations which inhibit HTGL but allow full LPL activity to be 
Treasured. However, neither this nor a subsequent report (Baginsky,
1981) appears to investigate its use with a wide range of PHP lipase 
activities. The results reported here in Section 3.2.3, vi) using 
the NES assay indicate that a precise SDS concentration is needed to 
inhibit the HTGL without affecting LPL. If this is so, the concen­
tration required will not only be different for high and low acti­
vity PHPs, but may also differ with the proportion of the two 
enzymes present. Preliminary testing of SDS levels necessary for 
accuracy would considerably lengthen the assay time making it an 
unsatisfactory method. However, use of SDS may be more effective 
with a gum arabic-stabilized emulsion. It should be noted, however, 
that SDS will affect many proteins other than HTGL with unknown 
consequences in so complex a system.
A surer means of selective inhibition is to use antisera speci­
fic to each enzyme: following inhibition of one enzyme, the other 
may be assayed under its optimal conditions. An attempt was made to 
raise antiserum in the rabbit against rat HTGL, but this was not 
successful (see ^pendix III).
In assays of an enzyme's activity, similarity to the natural 
substrate and environment does not necessarily allow reliable quanti­
tation of the enzyme. The nature of the substrate enulsifier/ 
stabilizer may greatly affect the measured activities of LPL and 
HTGL. Bengtsson and Olivecrona (1981b) found considerable variation 
in activity between different types of substrate emulsion used, and 
gave the explanation that 'the quality of the lipid-water interface 
determines to what extent the enzyme becomes properly orientated for
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effective catalysis'. In the case of LPL this will also depend on 
how well apo CII is bound, which as mentioned earlier, is inproved 
by the use of a phospholipid emulsifier.
Phospholipid may also affect the 'presentation' of TGs at the 
emulsion surface (Bengtsson and Olivecrona, 1980c). Also relevant 
is the fact that, although inclusion of phospholipids in (prepara­
tion of) emulsions provide a good model for lipoproteins, they may 
also interfere with measured activity since both the lipases have 
some phospholipase activity. This will affect especially the HTGL 
measurements, since this enzyire has higher phospholipase activity 
than LPL. This may provide an explanation for the report (Jansen, 
personal communication) that the substrate of the NES assay is not a 
'good one' for HTGL. Such interference may be eliminated by sub­
stitution of phosphatidylcholine with its lyso-derivative which is 
not hydrolysed by LPL or HTGL (Bengtsson and Olivecrona, 1980c).
Other detergents used for the preparation of the substrate may 
also affect the two lipases in different ways (Baginsky and Brown, 
1977). For exaitple, SDS can protect and even activate LPL (by 
preventing its aggregation and reducing dénaturation) whilst inhi­
biting HTGL . It has also been reported (Bengtsson and Olivecrona, 
1980c) that although some of the problems of using phospholipid are 
circumvented by use of gum arabic or Triton X-100, there may be 
non-specific binding of protein to the substrate which reduce its 
availability for LPL. In various ways then, optimal activities of 
the two enzymes would be achieved by using different emulsifiers/ 
stabilizers in preparation of their test substrates.
In conclusion, in determining what sort of substrate prepara­
tion to use for a lipase assay it is necessary to decide first what
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is the purpose of the measurement. In some studies, for example 
that described in Chapter 6 carparing release of LPL and HTGL by 
various polysaccharides, perhaps measurements in terms of mg protein 
by a radioimmuno assay (Olivecrona and Bengtsson, 1983) would also 
be appropriate. Measurement of activity is of course also impor­
tant, but it must be emphasised that LPL and HTGL are different 
enzymes, with different (albeit overlapping) substrate specifi­
cities. Instead of using the same substrate for both, a more 
reliable measure of the in vivo effect of the enzyme released into 
the bloodstream might be achieved by using TG-radiolabelled 
emulsions for LPL and phospholipid-labelled substrates for HTGL.
The NES assay has been modified to allow reliable measurement 
against a glycerol/phospholipid-stabilized TG substrate, with a 
degree of differentiation between LPL and HTGL. The '% HTGL' calcu­
lated from the results of low and high salt substrates will be lower 
than that of many other assays, because of the presence of phospho­
lipid competing with TG for hydrolysis. However, so long as this 
and other limitations of the assay are appreciated, it can be 
usefully employed to make valid comparison of LPL and HTGL in a 
series of post-injection plasmas.
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CHAPTER 3
PURIFICATION OF LIPASES FROM POST-HEPARIN PLASMA AND BOVINE MILK
79
3.1 INTRODUCTION
Heparin-Sepharose chromatography has been widely arployed for 
purification of triglyceride lipases from milk and PHP since its use 
was first reported by Olivecrona and co-wDrkers in 1971. The method 
permits a many-fold purification from the high protein content 
present in these starting materials. However, heparin, being a 
highly charged ionic species, also binds several other proteins 
including At III and some lipoprotein classes. Removal of contami­
na tory At III especially has caused problems since like LPL and HTGL 
it is a glycoprotein with an approximate MW of 60,000. (However, 
there has been a single report (Becht et al., 1980) of the use of 
gel filtration for separation from At III. The method relies on LPL 
being aggregated after heparin-Sepharose, so that it is eluted in 
the void volume on gel filtration).
Purification of LPL and HTGL in this project was undertaken 
primarily to allow the study of the effect of these enzymes on 
plasma anti-Xa activity. Since At III is responsible for most of 
the anti-Xa activity present in normal plasma, various methods of 
avoiding contamination with At III have been investigated.
Unpasteurized bovine milk contains no At III and is a con­
venient source of LPL, so was used as starting material. Both HTGL 
and LPL can be purified from PHP using their difference in affinity 
for heparin. Despite the extra problems in using PHP, LPL was puri­
fied from PHP as well as from milk since complete identity of action 
of the enzyme from the two sources cannot be assumed (although there 
have been reports (Wallinder et al., 1982) of similar immunotitra­
tion curves, and molecular and kinetic properties).
Alternative ligands to normal heparin were tried because of
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their lower affinity for At III in order to reduce the degree of 
adsorption of At III to the gel.
3.2 MATERIAL AND METHODS
3.2.1 Enzyme source
i) Bovine milk Fresh unpasteurized bovine milk was obtained 
from a local farm and used on the same day as collection.
ii) Human PHP Healthy human volunteers were injected i.v. with
5,000 u heparin and plasma obtained after 10 mins. by plasma­
pheresis. The PHP was stored at -40°C until used.
lii) Rat PHP PHP was obtained from male Sprague-Dawley rats by 
cardiac puncture 10 mins. after i.v. injection of 250 u heparin/kg. 
The blood was mixed 9:1 with 3.8% trisodium citrate, spun at 48,000 g 
for 10 mins., and the plasma stored at -20°C or used fresh.
3.2.2 Affinity gels
i) Heparin-Sepharose Sepharose 4B (Pharmacia (GB) Ltd., 
Hounslow, Middx., U.K.) was activated with cyanogen bromide and then 
coupled with heparin as described in Appendix IVa. In addition, 
Sepharose CL6B was purchased from Pharmacia. Although the cross- 
linked Sepharose has lower capacity, it is more resistant to packing 
down under the pressure used in punping.
ii) Modified heparin-Sepharose Heparin with low affinity for 
At III was prepared from commercial heparin by N-desulphation and 
reacetylation as described in Appendix IVc. The At Ill-binding 
ability was determined by APTT clotting assay (Casu et al., 1983) 
and gave a value of 16 u/mg compared to 150 u/mg for the starting 
(unmodified) heparin. The modified heparin was coupled to Sepharose 
4B using the one-step method of Andersson et al. (1975) as described 
in Appendix IVb. In this læthod heparin, cyanogen bromide and
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Sepharose are all mixed together which should allow a more complete 
binding of heparin to the gel.
The gel was compared to normal heparin-Sepharose for its 
ability to bind At III frcm plasma. Normal human plasma was mixed 
with the gels, and the supernatant tested iitmunologically for At 
III (Barrowcliffe et al., 1982). The modified heparin-Sepharose 
œuld bind just 0.9 u At III/ml* gel compared with 8.2 u/ml normal 
heparin-Sepharose gel, so there is a 90% reduction of At III bound 
using the modified heparin gel.
iii) Dextran sulphate-Sepharose Dextran sulphate (Pharmacia 
(GB) Ltd.) was coupled to Sepharose 4B (Pharmacia) by the method 
described in Appendix I Va.
3.2.3 Protein determinations
Estimation of protein œncentrations were made by measuring 
absorption at 280 nm.
3.2.4 Concentrating methods
i) Ultrafiltration An Ami con 50 ml cell was used with a Diaflo 
FMIO membrane (approximate MW c:ut-off of 10,000 dal tons) and a 
pressure of 15-20 psi supplied by nitrogen. Since proteins of 
smaller size than that of the mennbrane pore will pass through, there 
is also a degree of purification by this method.
ii) Precipitation by ammonium sulphate This technique of
'salting out' of proteins is based on the tendency of hydrophobic 
sections of proteins to aggregate at high salt concentrations.
The protein solutions to be concentrated were dialysed over­
night at 4°C against 3.6 M ammonium sulphate - 0.01 M sodium phos­
* Normal plasma contains 1.0 u At Ill/ml by definition.
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phate (pH 6.5) (Ostlund-Lindqvist and Boberg, 1977). After centri­
fugation at 40,000 g for 15 mins., the protein pellet was made up in 
approximately two volumes of 0.01 sodium phosphate - 0.145 M NaCl 
(pH 7.5), the insoluble protein separated by further centrifugation, 
and salt rennoved by dialysis against 0.01 M sodium phos^ate (pH 
7.5) - 50% glycerol (v/v).
iii) Use of polyethylene glycol High MW cotplexes of poly­
ethylene glycol can be used to remove water and low MW salts by 
solid dialysis.
The solution to be concentrated was put into dialysis tubing 
and packed round with 'Carbowax' ( 20“M Flaked (MW 20 x 10&) from 
Union Carbide Corporation, New York, USA).
3.2.5 Polyacrylamide gel electrophoresis
Final lipase preparations were tested for purity using a method 
for gel electrophoresis in SDS modified from that of Weber and 
Osborn (Olivecrona, personal communication). Gels were made up as 
slabs or rods by the method described in Appendix VI containing SDS 
concentrations of 10% for the main gel and 4% for the stacking gel.
Samples were prepared for electrophoresis by incubation for 1 
hour at 60°C in 0.01 M phosphate buffer containing 4 M urea and 1% 
SDS. A preparation of low molecular weight calibration proteins 
(Pharmacia) was similarly treated.
Approximately 1 yg of protein was loaded of each sample in 
sucrose containing bromophenol blue as tracker dye. The gels were 
run in a Biorad Protean Dual Vertical Slab Gel electrophoresis Cell 
(Biorad Laboratories, Richmond CA, USA) at room temperature for 2 
hours at 100 v then for 18 hours at 60 v. The gels were stained in 
0.2 % Coomassie brilliant blue in a mixture of water:ethanol;acetic
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acid (4:5:1) for 2 hours at roan tanperature, then de-stained in the 
same solvent.
3.2.6 Lipase assay
Lipase activity of the starting material and fractions at all 
stages of the procedure were assayed by the modified NES assay as 
described in Chapter 2. Unless stated, eluted column fractions for 
total lipase measurements were diluted before assaying to give salt 
concentrations of not more than 0.2 M.
3.3 RESULTS
3.3.1 Purification of milk LPL with heparin-Sepharose
Five litres of fresh unpasteurized milk were centrifuged at
3,000 g for 20 mins. to separate the cream which was discarded.
Solid NaCl was added to the skimmed milk to give a final concen­
tration of 0.5 M, and this was equilibrated for 90 mins. with 150 ml 
heparin-Sepharose (prepared as described in ^ pendix Ilia). The gel 
was then washed with 3 volumes of 0.5 M NaCl, 5 mM sodium barbitone 
buffer (pH 7.4) and packed into a column. The column was further 
washed until no protein could be detected by absorbance at 280 nm, 
then the LPL eluted with 1.5 M NaCl-sodium barbitone buffer (pH 7.4) 
at a flow rate of 0.8 ml/min. Lipase activity was eluted in a 
single peak, the fractions of which were pooled and dialysed exten­
sively against the washing buffer and then stored at -40°C.
The purification scheme is summarized in Table 1. Under the 
conditions given, only 40% of active LPL from the starting material 
bound to the heparin-Sepharose. Protein concentrations could not be 
reliably determined at 280 nm because of the interfering effects of 
the barbitone buffer.
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3.3.2 Chronatography on dextran sulphate-Sepharose
The suitability of using dextran sulphate-Sepharose gel for 
purifying LPL and HTGL from human PHP was tested. Dextran sulphate 
has low affinity for At III and is used in the purification of 
Factor Xa from plasma.
Human PHP was loaded on to a column of dextran sulphate- 
Sepharose, washed with 0.05 M NaCl in 0.05 M Tris/HCl buffer (pH 
8 .2 ) and either eluted stepwise with increasing salt concentrations 
of 0.8, 1.0 and 1.5 M or by a linear salt gradient of 0.5-1.5 M (in 
the same buffer ). Immunological ræasurement of At III showed that 
there was no difference in the amounts of it bound by unsubstituted 
Sepharose and dextran sulphate-Sepharose. Over 85% of total plasma 
At III loaded was detectable in the supernatant and the 0.5 M NaCl 
wash.
However, although there was close to 100% binding of both 
lipases by the gel, there were difficulties in eluting them. Very 
little of either enzyme was eluted up to 1.5 M NaCl; a small amount 
of HTGL was eluted at all concentrations above 0.7 M and continued 
after 1.0 M which was where the LPL started to elute (results not 
shown). This meant that LPL and HTGL could not be resolved under 
the conditions used, and was therefore not a useful system.
3.3.3 Use of aluminium hydroxide
Aluminium hydroxide (AKOH)^) absorption is a standard method 
of removing At III and other clotting factors frcxn plasma. Its use 
was investigated as a step prior to heparin-Sepharose chromatography 
to remove At III. 0.1 ml of 20% (w/v) of AKOH)^ was mixed with 1 ml 
human PHP for 30 mins. at 4°C, and the lipase activity tested before 
and after the treatment. As well as removing At III however, total
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lipase activity of the PHP was reduced by > 50%, so this technique 
was not looked at further.
3.3.4 Use of heparin-Sepharose chronatography for purification of 
LPL and HTGL from PEiP 
LPL and HTGL were purified from PHP either by chromatography on 
a single column of normal heparin-Sepharose (Column I) or by using 
in addition a second column (Column II) of Sepharose substituted 
with heparin modified to have low affinity for At III (as used by 
Ostlund-Lindqvist and Boberg, 1977).
i) Column I, heparin-Sepharose Solid sodium chloride was added 
to human or rat PHP to give a final concentration of 0.35 M, then 
the plasma mixed with heparin-Sepharose in a ratio of 10:1 (v/v) 
and left to stir for 2 hours. This and all subsequent steps were 
carried out at 4°C. In some runs EDTA was added with the sodium 
chloride to a concentration of 5 mM to prevent any formation of 
fibrin strands. The column was poured and washed with six volumes 
of 0.35 M NaCl - 0.1 M phosphate buffer (pH 7.4) containing 20% 
glycerol (v/v) for stabilization of the lipases. Stepwise elution 
at a flow rate of 0.5 ml/min. was carried out with increasing salt 
concentrations in phosphate buffer and 20% glycerol. The bulk of 
the loaded HTGL (generally > 60%) eluted with 0.7 M NaCl; a mixture 
of LPL and HTGL with 0.8 M NaCl, and finally LPL (50-80% of loaded) 
eluted with 2.0 M NaCl (see Fig. 1). There appeared to be contami­
nating HTGL present in the LPL fractions, but this may be due to a 
lack of absolute differentiation in the lipase assay used (see Ch. 2) 
The peak activity fractions of HTGL and LPL were separately 
pooled, and if column II was not used, concentrated by one of the 
methods described in section 2.5 of this Chapter. Their effective-
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ness is compared in Table 2. Precipitation by dialysis against 
concentrated ammonium sulphate solution was found to be the most 
useful technique in producing a concentrated sanple, although it did 
not give the best yield. The low yield is possibly due to the for­
mation of insoluble aggregates of the lipase which are inactive.
Adsorption of lipase by heparin-Sepharose was generally around 
80% of the total activity loaded (Table 4). In runs where the super­
natant and column wash contained more than 25% of the starting acti­
vity, the lipase was recovered from this by partial fractionation 
using sequential ammonium sulphate precipitation (Frost et al.,
1982). The final precipitate (from 30-60%) was then well dialysed, 
reloaded on to a fresh heparin-Sepharose column, washed then eluted 
with a salt gradient of 0.15 M to 2.0 M NaCl. The peak fractions 
from this were added to those of the main run.
The instability of LPL in dilute solutions is shown in Table
3. In 24 hours, the eluted activity had fallen by 80% and after 24 
hours of dialysis at 4°C, this was further reduced by 50%. After 
the dilute enzyme had been stored at 4°C for 5 days, only 5% 
remained of the activity eluted. Since LPL'is known to be surface- 
active, especially in dilute solutions (Bengtsson, personal carmuni- 
cation), part of this loss may be a result of the enzyme sticking to 
the storage container or dialysis tubing.
ii) Column II, modified heparin-Sepharose After dialysis 
against 0.15 M NaCl in phosphate buffer (20% glycerol), the LPL and 
HTGL samples from column I were separately applied to 2 ml columns 
of modified heparin-Sepharose. The gels were washed with 0.35 M 
NaCl and HTGL eluted with 1.0 M NaCl (Fig. 2a) and LPL with 2.0 M 
NaCl (Fig. 2b).
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TABLE 2; Comparison of methods for concentrating lipase fractions
Technique Enzymic activity of 
concentrated sample 
(mU/ml )
% recovery
Amnonium
sulphate
precipitation
430 37
Ultrafiltration 70 58
Carbowax 23 72
The starting volume and enzyme activity were the same for each 
method used
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TABLE 3: Stability at 4°C of dilute LPL solutions
Storage time after 
elution off heparin- 
Sepharose column
Total enzymic 
activity 
(mU)
Calculated total 
activity in 
eluted fractions
30 mins. 6,500
Pool of above 
fractions 24 hours 1 , 2 0 0
Dialysed pool 48 hours 680
5 days 290
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Fig 2 Affinity chromatography on modified
heparin-Sepharose
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The results of protein estimations of loaded and eluted frac­
tions indicate that > 80% of protein was removed from the lipase 
sample by use of this column. This was accompanied, however, by a 
loss of approximately 50% of overall lipase activity, and the final 
yield after both columns was low - approximately 4% for LPL and 3% 
for HTGL (see Table 4). Purification from starting plasma was 
approximately 1,000-1,500-fold based on mU enzymic activity per mg 
protein).
3.3.5 Gel electrophoresis
Purity of lipase preparations from columns I and II was studied 
by SDS-PAGE and protein markers used for MW calibration (see Fig.
3 ). The major Coomassie blue-staining bands in the LPL and HTGL 
samples off column I gave approximate MW values of 69,000-70,000, 
with the HTGL also having minor bands of approximately 185,000 and 
two or three other high MW proteins close to the origin. The 
protein concentration of the samples eluted from column II was too 
low to be detected by the staining method used.
3.4 COMMENTS
This chapter has been concerned with the purification of LPL 
and HTGL from PHP and LPL from milk by affinity chromatography. Use 
of skimmed milk with heparin-Sepharose gels produced a 10% yield of 
LPL with approximately a 600-fold purification. The same gel used 
with PHP as starting material produced a 60% yield of both lipases 
representing a 200-400-fold purification (based on mU enzymic acti­
vity per mg protein). This yield was reduced to 20-45% however 
after concentrating the samples, depending on the method employed.
A major problem of using heparin-Sepharose chromatography for 
purification of lipases from PHP is contamination with At III. This
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is especially so for LPL since > 90% of inmunoreactive At III has 
been shown by McKay and Laurel1 (1980) to be eluted at NaCI concen­
trations above 0.8 M. Various ways of avoiding this contamination 
were tried. At III can be absorbed from plasma using Al(Œi)3 , but 
this also removed at least 50% of PHP lipase activity. Because of 
this loss, this technique was not further investigated, but in the 
light of the low yields achieved using other methods, this would be 
worth more study. Sepharose substituted with dextran sulphate in 
place of heparin was used, since this polysaccharide has only low 
affinity for At III. However, although there was good binding of 
lipase from PHP, there was poor recovery and elution did not allow 
good separation of LPL and HTGL.
Use of a second affinity gel substituted with a heparin chemi­
cally modified to have low affinity for At III was successful in 
purifying lipase from the bulk of the contaminating protein obtained 
after unmodified heparin-Sepharose chromatography. This allowed 
> 1 ,0 0 0 -fold purification from starting plasma but with a low yield 
of 3-4%. A better yield might be obtained if, as was done by 
Gstlund-Lindqvist and Boberg (1977), several preparations from column 
I were combined for loading on to column II. Also, desalting with a 
small ion-exchange column would be an improvement on dialysis 
because of the surface active properties of the enzymes.
Both lipases, and especially LPL are extremely unstable in 
dilute solutions (Iverius and Ostlund-Lindqvist, 1976) and this was 
only partly overcome by inclusion of 2 0% glycerol in all buffers. 
H^)arin has been used by some workers as a stabilizing agent, and is 
also useful in deaggregating lipase after ammonium sulphate 
precipitation (Olivecrona, personal communication), but this could
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not be used since the lipase was to be used in clotting assays. Use 
of BSA as a 'carrier' for LPL has also been suggested (Olivecrona, 
as above). The purified enzyme was stored in 50% glycerol and 0.01 
M phosphate buffer (pH 7.4) both at +4°C and -20°C; there was no 
loss in activity over a two-month period at -20°C or for at least 10 
days at +4°C.
Protein in lipase samples run by SDS-PAGE could only be detec­
ted in those from column I, (normal heparin-Sepharose), where the MW 
of the major band from both LPL and HTGL preparations was 69,000- 
70,000. The detected protein may be At III however, since its conta­
mination of these samples is both possible in HTGL and likely in 
LPL.
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ŒAPTER 4
RELEASE OF LIPASES IN VIVO
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4.1 INTRODUCTION
Most of the studies on the lipase-releasing activity of GAGs 
have been carried out using heparin and there have only been limited 
reports of the use of other sulphated polysaccharides (Bengtsson et 
al., 1980; Casu et al., 1983). The work described in this Chapter 
investigates the effect of a number of different GAGs and of par­
tially synthetic heparin analogues on lipase release in rats under 
controlled conditions. Dose and time related studies of lipase 
release were carried out.
4.2 MATERIALS AND METHODS
4.2.1 Polysaccharides used for injection
Physicochemical parameters are given in Table 1 determined as 
in Casu et al. (1983).
Heparin I Prepared from porcine mucosa. A significant amount 
of free NH2 groups are detectable by NMR, so it is partially 
N-desulphated (probably a result of it being subjected to acid pH 
during preparation). Supplied by Bioiberica, Barcelona, Spain 
(Batch F4).
Heparin II Prepared from porcine duodenum. Supplied by Crinos 
SpA, Milan, Italy. (PD in Casu et al., 1983).
Heparin III A mucosal heparin (sodium salt). Supplied by Leo 
Laboratories, Princes Risborough, Bucks., U.K. (Batch H 64578).
Depolymerized heparin (IJMW heparin) A mucosal heparin treated 
by partial nitrous acid degradation. Supplied by Riker Laboratories 
Ltd., Loughborough, Leics., U.K. (Batch P2658).
Heparan sulphates HSI and HSII Prepared by E.A. Johnson as 
described in Casu et al. (1983) (where they are termed HSI and 
HSIIA,respectively) from a pig mucosal fraction supplied by
91 8.
TABLE 1: Physicochemical parameters of the polysaccharides injected
Mean
MW
Sulphate
(meq/g)
*Ratio
carboxylate
Heparin I 12,500 3.66 2 . 1 1
Heparin II 15,000 J..43 2.15
LMW heparin 5,500 3.44' 2 . 0
HSI 2 0 , 0 0 0 1.94 1 . 0
HSII 7,500 3.03 1.67
SP54 3 , 0 0 0 5.48 no carboxyl groups
SSHA 8 , 0 0 0 4.22 2.75
DeS n.d. 2.03 1.05
* residues per disaccharide 
n.d. values not determined
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Laboratori Derivati Organic!, Milan, Italy.
Sodium pentosan polysulphate (SP54) A semi-synthetic polymer 
prepared from vegetable raw materials. It is composed of 6-D- 
xylopyranose pentose base units, linked (1-^4). Supplied by 
Benechemie, Munich, West Germany (see Fig. 1).
Semi-synthetic heparin analogue (SSHA) An artificially sul­
phated bovine chondroitin. The SO4 groups are thought to attach 
mainly to the 6 -carbon of the galactosamine residues. Supplied by 
Luitpold-Werk, Munich, West (Germany (Eleparon M705A).
Dermatan sulphate Prepared by E.A. Johnson from porcine 
mucosal GAGs supplied by Laboratori Derivati Organic!, Milan, Italy. 
Other materials
Trisodium citrate BDH Chemicals Ltd., Poole, Dorset, U.K.
Diethyl ether (containing pyrogallol as antioxidant). BDH 
Chemicals.
Hypnorm (Janssen) (Grown (Chemical Co. Ltd., Lamberhurst, Kent,
U.K.
Animals Male Sprague-Dawley rats were used throughout supplied 
by Olac 1976 Ltd., Bicester, Oxon., U.K. The rats were fed on R and 
M diet No. 1 (BP Nutrition) and water ad lib.
4.2.2 Preparation of the solutions for injection
The polysaccharides were made up from the solid in 0.15 M NaCI 
(with the exception of Heparin III, which is supplied as a solu­
tion). 1 2 % by weight was allowed for water in the sample (average 
loss on drying of stored samples). A range of doses was made up for 
each polysaccharide so that the same volume per kg could be injected 
into the rat irrespective of the dose.
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Fig 1 Structure of SP54
OSO,Na
OSClNa
OSOjNa
n=3 6
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4.2.3 Lipase release in the rat
i) Single time samples Rats of 200 ± 10 g were used without 
prior fasting. To avoid possible changes in lipase activity due to 
the diurnal rhythm of the rat, injections were always made between 
2-5 pm (see Footnote 1). The rats were anaesthetized with diethyl 
ether and the polysaccharide injected into the blood stream via a 
tail vein (0.1 ml second"^). Blood was sampled 10 mins. later by 
cardiac puncture using needles and syringes that had been rinsed 
through with 3.8% trisodium citrate, and mixed with a 10% volume of 
citrate in polycarbonate tubes. Samples were then kept at 4°C and 
the plasma separated by centrifugation at 48,500 g for 15 mins. on a 
Sorvall SS-22 rotor. Aliquoted plasma was tested fresh or snap- 
frozen in a dry ice bath, and stored at -20°C. Control injections 
of 0.15 M saline were included in each batch of rats.
ii) Time course Larger rats of 310-475 g were used to allow 
several blood samples to be taken. The animals were anaesthetized 
with an intra-muscular injection of Hypnom (Janssen) (0.1 ml/100 
g). The neck area was exposed and either jugular vein used for 
administration of the polysaccharide and for blood sampling. In 
both cases the needle was passed through the overlying muscle to 
prevent bleeding from the vein. A pre-injection blood sample of
0 .2 -0 .5 ml was taken and further samples taken at specified times 
after injection.
Footnote 1; Recent data presented by Jansen (1984) indicate that in 
the rat the amounts of heparin-releasable enzyme may vary noticeably 
in the afternoon and that the morning may thus be a better time to 
obtain PHP samples.
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Before the experiment, known blood volumes had been carefully 
weighed to calculate a conversion factor for blood weight to volume. 
This enabled quick estimation of blood sample volumes by weighing, 
and so the volume of citrate solution to be added.
4.2.4 Lipase assays
Lipase activity was assayed on fresh plasma by the NES assay 
using 1 0 min. incubation times and samples volumes of 30 yl. 50 yl 
of plasma sairples that had been frozen were also tested in the 
Intralipid assay using 20 min. incubation times.
4.3 RESULTS
4.3.1 Control injections
Normal saline (0.1 ml/kg) was injected into rats and blood 
taken after 10 mins. as for test samples. A low level of lipase was 
measured, with no differences found between different rat batches. 
The total lipase activity detectable in control plasmas was 1.3 
mU/ml (n = 20) and that of HTGL only 1.1 mU/ml (n = 10).
4.3.2 Effect of anaesthetic on lipase release
Ether stress has been reported (Jansen, 1984) to decrease HTGL 
activity releasable by heparin six hours after the use of ether as 
anaesthetic. In order to determine whether ether stress affects the 
release of lipase within the time scale used in these experiments, 
male rats were injected with identical doses of heparin with and 
without the use of ether. Blood was taken after 10 mins. in the 
normal way using ether anaesthesia. No significant differences were 
found in the lipase activities of plasmas from the two sets of rats 
(results not shown).
4.3.3 Effect of freezing on lipase activity
The effect on PHP lipase activity of freezing and thawing was
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tested. PHP aliquots were either kept at 4°C, or quickly frozen and 
re-thawed, then the two sanples assayed. No differences were found 
in the lipase activity measured (results not shown).
4.3.4 Lipase activities 10 minutes post-injection
The results quoted for total, HTGL and LPL activities are those 
calculated from use in the NES assay of low salt substrate, high 
salt substrate and the difference of these two respectively, as des­
cribed in Chapter 2. The limitations of these distinctions should 
be borne in mind.
As shown in Figures 2-4, the polysaccharides used for injec­
tions can be divided into four major groups based on their dose- 
response curves. These four groups are:-
1. The heparins
2. The heparin analogues, SP54 and SSHA
3. LMW heparin and HSII
4. DeS and HSI
The highest release at all doses was achieved by the three 
heparins, with a peak total lipase of approximately 300 mU/ml at 2.0 
mg/kg (Fig. 2). The analogues gave low release up to 0.5 mg/kg, then 
the total activity rose to a peak at 2.0 - 4.0 mg/kg with 180 mU/ml.
This is approximately 60% of that of the heparin peak. The U4W
heparin produced a dose response curve very similar to that for HSII. 
Like the analogues they gave poor release at low doses (only approx. 
30 mU/ml at 0.5 mg/kg compared with approx. 150 mU/ml for the 
heparins at this dose), but a steady increase approaching a plateau 
at 8.0 mg/kg gave a value 70% of that of the heparin peak, at around 
200 mU/ml.
DeS and HSI both gave low release. At doses up to 1.0 mg/kg.
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DeS apparently released no lipase additional to that measurable in 
control plasmas (see Section 3.1 of this Chapter), but a low and 
similar level was released by 4.0 and 8.0 mg/kg. In contrast to 
this, the HSI shows more definite signs of release increasing 
with dose from 0.5 through to 8.0 mg/kg, but even at this highest 
dose, the activity is only 5% of the heparin maximum.
The general order of effectiveness of the polysaccharides in 
releasing HTGL is similar to that of total lipase, but there are 
greater similarities of the peak levels and less changes with dose 
(see Fig. 3). The heparins are again the best releasers, with peak 
values of approximately 110 mU/ml, SSHA and LMW heparin reach a peak 
at 4.0 mg/kg with 70 mU/ml, whereas the activity from the post-SP54 
and HSII plasmas still appears to be rising at 8.0 mg/kg. It is 
uncertain whether this latter difference is significant.
Figure 4 illustrates the release of LPL, and shows more clearly 
than total lipase release that the major lipase-releasing polysac­
charides studied here can be separated into three groups. The peak 
of lipase release by both the heparins and the analogues is at 2 . 0  
mg/kg, with the activity of the analogues 50% of that of the 
heparins. LMW heparin and HSII again show a high threshold of 
release, with the shape of the dose-release curve roughly running 
parallel to that of the heparin curve.
The low activity released by HSI appears to be equally divided 
between LPL and HTGL, whereas that released by DeS appears to be 
mainly HTGL.
The peak LPL and HTGL activities released by the different poly­
saccharides are compared in Table 2. All the HTGL peaks are close 
to 100 mU/ml (± 13). However, there is a clear distinction in
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TABLE 2: Peak lipase activities released by sulphated 
polysaccharides by i.v. injection
Enzymic activity 
mU/ml
HTGL LPL
Heparin I 116 2 2 0
Heparin II 108 196
I>1W heparin 90 > 136*
HSII > 8 6 * > 129*
SP54 > 98* 1 0 1
SSHA 83 1 1 2
For dose at peak, see Figures 3 and 4
* Indicates lipase activity at the highest dose given 
(8 . 0  mg/kg). In all these cases, the lipase level 
was approaching a plateau.
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release of LPL between the high level from that of the two heparins 
(at 200 mU/ml) and that of the other four polysaccharides. Of these 
latter, the LMW heparin and HSII are the more potent LPL releasers, 
with a peak value of around 130 mU/ml canpared with the analogues 
which released an average of 105 mU/ml.
In all three lipase activities determined (that is, total,
'HTGL only' and 'LPL only') an increase of dose above that required 
to give peak release resulted in lower measured activity (see Figs. 
2-4).
Plasma lipase activities were also measured using the Intra­
lipid assay. The dose-response curves thus obtained (Fig. 5) were 
of a similar shape to those from use of the high salt substrate of 
the NES assay (Fig. 3), although with higher calculated activities, 
as is usual with Intralipid. Both substrates are stabilized with 
phosphatidylcholine, with all that this means in the relative 
neasurement of the two lipases (see Ch. 2) but, since Intralipid has 
been reported to be a much better substrate for LPL than for HTGL, 
it is surprising that the activity curves do not fit in closer with 
calculated NES LPL measurements.
The tables of values relating to Figures 2-4 are given in 
Appendix VI. The lipase levels released at a single dose (0.5 
nq/kg) are compared with the anticoagulant activity of the poly­
saccharides (as determined by the in vitro APTT and anti-Xa assays) 
in Table 3. These figures show, as discussed in Chapter 1, that 
different sets of physicochemical parameters are important in 
determining the two activities of the polysaccharides.
4.3.5 Time course of lipase
Polysaccharides were chosen out of the group studied previ-
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TABLE 3: Comparison of anticoagulant and lipase-releasing 
activities of the tested polysaccharides
In vitro Post-injection
anticoagulant lipolytic
activity activity
APTT* Anti-Xa* LPL HTGL
(u/mg) (mU/ml)**
Heparin I 187 160 98 38
Heparin II 175 170 76 49
LMW heparin 25 118 17 14
HSI 4 10 < 1  < 2
HSII 34 8 8 1 0 2 0
SP54 18 6 34 18
SSHA 16 <5 40 24
* Determined as in Casu et al. (1983)
** PHP activity 10 mins. an ter injection of 0.5 mg/kg
98
ously: a 'normal' heparin (Heparin 1), IMW heparin, HSII and the two 
analogues. Since HSI and DeS released such low levels of lipase, 
these were not studied. Doses were selected to give approximately 
the same level of release.
(Generally, both enzymes were released quickly and cleared in an 
exponential manner after all the polysaccharides tested. HTGL 
release (Fig. 7) was complete within 5.0-7.5 mins. after all polysac­
charide injections. LPL release (Fig. 8 ) tended to be more gradual, 
most notably after SSHA and SP54 injections, where the levels of 
lipase reached a peak only after 15 mins. Once the peak was 
reached, the activity of both enzymes was cleared from the blood 
stream in a similar way independent of the polysaccharide used. 
However, by corparing peak values to the activity after 90 mins. 
(Table 4) it can be seen that LPL is cleared quicker than HTGL.
4.4 DISCUSSION
4.4.1 Lipase-releasing activity of different polysaccharides
The release of HTGL and LPL by different polysaccharides has 
been compared. It appears that the release of HTGL is less specific 
than that of LPL, and much of the following discussion will thus 
apply more to LPL than to HTGL.
Corparison of the physicochemical parameters (Table 1) and the 
peak lipase results (Table 3) shows that there is strong correlation 
between sulphate content and lipase release in that all good 
releasers have > 3.00 meq sulphate/g. This is not, however, a 
quantitative correlation like that described for a group of heparins 
and heparans by Casu et al. (1983).
MW is also important in determining lipase-releasing ability, 
as shown by the LMW heparin which gave reduced release of both
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lipases, although its sulphate content is similar to that of 
the heparins. Clarke et al. (1983) have suggested that a minimum 
GAG MW of 10,000 daltons is necessary for strong binding of sites 
present on both LPL subunits.
The ' balance ' of MW and sulphation is shown by the similar dose- 
response curves obtained with HSU and IMW heparin. This curve is 
of a similar basic shape to that of the heparins, with the lipase 
levels reduced at all doses. It can be assumed that heparins with 
intermediate MWs and/or sulphation would also give intermediate 
shaped curves. There are great differences in the two heparan sul­
phates tested in their sulphation, MW and the lipase activity 
released. The high MW of HSI has not compensated for its low sul­
phation. In terms of sulphation and MW, heparans tend to fall into 
two widely differing groups of which these two are examples 
(Johnson, 1984).
It has been reported (Bengtsson et al., 1980) that free amino 
groups impede the interaction between heparin and LPL, but their 
presence on Heparin I does not appear to affect its lipase-releasing 
ability as compared with Heparin II.
The results from injections of SSHA and SP54 suggest that 
factors other than sulphation and MW are also important for lipase 
release. These two semi-synthetic analogues have the highest sul­
phate contents of this group of polysaccharides, and whilst the MW 
of SP54 is low, that of SSHA is close to that of HSU, yet it is not 
able to release as much LPL as the heparan. The dose-response 
curves of the analogues are also distinctly different from those of 
the natural GAGs tested.
As mentioned in Chapter 1 (Section 4) it has been suggested
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that the release of lipase by sulphated polysaccharides from its 
site on the endothelium is mediated in one of two ways: by competi­
tion with membrane-bound HS for binding of the LPL, or by induction 
of a conformational change of the LPL (Olivecrona et al., 1977).
The former view is now generally accepted (see '1' in Fig. 9). 
Results from cultured endothelial cells have indicated that whilst 
scxne of the HS proteoglycans are firmly embedded in the membrane 
core protein, others can be displaced from the surface by the addi­
tion of heparin (see Williams et al., 1983). There is an excess of 
HS chains over LPL molecules bound on porcine endothelium (HSrLPL, 
4:1) (Williams et al., 1983), and it is possible that all the LPL is 
attached via the covalently-bound HS. If, however, LPL is bound by 
both HS populations, there is the possibility of two 'sites' of 
release. In addition to compétition by the injected polysaccharide 
with the HS for the LPL GAG-binding site (as already described), it 
could also compete at the membrane protein (see '2' on Fig. 9).
There is no published evidence that the structure of the covalently 
bound HS from the electrostatically bound one, but if it is, then 
this would mean that there are effectively three sites of release, 
which could have different affinities for the injected polysac­
charides.
The decrease in enzyme activity in the dose-response curves at 
doses above the plateau has also been noted by other workers (R. 
Pescador, personal ccmmunication). It is unlikely that the 'excess' 
polysaccharide is affecting the clearance rate of the lipase 
(Wallinder et al., 1979), and probably affects instead the assay 
measurements of activity. Work with purified milk LPL has shown 
that heparin does not affect the enzyme's catalytic activity under
lOOa
Fig 9 Possible sites of release of lipase by 
suiphated polysaccharides from the endothelium
LPL
GAG-binding site
o
101
otherwise optimal conditions (Olivecrona et al., 1977). However, 
the effect in crude systems such as that using skinwed milk (Iverius 
et al., 1972) can be substantial, with activation at low and inhi­
bition at high heparin concentrations. The highest dose injected in 
the present study (8 . 0  ng/kg) would give a final assay concentration 
of the order of 30 yg/ml,* a level which was shown to inhibit 
skimmed milk LPL (Iverius et al., 1972). This could be checked by 
the addition of heparin and the other polysaccharides to the assay 
substrate to test PHP obtained with low doses.
Iverius et al. (1972) also showed that the inclusion of dif­
ferent GAGs has different effects on the activity of skimmed milk 
LPL. It is possible that conplex activation/inhibition effects are 
influencing the dose-response curves. HTGL is measured in high salt 
conditions where there would be reduced interaction between lipase 
and polysaccharide, and this may partially explain the relative 
closeness of the dose-response curves (Fig. 3) compared with LPL 
(Fig. 4).
4.4.2 Time course
It is known that the presence of heparin affects LPL uptake by 
the liver (Wallinder et al., 1979), and there have been reports (De 
Swart et al., 1980) that the clearance of both LPL and HTGL activi­
ties varies with the heparin used. Time course studies on selected 
polysaccharides were carried out to investigate whether there were 
significant differences in the group studied.
In agreement with published results (Huttenen et al., 1975) LPL
* Based on: rat blood volume of 64 ml/kg, packed red blood cell 
volume of 4 5 %, use of 30 yl enzyme and 2 0 0  yl substrate in the 
assay.
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is found to be released more slowly and cleared more quickly than 
HTGL. The analogues differ from the heparins and HS by releasing 
LPL more slowly, but the subsequent clearance is the same. Similar 
HTGL time courses in all respects were achieved with different 
polysaccharides. De Swart et al. (1980) compared the time course of N  
the enzymes with that of the heparins used and on the basis of their 
results suggested that the removal of HTGL especially is determined 
by the polysaccharide used for injection. The current work provides 
no support for this (at least for the polysaccharides studied).
A fuller investigation of lipase time courses could be carried 
out, using a wider series of polysaccharides tested over a more 
extensive range of doses. The rates of clearance of LPL from the 
circulation appears to be largely independent of its levels present 
over a very wide range (Wallinder et al., 1979). These workers 
found that purified LPL injected at a level 100 times that normally 
present in PHP, was cleared from the circulation by the liver at the 
same rate as much smaller doses. Heparin injected prior to the LPL 
slowed down clearance substantially. No such studies (with purified 
enzyme) have been carried out with HTGL however. Huttenen et al.
(1975) found that clearance of HTGL was slower after high heparin 
doses, suggesting that uptake by the liver is affected by the GAG.
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CHAPTER 5
EFFECT OF DILUTION OF POST-HEPARIN PLASMA ON THE ENZYMIC 
ACTIVITY MEASURED IN THE NILSSON-EHLE AND SCHOTZ LIPASE ASSAY
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5.1 INTRODUCTION
Because of the problems encountered in achieving intra-assay 
reproducibility of the modified NES lipase assay (see Ch. 2). the 
possibility of using a series of PHP dilutions to provide a 
'standard curve' was investigated. Preliminary studies of diluting 
PHP with either saline/buffer or pre-injection (normal) plasma, 
gave the unforeseen result of significant deviation from the expec­
ted value. Total and HTGL activities were differently affected by 
the two diluents. At this stage a thorough re-appraisal of the 
literature was undertaken.
Previous work on the effect of a range of serum concentrations 
on LPL and HTGL activities has been done mainly on either the 
enzymes purified by heparin-Sepharose or as whole PHP with only 
total lipase measurements (with no attempt at differentiation). As 
discussed in Chapter 1 (section 2.5.Ü), it is well accepted that 
LPL requires apo CII from serum for full activity under sub-optimal 
conditions. However, it has also been reported that assaying LPL 
in the presence of serum concentrations greater than that needed 
for maximal stimulation (generally 15-25% of total substrate 
voluiæ) may lead to inhibition of both the activity in PHP 
(Huttenen et al., 1975) and of the purified enzyme (Hernail et al., 
1975; Feliste et cil., 1982). The extent of this may vary between 
serum batches (Baginsky, 1981). The apo Cl and CIII components of 
CMs and VLDL appear to be responsible for this inhibition (Chung 
and Scanu, 1977; Oæn and McIntyre, 1982). There have also been 
reports (Baginsky and Brown, 1977) that incubation at 25°C of puri­
fied LPL diluted with buffer may lead to aggregation with conse­
quent loss of activity.
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The wide range of reported results on the effect of serum ccm- 
ponents on the activity of purified HTGL has also been covered in 
Chapter 1. This disparity is itself worthy of note. There is dis­
agreement both as to whether serum stimulates or inhibits HTGL 
activity at low concentrations (see Ch. 1) (all agree that it inhi­
bits at high concentrations) and also to which serum corponents are 
responsible. Apo A has been implicated as the activator of HTGL at 
low concentrations (Jahn et al., 1983) and as the inhibitor by 
other workers (Haberbosch et al., 1984) in addition to apo Cl and 
III (Jahn et al., 1984; Bengtsson and Olivecrona, 1980b). Huttenen 
et al., (1975), testing the effect of serum on the activity of HTGL 
in v^ole PHP, reported inhibition with serum levels > 10% of the 
total substrate volume.
It was considered that further study of the effect of dilution 
of PHP lipases on their assay measurements was warranted, to 
clarify the position under the specific conditions used.
5.2 MATERIALS
5.2.1 Source of plasma
i) PHP Rat PHPs (prepared from blood as described in Ch. 4) 
of mid range lipase activity (i.e. total activity 70-120 mU/ml) 
were generally selected for use. A record was kept of the heparin 
type and dose used for injection. These included Leo heparin 
(heparin III in Ch. 6 ), Crinos F5, Bioiberica heparin (heparin I in 
Ch. 6 ) and LMW heparin.
ii) Diluting plasma Normal blood samples were taken from rats 
with or without a prior injection of saline. Sane tests for compari­
son were done using serum.
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Buffer
The buffer used for dilution was 0.2 M tris/HCl (pH 8.3) con­
taining 2 0 mg albumin/ml, as was used for preparation of the assay 
substrate.
5.3 RESULTS
5.3.1 (General Findings
PHPs were mixed with either plasma or buffer to give a final 
PHP volume of 50% or 25% (1 in 2 and 1 in 4 dilution respectively). 
Aliquots of each mixture were assayed by the NES lipase assay within 
15 mins. of mixing, alongside undiluted PHP. As mentioned in the 
Introduction, the first results appeared to follow a pattern. The 
effect of the two diluents on LPL and HTGL activity can be 
sumnarized as:-
HTGL decreases v^en diluted with plasma
activity increases when diluted with buffer
LPL increases when diluted with plasma
activity decreases when diluted with buffer
However, as more tests were done, it became apparent that many 
results did not fit this pattern and there were great differences 
in the direction and extent of the effect on measured activity. As 
an example of this variation. Figure 1 shows the effect of buffer 
on HTGL activity using the results from 15 experiments using dif­
ferent PHPs. The activity values from the assays were adjusted for 
dilution and compared to the neat plasma which was given a value of 
100%. Figure 1 illustrates the great range of responses obtained 
(total and LPL only results are not shown). It should be noted, 
however, that in any given test the direction of the effect on 
activity was consistent, so that with increasing dilution the
I06a
Fig 1 Effect of dilution of PHP with buffer on 
theHTGLactivity measured in the NES assay
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increase (or decrease) in activity was more marked. In some tests 
there was no significant change. Duplicates were within the 
normal variation of the assay (< 4%). There was no difference 
between the effect of plasma and serum prepared from the same blood 
sanple, or between saline and buffer, when used to dilute the same 
PHP. Various possible reasons for the variability of the results 
were investigated.
5.3.2 Test of Possible Sources of Variability
i) Effect of the heparin used to release lipase
Sets of PHPs collected after injection of different heparin 
batches were conpared under otherwise identical conditions. No 
significant differences were found on the effect of dilution. A 
review of the effect on all the PHPs studied showed up no corre­
lation with the heparin type or dose. Similarly, there did not 
appear to be any correlation between the PHP lipase levels and the 
result obtained, within the activity range that was studied 
(results not shown).
ii) Effect of the time of pre-incubation
The time of pre-incubation of FHP with diluent had no effect 
on the lipase activity of LPL or HTGL measurable in this assay.
iii) Effect of seasonal variation
The effect of dilution of PHPs collected from rats in June and 
November after an identical heparin dose was compared, using the 
sane control plasma and buffer batch. No difference was found in 
the response (results not shown).
5.3.3 Effect of dilution of purified lipase
HTGL purified by single heparin-Sepharose chromatography (as 
described in Ch. 3, section 3.4 (i)) was diluted with plasma and
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buffer and tested as described for PHP. The results in Figure 2 
show that whilst there was little change after dilution with buffer, 
there was increasingly reduced activity when diluted with plasma. 
Although the results of just a single experiment are reported here, 
confirmation of this effect came from assays run during the purifica­
tion procedures, where activities were always lower in the presence 
of plasma than with saline.
5.4 DISCUSSION
Whilst the effects of serum on the activity of purified tri­
glycerides have been well-studied, it was thought necessary to con­
tinue investigation of the discrepancies found on dilution of full 
FHP prior to assay. The results in this chapter have shown that 
pre-incubation of PHP with plasma and buffer can affect the measured 
activity in this assay but the direction of this effect appears to 
be unpredictable. Different results are obtained dependent on the 
PHP and/or the plasma diluent used, both as to the extent and direc­
tion of the change, and to whether LPL and HTGL are similarly or 
differently affected.
Since the effect of diluents on purified HTGL is in line with 
results of other workers, it is difficult to attribute these irregu­
larities to some peculiarity of the assay used (modified NES assay). 
No simple explanation can be offered for them - no correlation could 
be made with the heparin type and dose used, to the level of enzymic 
activity of the PHP or to the time of pre-incubation. It seems 
likely that the differences are due to variations in the plasma can- 
position, especially apoproteins, although it should be noted that 
some workers (Kubo et al., 1983) have found that, in its effect on 
HTGL, the best equivalent to serum is a mixture of ultracentri-
I08a
Fig 2 Effect of dilution of purified HTGL on 
the activity measured in the NES assay
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fugally-separated HDL and d = 1.21 fractions (the latter containing 
most of the serum proteins ). This indicates that the lipases may 
also be affected by proteins other than the apoproteins.
As would be expected frcm a laboratory animal such as the rat, 
kept under controlled conditions, the time of the year the PHP was 
taken could not be shown to affect the result. However, the time of 
day of collection of PHP and of diluting plasma was not noted, and 
this may be of importance; it has been reported that PHP lipase acti­
vity varies with the time of day (Jansen, 1984, see Footnote 1, 
p. 8 8 ). The proportion of the apo C and A ccxrponents present in the 
plasma sairples will not necessarily be constant and may vary both 
with the time after feeding and with the diurnal rhythm of the 
animal. This would result in LPL and HTGL activities being differ­
ently affected - the complications of the inhibitors and activators
of the enzymes have been suggested by the results of Feliste et al.
(1982), using irradiated rabbit lipoprotein fractions.
As well as the effect of the apoproteins, inhibition may be 
caused by conpetition of lipoprotein with the assay substrate.
This should show up particularly with short assay times, and could 
provide an explanation for the observed variations despite the fact 
that the final serum/plasma volume in the substrate is not altered.
However, the finding that the time of pre-incubation does not alter
the effect gives no support to this hypothesis.
The percentage 'HTGL' and composition of this lipase fraction 
may have a bearing on the results. The salt-resistant lipases 
found, in addition to that from the liver, also to be released by 
heparin into PHP from bovine and rat adrenals and ovaries (Cordie 
et al., 1984) have been shown to react to a different degree to
110
serum inhibition, depending on tissue origin.
This work has left many questions unanswered as to the reason 
for the effect of pre-dilution on PHP lipases. However, it may 
serve to caution against over-simplified interpretation of lipase 
assay results. Measured enzyme activity may not always be directly 
proportional to the amount of enzyme present because of variations 
in other interacting components from one sample to another.
Ill
CHAPTER 6
RELEASE OF LIPASE FROM ISOLATED TISSUES
112
6 .1 INTRODUCTION
In order to reduce the number of experimental animals used to 
test the effectiveness of various suiphated polysaccharides in 
releasing lipases, the suitability of using adipose tissue prepara­
tions was investigated. This would provide a back-up to the results 
of post-injection plasmas on LPL release in vivo, and if enough 
tissue could be prepared in one batch the different G^Gs and doses 
could be tested together without the risk of animal variability.
Isolated mammalian tissues have been widely used, in addition 
to PHP and milk, to provide a source of triglyceride lipases. The 
enzymes have either been released from perfused tissues, most 
conmonly of the liver, with heparin-containing buffer (Augustin and 
Greten, 1979a) or extracted (with or without the use of heparin) 
after treatment of the tissue. Adipose tissue has been used in one 
of three forms for the extraction of LPL; as tissue pieces, as 
aqueous homogenates, or as acetone-ether powders (Chilliard et al., 
1977). These methods have generally been used as the first step in 
the purification of the enzyme, but there have also been reports on 
the use of isolated tissue for clinical studies of LPL activities 
such as that of Lithell and Boberg (1977) on adipose tissue, or 
Reitman et al. (1982) on adipose tissue and muscle.
6.2 METHOD 1 - Incubation of tissue pieces
The stimulatory effect of heparin in releasing lipase in vitro 
from adipose tissue has previously been studied both as whole paired 
fat bodies (Salaman and Robinson, 1966) and tissue slices (La Rosa 
et al., 1973) from the rat, and as tissue pieces fran man and goat 
(Lithell and Boberg, 1977; Chilliard et al., 1977). This method is 
thought (Chilliard et al., 1977) selectively to release, during
113
short-term incubations (30-60 mins.), the extra-adipocyte fraction 
of the LPL which is localized at the surface of the capillary lumen 
(see Footnote 1). In extended incubations of 3-5 hours however, 
surface LPL is replaced by newly- synthesized enzyme from inside the 
cell, as judged by the inhibitory effect of puromycin (a protein syn­
thesis inhibitor). Furthermore, adequate oxygenation of the tissue 
was required for continued release of the enzyme (Wing et al., 1966), 
In this study, adipose tissue pieces were used to oonpare in 
vitro release of LPL by heparin with other suiphated polysacchar­
ides. Short incubation times of one hour were used, so that only 
extra-adipocyte LPL should be released. Oxygen was not supplied.
The incubation medium used was that suggested by J. Stocks (personal 
communication). In preliminary studies on human and rat adipose 
tissue (unpublished, St. Bartholomew's Hospital, London), Stocks 
obtained both a graded response with dose, and differences in the 
level when using different polysaccharides to release LPL.
6.2.1 Preparation of tissue
Male Sprague-Dawley rats weighing 300-500 g were killed by a 
blow on the head and the fat bodies immediately removed and placed 
in ice-cold physiological saline (0.145M NaCl). The fat was blotted 
dry then cut into small pieces of 5-10 mg and about 100 (± 0.1) mg 
weighed accurately into tubes. The samples were kept on ice until
Footnote 1: 'Hormone-sensitive lipase' (responsible for intra­
cellular TG breakdown during fat mobilization) is also present in 
adipose tissue could also be released under these conditions 
(e.g. through cell damage). However, this enzyme would not be 
active at the pH used for the LPL assays (Chilliard et al., 1977).
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used (within 2 hours of being removed from the rat).
6.2.2 Incubation medium 
Materials
Earles balanced salt solution (BSS) x 10 (without phenol red,
without NaHCOg) (frcm Media roan, NIBSC)
4.2% (w/v) NaHOOi BDH Chemicals Ltd.
Bovine serum albumin (Fraction V) BfH Chanicals Ltd.
Heparin 1,000 u/ml, 'Pularin', Duncan Flockart, U.K.
SSHA (see Ch. 4).
Heparan sulphate (HSII - see Ch. 4).
Method of Preparation
5 ml Earles BSS (x 10) were mixed with 2.5 ml NaHOOg, and water 
added to 30 ml. After addition of 1.5 g albumin, the volume was 
made up to 5 ml with water. This medium was used in control incu­
bations , with 1 or 2 u/ml heparin added for the tests. In further
tests, SSHA and HSII were added to give similar concentrations to
these (i.e. 6.5 and 13.0 yg/ml respectively) based on an approxi­
mated heparin potency of 150 u/mg.
6.2.3 Incubation of tissue
At zero time 1 ml of medium was added to the tissue (n = 3 or 
4) and shaken well to ensure adequate suspension of tissue pieces in 
the medium. The suspension was then incubated in a shaking water 
bath for 1 hour at 37°C.
1 0 0  yl of each incubation mixture were tested in duplicate in 
the NES assay (low salt substrate only, since only LPL will be 
present). The results were calculated to give mU released g~l fat 
in 1 hour.
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6.2.4 Results
Different tissues gave very different levels of activity and 
also varied in their response to the two concentrations of heparin 
used. Results from two fats are shown in Figure 1.
With Fat No. 1 there was good release of LPL even in the 
absence of heparin (approx. 90 mU LPL/ml g“l fat) and a graded 
increase with heparin concentration of 30% and 100% for 1 u/ml and 2 
u/ml respectively. Fat No. 2 gave much lower release overall (blank 
of approx. 20 mU/ml g“l fat) with an approximate doubling of acti­
vity with both 1 u/ml and 2 u/ml heparin. Figure 2 shows the effect 
of the use of different suiphated polysaccharides. It was found 
that HS was not as effective as heparin in releasing lipase under 
these conditions (approx. 70% increase for both concentrations 
conpared with 100% for heparin) but better than SSHA, which gave 
values not significantly different from those of the blank. It must 
be noted however, that the enzyme levels per tube for these 
incubations were very low.
6.2.5 Comments
The relatively high values of LPL activity obtained in the 
blank incubation (no heparin present) indicate that under these 
conditions a large proportion of the enzyme is released non-speci- 
fically from the tissue surface. This has also been reported by 
other workers using a similar method (Lithell and Boberg, 1977).
The great difference in the general levels obtained from incu­
bation of tissues from different animals emphasizes that direct com­
parisons can only be made from the tissue of one animal. The poor 
repoducibility between duplicate sanples is particularly evident 
with use of tissues that give low levels of release (e.g. Fat No. 2,
115a
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Fig. 1). Sources of variability would include how finely the tissue 
is cut and the amount of moisture left on the tissue by blotting 
before weighing. The surface area presented to the medium is 
crucial in determing lipase release, so the size of the tissue piece 
is inportant.
Because of the problems in reproducibility and the practical 
difficulties in handling wet adipose tissue, an alternative method 
was tried (Method 2).
6.3 METHOD 2 - Extraction of LPL from acetone-ether powders of 
adipose tissue
The technique of drying adipose tissue with acetone and ether 
frcm which LPL can then be extracted has been used frcm some of the 
earliest (Korn and Quigley, 1957) to some of the most recent work 
(Hansson et al., 1983). Extraction of LPL was commonly performed in 
the absence of heparin with NH4OH-NH4CI buffers (Korn and Quigley, 
1957; Homer, 1972), although other workers noted the increased 
yield obtained with the use of heparin (Chilliard et al., 1977; 
Bensadoun et al., 1974). The method followed here (Fielding, 1968) 
uses a Tris/HCl buffer and a heparin concentration lower than that 
of many workers. This was used because the aim of this study is to 
enable comparison of the lipase-releasing ability of different poly­
saccharides from the tissue rather than maximum yield.
A disadvantage of this method is that approximately 60% of the 
total activity is destroyed in the drying process (Fielding, 1968). 
In addition, both intra- and extra-adipocyte forms of the LPL enzyme 
are thought to be extractable after this treatment (Chilliard et 
al., 1977) and this may mean that there is a large degree of 
non-specific release, i.e. that occurring in the absence of heparin.
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However, there are indications (Horner, 1972) that specific release 
by heparin can still occur.
6.3.1 Preparation of tissue
The method used was based on that of Fielding (1968). Adipose 
tissue taken out of freshly-killed rats was at once placed into ice- 
cold 0.145 M NaCl (0.5 ml saline/g tissue). The mixture was homo­
genized in an overhead Silverson blender for 10 secs. The hono- 
genate was added to approximately 40 volumes of acetone:ether (2:1), 
and stirred for 1 hour at 4°C. It was then either spun at 7,000 g 
for 15 mins., or rapidly filtered on a Buchner. The precipitate was 
dried at 4°C under vacuum over phosphorus pentoxide to constant 
veight.
6.3.2 Incubation of tissue
Approximately 5 or 10 mg portions of the dried tissue were 
accurately weighed out and incubated with 0.5 or 1.0 ml respectively 
or 0.05 M Tris/HCl buffer (pH 8.1) containing heparin (1 u/ml) or 
other polysaccharides (equivalent weight 6.5 yg/ml). These were 
shaken at 4°C for set lengths of time, then briefly centrifuged and 
100 yl aliquots of the medium immediately tested in the NES lipase 
assay.
6.3.3 Results
Different tissue preparations gave one of two results. In 
approximately 50% of preparations the activity released was low (<
10 mU/ml per 10 mg dried tissue) and with these the inclusion of 
heparin in the incubation buffer had little or no effect on the 
activity (see Table la). Increasing incubation times to more than 
15 mins. ccmmonly led to a fall off in both sets of lipase activity 
(i.e. in the presence and absence of heparin). In the other tissue
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TABLE 1: Release of LPL from acetone-ether dried adipose tissues 
on incubation in the presence and absence of heparin
Incubation 
time (mins.)
Enzymic activity 
(a)*
Heparin 
Buffer (1 u/ml) 
only in buffer
mU/ml ( 1 0 mg)-l 
(b)*
Buffer
only
tissue
Heparin 
(1 u/ml) 
in buffer
1 0 . 0 ]2 . 1 20.4 23.2
1
10.3 1 2 . 2 19.2 23.9
8.4 9.7 25.5 30.7
5
9.3 1 1 . 8 24.1 30.5
10.4 9.8 2 0 . 6 31.7
15
9.9 7.6 23.6 34.9
9.0 8 . 0
30
7.9 8.5
7.2 8 . 0 2 2 . 1 27.3
60
7.4 7.8 20.5 27.3
a) and b) refer to different tissue preparations
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preparations however, the activity was approximately twice that of 
the first group, and in all such cases the presence of heparin in 
the incubation buffer gave a modest but definite increase in the 
enzymic activity measured (see Table lb). This increase was of the 
order of 25% after 5 mins., rising to 50% after 15 mins., then dec­
lining after 30-60 mins.
Polysaccharides other than heparin that are known to release 
the lipase to different extents in vivo were also incubated with the 
defatted tissue. The enzymic activities obtained after use of DeS 
and SP54 were low, and not significantly different from the blank 
value (results not shown).
6.3.4 Comments
Extraction of LPL from acetone-ether dried adipose tissue has 
been extensively used as an early step in the preparation of puri­
fied enzyme (Korn and Quigley, 1957; Havel et al., 1973; Bensadoun 
et al., 1974). It does not appear from the results reported here 
however, to be a method that can be used to quantify the lipase- 
releasing ability of different polysaccharides. In only half the 
tissue preparations did the presence of heparin result in additional 
LPL activity after incubation. This inconsistency of tissue res­
ponse (also found in Method 1), may be a result of real differences 
in tissue state from different rats, or to slight variation in the 
irethod of preparation, which has an effect both on overall enzyme 
activity and on how much can be released.
In those tissue preparations where heparin did increase acti­
vity on incubation, it is possible that heparin acted as a stabi­
lizer rather than an active releaser. A recent paper by Parkin et 
al. (1982) describes the fine sensitivity of LPL extracts from
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adipose tissue over a small range (0.05-1.0 u/ml) of heparin concen­
trations. The results (not shown) of a single experiment using 
Earles BSS and albumin medium (as used in Method 1) in place of 
Tris/HCl buffer support the importance of the stabilizing effect of 
heparin. In this test, the addition of heparin to the rædium made 
no difference to the enzymic activity measured after 2 0 mins.' incu­
bation, suggesting that the LPL was already well stabilized by the 
medium. However, other results (Table la) show that the released 
enzyme incubated for an hour at 4°C does not appear to be more 
stable in the presence than in the absence of heparin.
This method was not further considered for future use, both 
because of the variability of the results and because of the uncer­
tainty that heparin does actually act, under these conditions, to 
release the enzyme from its endothelial-bound site. Due to the 
inflammability of acetone and ether, the large voluires used make 
this an unsuitable method for routine use.
6.4 METHOD 4 - Adipose tissue hanoqenates
Preliminary studies were performed using adipose tissue homo- 
genates, in an attempt to circumvent some of the unreliability and 
unsuitability of the other two methods. In making a homogeneous 
mixture, it was hoped to eliminate some of the errors due to 
weighing problems of Method 1, whilst being a more physiological 
model than the acetone-dried tissue of Method 2. The preparation of 
large homogeneous batches, using adipose tissue from different rats, 
would allow many polysaccharide samples to be tested together.
6.4.1 Preparation of tissue
Adipose tissue was homogenized in 0.145 M NaCl (2 g tissue/ml 
saline) in a Silverson blender. 150 yl (approx. 150 mg) aliquots of
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the homogenate were dispensed with an automatic pipette into weighed 
tubes. These were incubated for 1 hour at 37°C in a shaking water 
bath, in 1 ml 0.05 M Tris/HCl (pH 8.1) with or without heparin (1 or 
2 u/ml).
6.4.2 Results and Comments
Figure 3 shows the results of the incubation in the presence 
and absence of heparin. Although these are definite increases in 
the presence of heparin, the lipase levels are very low.
6.5 CONCLUSIONS
It was desirable to have a usable in vitro model for LPL 
release, in order to reduce both the number of animals used in in 
vivo work and the risk of animal variability. Three methods of pre­
paring adipose tissue prior to inducing release with heparin were 
tried, but none was found to be satisfactory. The best results were 
obtained with incubation of tissue pieces, but even with this method 
the lipase levels released were generally low with relatively high 
blank values. There were also great differences between tissue 
batches, and difficulties in handling the tissue made it a cumber­
some method. Use of other polysaccharides showed up only general 
differences in their ability to release lipase.
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CHAPTER 7
the effect of LPL AND HTGL ON TEŒ ANTI-XA ACTIVITY OF PLASMA
12 2
7.1 INTRODUCTION
Several pieces of recent research have pointed to the possibi­
lity that the triglyceride lipases released by heparin and other 
polysaccharides have a direct or indirect effect on plasma coagula­
bility. The heparin analogues, SSHA and SP54, have virtually no 
anti-Xa activity in vitro, but there is enhanced activity present 
in ex vivo plasmas (Thomas et al., 1980; Fischer et al., 1982).
This suggests that some factor has been released into the blood.
The work described in this chapter was designed to test the hypo­
thesis that the increased anti-Xa activity of post-SSHA and -SP54 
plasmas is associated with the presence of LPL and/or HTGL, since 
both these analogues are potent releasers of the lipases. This was 
tested by the use of purified lipase enzymes (both from FHP and 
milk) in the anti-Xa clotting and amidolytic assays.
7.2 MATERIAIB AND METHODS
7.2.1 Source of LPL and HTGL
i) Post-heparin LPL and HTGL LPL and HTGL were purified by 
single heparin-Sepharose chromatography from rat PHP as described in 
Chuter 3 (Section 3.4.1).
ii) Milk LPL LPL was purified from skimmed bovine milk by 
heparin-Sepharose chromatography as described in Chapter 3. A 
sample of milk LPL was kindly provided by Dr. T. Olivecrona, Umeâ, 
Sveden.
7.2.2 Plasmas for Incubation
i) Human lipid-rich plasma Blood was collected from normal 
volunteers li hours after a fatty meal, and mixed 9:1 with 8.3% tri­
sodium citrate. Plasma was prepared by centrifugation at 48,000 g 
for 10 mins. and stored at -40°C until used.
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il) Normal human plasma Plasma from six donors was provided 
by the North London Blood Transfusion Centre, Edgware, Middx, 
(anticoagulant CPD and adenine) and the chylomicra were ranoved by 
centrifugation at 90,000 g for 90 mins.
iii) Lipoprotein-free plasma This was prepared (by Ms. E.
Gray, Division of Blood Products, NIBSC) frcm normal human plasma 
by density gradient ultracentrifugation at 2 0 0 , 0 0 0  g for 3 hours in 
a Sorvall TV-850 vertical rotor. It was dialysed overnight against
0.05 M Tris, 0.15 M NaCl (pH 7.4), and stored at -40°C until used.
7.2.3 Anti-Xa Clotting Assay
i) Principle of Assay This is a two-stage assay designed to 
test the effect of plasma (plus any additions) against one parti­
cular clotting factor. Test plasma is allowed to act against a 
precise amount of purified Factor Xa for a set length of time. The 
amount of Factor Xa remaining is then determined by addition to 
Factor Xa-deficient plasma. In this assay, the higher the anti-Xa 
activity in the test plasma, the longer the clotting time,
ii) Reagents
Calcium chloride
50 mM (supplied as 1 M solution, BDH Chemicals, Poole, Dorset,
U.K. )
CAG buffer, pH 7.4
150 volumes glyoxaline buffer (0.05 M glyoxaline, 0.1 M NaCl,
pH 7.4)
30 volumes 3.8% trisodium citrate (BDH Chemicals)
1 volume 20% (w/v) bovine albumin. Fraction V (Sigma, Poole,
Dorset, U.K.)
Factor X-deficient plasma Diagnostic Reagents Ltd., Thame, Oxon
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Factor Xa (bovine) Diagnostic Reagents Ltd,
Phospholipid (bovine brain) NIBSC reagent 79/508 
BHA water
2 mM butylated hydroxyanisole (BDH Chemicals) in ethanol, 
diluted 1 in 1 0 0 0  in distilled water.
BHA saline
2 mM butylated hydroxyanisole in ethanol, diluted 1 in 10 with 
distilled water, then 1 in 100 in 0.145 M NaCl.
The Factor Xa is made up in 0.5 ml distilled water, then
diluted 1:100 or 1:1000 in CAG buffer. The freeze-dried phospho­
lipid is reconstituted with 1 ml BEîA water then diluted 1 in 400 
with BHA saline, and mixed 1:1 with Factor X-deficient plasma 
(reconstituted as directed by the manufacturers, with distilled 
water ) to prepare the ' substrate mix '.
iii) Method
1. All reagents are preincubated at 37°C.
2. Prepare 100 yl calcium chloride in clotting tubes.
3. Mix 300 yl Factor Xa with 100 yl of the plasma + lipase 
mixture. Start a clock at the same time.
4. After 1 min. 45 secs, subsample 100 yl from the above and
add to the calcium chloride.
5. At exactly 2 mins. add 200 yl 'substrate mix' and measure 
clotting time from this final addition.
The tests were performed using semi-automated coagulometers 
(Burkard Scientific, Uxbridge, Middx., U.K.)
7.2.4 Amidolytic Assay
i) Principle of assay Factor Xa catalyzes the hydrolysis of 
p-nitroaniline from the substrate Bz-Ile-Glu-Gly-Arg-pNA (S-2222).
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This release is measured spectrophotcmetrically at 405 nm, and the 
rate of release can be related to the concentration of Factor Xa 
present.
ii) Reagents
Bovine Factor Xa Diagnostic Reagents Ltd., Thame, Oxon, U.K. 
Chromogenic substrate, S-2222 Kabi Diagnostica AB, Stockholm,
S\æden
CAG buffer (pH 7.4) (see anti-Xa clotting assay)
EDTA/tris buffer (pH 8.4) 0.05 M Tris, 7.5 irM EDTA, 0.175 M NaCl 
The Factor Xa is made up as directed by the manufacturer with
0.5 ml distilled water, and then diluted 1:4 with CAG buffer. The 
S-2222 is made up to 4 mM with distilled water, diluted to 0.4 mM 
with distilled water then mixed 1:1 with EDTA/Tris buffer.
Incubation mixtures of enzyme and lipid-rich plasma were made 
up as described for the clotting assays (in Section 7.3.1).
iii) Method
1. All reagents are preincubated at 37°C.
2. At zero time add 0.1 ml plasma + lipase mixture 0.3 ml
Factor Xa. Incubate at 37°C for 2 mins.
3. Add 1 ml of S-2222/buffer mixture, mix thoroughly and 
iiriædiately measure absorbance at 405 nm.
7.3 RESULTS
7.3.1 Effect of lipases on plasma anti-Xa clotting activity in the 
absence of heparin 
Human lipid-rich plasma was mixed with LPL or HIGL to give 
lipase activities similar to those achieved in man after i.v. injec­
tion of 1,000-2,000 U heparin (i.e. 30-50 mU/ml as tested by the
modified NES assay. Ch. 2), and incubated at 37°C for the time indi-
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cated under each section. Incubation mixtures were made up, in the 
order given, as follows:
8 volumes human lipid-rich plasma 
+
1 volume LPL or HTGL (approx. 350 mU/ml)
+
1 volume 0.145 M saline
Controls where the active enzyme was replaced with an equal 
volume of either heat-denatured enzyme (treated at 56°C for 15 
mins.) or 0.15 M NaCl in 0.01 M phosphate buffer - 50% glycerol (pH 
7.4), were included in all assays.
The incubation mixtures were tested by anti-Xa clotting assays 
as described in Section 7.2.3, using Factor Xa diluted 1:1000 to 
increase sensitivity. Clotting times were determined by duplicate 
or triplicate runs.
i) Effect of LPL No change in anti-Xa activity of human 
plasma was detected after incubation with LPL preparations from 
milk at 37°C for 45 mins. (see Table 1). The same result was 
obtained with several preparations of the enzyme purified in one 
step by heparin-Sepharose chromatography, and that provided by Dr. 
Olivecrona.
The LPL enzyme from PHP was also incubated with four different 
plasmas (3 lipid-rich and 1 normal) and the anti-Xa activity 
measured. There was little or no change in clotting time; an 
average lengthening of 2.3 secs., with a maximum difference of 3.5 
secs, for one of the plasmas (batch IV) (see Table 2).
The tine course of the action of LPL purified from PHP was 
followed by subsampling at various times up to 1 hour. There was a
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TABLE 1: Effect of LPL from bovine milk on 
plasma anti-Xa clotting activity in the 
absence of heparin
Mean clotting time
(secs.)
Source 
of lipase
Buffer Lipase
NIBSCl 31.6 30.6
Ume& 2 50.0 50.3
1. Prepared in one step by heparin-Sepharose 
chromatography as described in Chapter 3, 
Section 3.4.1.
2. Provided by Dr. Olivecrona, Umeâ.
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TABLE 2: Effect of LPL purified fron PHP on plasma anti-Xa clotting 
activity in the absence of heparin
Plasma batch LPL prep.
Mean clotting time (secs.) 
± s.d.
Buffer Lipase
I Lipid-rich a 56.7 ± 1.3 56.9 ± 0.3
II i j 11 a 45.2 ± 1.4 47.2 ± 1.3
III Normal a 44.3 ± 1.3 47.6 ± 2.5
IV Lipid-rich b 52.1 ± 0.6 55.6 ± 1.4
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slight lengthening in clotting time of 2 - 3 secs, after all incuba­
tion times, including the zero time (see Fig. 1).
ii) Effect of HTGL Incubation of HTGL with lipid-rich plasma 
for 45 mins. at 37°C led to a significant lengthening of clotting 
time (i.e. anti-Xa activity increased) by an average of 12.6 secs.
A smaller increase was obtained using HTGL with normal plasma 
(batch III), suggesting the role of lipid in alteration of anti-Xa 
activity on incubation with lipase (see Table 3).
The time course of HTGL action on lipid-rich plasma was also 
studied, and showed a steady increase in anti-Xa activity to a maxi­
mum after 45 mins.' incubation, vÉien it reached a plateau (see Fig.
2). The buffer control showed little change during this time.
Unless stated, incubation times of 45 mins. were used for all 
subsequent tests.
iii) Heparin equivalence of HTGL action The heparin equiva­
lence of HTGL action was estimated by substituting HTGL with a 
range of heparin concentrations in the clotting assay, and com­
paring the clotting times using the same plasma. The increase in 
clotting times induced by HTGL (mean, 15.4 secs.) was equivalent to 
using 0.05 iu/ml heparin (mean 13.1 secs.).
iv) Specificity of HTGL action It is possible that the 
lengthening in clotting times found with HTGL is due to a non­
specific action of the enzyme preparation, or its incubation 
products, independent of the anti-Xa activity. To test this, the 2 
mins. normally allowed for action of plasma against Factor Xa in the 
first stage of the assay were omitted. Instead, the plasma and HTGL 
were added to the Factor Xa and the plasma was immediately sub­
sampled for the second stage of the assay. In Control 1 (see Fig.
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TABLE 3: Effect of HTGL on plasma anti-Xa clotting activity in the 
absence of heparin
Plasma batch HTGL prep.
Mean clotting time (secs.) 
± s.d.
Buffer Lipase
I Lipid-rich 1 42.8 ± 0.6 58.2 ± 1.1
%% rr rr 2 44.3 ± 1.3 57.6 ± 1.3
III Normal 2 45.2 ± 1.4 48.2 ± 0.8
IV Lipid-rich 3 51.6 ± 1.4 61.1 ± 0 . 0
12 8
3), to investigate the effect of the enzyme preparation itself, 
plasma and HTGL were mixed and added without prior incubation to 
Factor Xa. To test the effect of the incubation products, plasma 
and HTGL were incubated together at 37°C for 45 mins. before sub- 
saitpling into Factor Xa (Control 2). These differences in procedure 
are compared in Figure 3 to the normal test.
As shown in Table 4, no significant differences in clotting 
times were obtained by the addition of either the HTGL preparation 
or the incubation products, as compared with buffer. This result 
indicates that the effect of HTGL to increase clotting times (as 
shown in the 'normal test', Table 4) is through action against Factor 
Xa. The longer plasma clotting times obtained with buffer in the 
normal test compared with the controls, is due to the action of 
plasma At 111 which acts on Factor Xa during the 2 minute' incu­
bation .
v) Use of lipoprotein-free plasma The results from the time 
course of HTGL action and its use with plasmas of different lipid 
contents (Table 3) suggest that the effect is through enzymic acti­
vity against lipoproteins. This was tested by using lipoprotein 
free plasma (lipoproteins removed by ultracentrifugation). Using 
this plasma, there was no change in anti-Xa clotting activity on 
incubation with HTGL or LPL for 45 mins. at 37°C (Table 5). This 
result shows the importance of lipoproteins in the effect HTGL has 
in lengthening plasma clotting times in the absence of heparin.
7.3.2 The effect of lipases on anti-Xa activity measured by the 
amidolytic assay
Thomas et al. (1980) have reported that although post-SSHA 
plasmas have good anti-Xa activity by clotting assays, little acti-
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Normal
Test
Control 1 Control 2
Plasma + lipase
45 mins. at 37°C 
subsample
Factor Xa
2 mins. at 37°C 
subsample
Ca2+
Factor Xa-deficient 
plasma 
phospholipid
Plasma + lipase 
subsample 
immediately
Factor Xa
subsample
imrtBdiately
As test
Plasma + lipase 
45' at 37°C 
subsample
Factor Xa
subsample
immediately
As test
FIGURE 3
Summary of test and control procedures
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TABLE 4: Test of the specificity of the action of HTGL 
or its incubation products on anti-Xa activity
Mean clotting time (secs.)
± s.d.
Buffer HTGL
Control 1
Effect of the 37.3 ± 0.4 35.6 ± 0.4
HTGL preparation
Control 2
Effect of the 36.9 ± 1.0 37.7 ± 0.6
HTGL incuba­
tion products
Normal test 42.8 ± 0.6 58.2 ± 1.1
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TABLE 5: Effect of LPL and HTGL on anti- 
Xa clotting activity of lipoprotein-free 
plasma in the absence of heparin
Mean clotting time 
(secs.) ± s.d.
Buffer 51.4 ± 0.4
HTGL 51.4 ± 0.4
LPL 50.8 ± 1.1
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vity is detected using the amidolytic assay. The results reported 
in Section 7.3.1 indicate that HTGL increases plasmna anti-Xa 
activity. Preliminary tests were carried out to see whether this 
effect of HTGL can also be detected by the amidolytic assay or 
whether, like post-SSHA plasmas, it can only be shown by the 
clotting assay.
As in the clotting tests, HTGL was incubated with lipid-rich 
plasma for various times at 31°C, and aliquoted into Factor Xa and 
left for 2 mins. The amount of amidolytically-active Factor Xa 
remaining in the incubation was cortpared with that of the buffer 
control by the rate of formation of the coloured product from the 
synthetic substrate, S-2222. A decrease in the AGO would indicate 
a reduction in Factor Xa and so greater anti-Xa activity in the 
incubation mixture.
The results given in Figure 4 show that there was little 
change of plasma anti-Xa activity with either HTGL or buffer up to 
incubation times of 30 mins. There was an apparent increase in 
anti-Xa activity with HTGL after 60 mins.' incubation.
7.3.3 The effect of lipases on plasma anti-Xa clotting activity in 
the presence of heparin
To simulate ex vivo PHP where heparin and lipase are both 
present, the in vitro effect of lipase was tested in the presence 
of heparin. As reported in Section 3.1 of this chapter, both 
heparin and HTGL increase the anti-Xa activity of plasma, and so a 
further enhancement of activity would be expected when both are 
present.
To test the effect of added heparin with both lipases, incu­
bation mixtures were made up as described for tests in the absence
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of heparin, except that 50 yl heparin (3rd International Standard, 
65/69 NIBSC) were added in place of saline to give a final incu­
bation concentration of 0.05, 0.1 or 0.2 iu/ml. These mixtures 
were tested in the anti-Xa clotting assay using purified Factor Xa 
diluted 1 :1 0 0 .
i) Effect of LPL LPL purified from PHP was incubated with 
lipid-rich plasma for 45 mins. at 37°C in the presence of heparin.
As in the absence of heparin, there was a slight lengthening in 
clotting times after incubation with LPL (see Fig. 5). This was 
true at all three heparin concentrations.
ii) Effect of HTGL HTGL was incubated with plasma and heparin 
as described for LPL. HTGL reduced the anti-Xa activity of heparin 
as shown in Figure 6 . In the presence of 0.1 iu/ml heparin, HTGL 
reduced the anti-Xa activity by approximately 40%.
iii) Time course of HTGL action in the presence of heparin 
The anti-Xa activity of plasma was tested after 15 and 45 mins. ' 
incubation with HTGL and 0.2 iu/ml heparin. A similar shortening 
in clotting times of approximately 9 secs. (Table 6 a) was obtained 
in the presence of HTGL at both incubation times. The result con­
trasts with the time-dependent action of HTGL in lengthening plasma 
clotting times in the absence of heparin (Fig. 2). It suggests 
that the effect of HTGL in the presence of heparin is not a result 
of its lipolytic activity, unless such action is completed by 15 
minutes. The parallel increase with both HTGL and buffer over the 
time studied is probably a non-specific effect of incubation on the 
plasma.
In the above test, heparin was present with plasma and HTGL 
for the full 45 mins. of incubation. In one incubation mixture
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Fig 6 Effect of HTGL on plasma anti-Xa clotting
activity in the presence of heparin
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TABLE 6 : Time course of HTGL action on plasma clotting time 
in the presence of heparin (0.2 iu/ml) (Test I) and the effect 
of preincubation in the absence of heparin (Test II)
Mean clotting time (secs.)
15 mins.' 45 mins.'
incubation incubation
a) Buffer 66.5 78.6
HTGL Test I 57.3 69.6
b) HTGL Test II 6 8 . 6
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however (Test II, Table 6b) heparin was added just before the 
mixture was tested in the assay. Ccrrparison of Tests I and II in 
Table 7 shows that there is no difference in the clotting times 
obtained. This means that although HTGL would presumably have had 
the normal effect of increasing plasma anti-Xa activity during incu­
bation in the absence of heparin, the effect is negligible compared 
with the reduction it immediately causes in the anti-Xa activity of 
heparin.
iv) Effect of a mixture of LPL and HTGL The effect of HTGL 
alone and that of both HTGL and LPL on plasma clotting times in the 
presence of heparin (0.2 iu/ml) was coctpared. There was not a sig­
nificant difference in clotting times (Table 7).
v) Test of lipase and heparin with the use of lipoprotein-free 
plasma HTGL and LPL were incubated with lipoprotein-free plasma, 
with heparin added to give a final concentration of 0.2 iu/ml. As 
shown in Table 8 , there was a significant 14 sec. shortening of 
plasma clotting time after incubation with HTGL but little change 
with LPL. This is a similar result to that obtained with lipid- 
rich plasma, which suggests that the effect of HTGL in the presence 
of heparin is a non-specific one, not involving its lipolytic 
action.
7.4 DISCUSSION
This study was designed to test the hypothesis that the anti- 
Xa activity present in post-SP54 and SSHA plasmas (Thomas et al., 
1980; Fischer et al., 1982) is due to the presence of triglyceride 
lipases. The polysaccharides have little detectable anti-Xa 
activity in vivo, and it has been suggested that the activity ex 
vivo is due to the presence of some factor(s) which has been
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TABLE 7: Comparison of the effect of HTGL and a 
HTGL/LPL mixture on plasma anti-Xa clotting 
activity in the presence of heparin (0 . 2  iu/ml)
Mean clotting time 
(secs.)
HTGL 69.4
HTGL + LPL 68.1
Buffer 78.6
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TABLE 8 : Effect of HTGL and LPL on anti-Xa 
clotting activity of lipoprotein-free plasma 
in the presence of heparin (0 . 2 iu/ml)
Mean clotting time (secs.) 
± s.d.
Buffer 73.6 ± 2.3
HTGL 59.1 ± 0.0
LPL 75.1 ± 1.8
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released into the circulation.
LPL from rat PHP or bovine milk did not significantly alter 
the anti-Xa activity of plasma. A slight increase in anti-Xa 
activity was detectable immediately on addition of the LPL from 
PHP. This is probably due to the presence of At 111 which co­
elutes with LPL when purified by normal heparin-Sepharose chroma­
tography as described in Chapter 3 (Ôstlund-Lindqvist, 1979). This 
explanation is supported by the finding that LPL from bovine milk - 
which should have no contaminating At 111 - gave no change in plasma 
clotting times.
In contrast, significant lengthening in plasma clotting times 
were induced by HTGL, especially in lipid-rich plasmas. The peak 
lengthening was similar to that achieved by the in vitro addition 
of 0.05 iu/ml heparin to the same plasma. This level of anti-Xa 
activity is also equivalent to that found in ex vivo plasma samples 
after subcutaneous injection of 5,000 units of heparin. Since this 
dosage of heparin has been used to prevent post-operative deep vein 
thrombosis (Kakkar et al., 1978) the anti-Xa activity mediated 
through lipase release after SSHA and SP54 may be of some clinical 
significance.
Virtually no change was found on incubation of HTGL with lipo­
protein-free plasma. Further tests showed that the effect in lipid- 
rich plasma was not due to the non-specific action of the enzyme pre­
paration nor its incubation products on the clotting process itself. 
There should be little At 111 contamination of the HTGL sample (from 
work on human plasma, McKay and Laurell, 1980). All these results 
indicate that it is the HTGL action against lipoproteins which is 
causing the increase in anti-Xa activity of the plasma.
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Work done by Barrowcliffe et al. (1982) shows that LDL and HDL 
possess anti-Xa clotting activity and that the activities of these 
lipoproteins are increased after they have been batch absorbed with 
Al(OH)]. It is feasible that HTGL acts on these lipoproteins in 
the same way as AKOH)^, particularly since HDL and LDL appear to 
be the major natural substrates of HTGL (Nilsson-Ehle et al.,
1980). In support of a common underlying mechanism, preliminary 
results showed that the increased anti-Xa activity induced by HTGL 
was not detectable by amidolytic assay up to 30 mins.' incubation, 
as was found both for Al(OH)3 -treated lipoproteins (Barrowcliffe et 
al., 1982) and for post-injection plasmas of SSHA and SP54 (Thomas 
et al., 1980; Fischer et al., 1982).
The anti-Xa activity demonstrable in plasma after heparin 
injection is generally assumed to be due totally to the presence of 
heparin, and the lipase released is not considered. The results 
shown in the first part of this Chapter suggest that, since HTGL 
does affect anti-Xa activity, the actual measured activity may be a 
result of the combined action of heparin and of the lipase. For 
this reason, the effect of both lipases on plasma anti-Xa activity 
in the presence of heparin was also studied. Plasma clotting times 
after incubation with LPL were lengthened by a few seconds, as was 
the case in the absence of heparin, and this can be similarly 
ascribed to At III contamination of the LPL preparation. The 
results using HTGL, however, are more puzzling. Although both HTGL 
and heparin alone have, or induce anti-Xa activity, plasma clotting 
times were reduced when they were incubated together. In terms of 
heparin units this shortening due to the HTGL represented, ^en 
using 0.2 iu/ml heparin, a decrease of 40% in anti-Xa activity (i.e.
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0.2 to 0.125 iu/ml). However, at 0.05 iu/ml, the lowest heparin 
concentration tested, there was little change in clotting time.
This effect of HTGL on heparin anti-Xa activity appeared to be 
imnediate and non-specific (i.e. not related to lipolytic activity) 
since the same shortening of clotting times by HTGL was also found 
using lipoprotein-free plasma (see Table 8 ).
The lengthening of clotting times suggests that HTGL binds 
heparin and prevents it from full interaction with plasma At III to 
catalyse anti-Xa action. However, from work with heparin-Sepharose 
gels (Bengtsson et al., 1980; McKay and Laurell, 1980) both LPL and 
At III have higher affinity for heparin than does HTGL, since higher 
salt concentrations are needed to elute them from the gel. Thus the 
action of HTGL and not of LPL in reducing heparin action is sur­
prising.
This apparent inconsistency could be due to a difference in 
the mode of binding of heparin by the two enzymes. Investigations 
have been carried out on the structure and stability of the LPL- 
heparin complex (Clarke et al., 1983) but no such studies have as 
yet been reported for HTGL. By the model proposed by Clarke et 
al., heparins of MW > 10,000 attach at GAG-binding sites on both of 
the two LPL subunits, which means that the heparin used in these 
studies - an unfractionated heparin of mean MV 15,000 - would be 
well bound by the LPL.
The lower affinity of HTGL for heparin is due to the active 
enzyme being monomeric and so only having one (GAG-binding site com­
pared with two on the dimeric LPL (Bengtsson et al., 1980). It has 
been suggested that in binding LPL, heparin wraps itself around the 
enzyme to reach the two binding sites (Clarke et al., 1983). With
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HTGL however, with only one binding site, the major part of the 
heparin molecule is likely to be only loosely associated with the 
protein, if at all, which may allow simultaneous binding of At III 
to the unbound section of the heparin chain. This means that 
although At III may then firmly bound to the heparin via specific At 
Ill-binding sequences (not required for binding of lipase: Bengtsson 
et al., 1980), its action against Factor Xa is prevented by steric 
hindrance due to HTGL. Thus, despite the fact that HTGL has lower 
affinity than LPL, for heparin, it will have a greater effect on 
heparin co-factor activity since it is not in direct competition 
with At III for its binding. This theory could be further tested 
out by use of heparins of different MWs, and also of other sulphated 
polysaccharides known to bind lipase.
An alternative explanation of the findings in the presence of 
heparin is that the effect of the HTGL is due to the co-purification 
of lipoproteins. It has been reported (Bleyl et al., 1975) that 
lipoproteins, present in normal serum or as added isolated fractions, 
bind heparin and thus compete with At III and reduce its anticoagu­
lant action. The 'anti-heparin' properties of LDL in particular have 
been suggested (MacGregor et al., 1980). However, although lipopro­
teins do bind heparin-Sepharose as used for lipase purification, more 
than 90% would be eluted at the NaCl concentrations used to wash the 
gel prior to elution of HTGL (Iverius, 1971).
In summary, this work has shown that HTGL can induce anti-Xa 
activity in lipid-rich plasma, which leads to significant leng­
thening of clotting times in the absence of heparin. It can however 
also decrease the anti-Xa clotting activity of heparin. LPL has 
little effect in the presence or absence of heparin.
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CHAPTER 8
FINAL DISCUSSION
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The prime concern of this thesis has been to compare the 
activity of heparin with other strongly anionic sulphated polysac­
charides in releasing triglyceride lipases from mammalian tissues.
A major part of the work was the necessary assessment of various 
methods to measure the relative contribution of HTGL and LPL to 
total activity released, since these enzymes play different roles 
in lipoprotein metabolism.
The lipase-releasing effect of parenteral heparin has 
generally been studied as a topic separate from its effects on 
coagulation; in most coagulation work (including that on possible 
heparin substitutes), the anti-lipaemic effect has been completely 
ignored. In an attempt to balance this, some of the work described 
in this thesis has explored possible relationships between the 
anti-lipaemic and anticoagulant activity of heparin and related 
compounds.
8.1 Assay Methods
A major problem encountered at the inception of this work 
concerned the reliability of some of the methods employed to assay 
lipase activities. These methods were compared and none was found 
to be entirely satisfactory in regard to all of the three necessary 
qualities of reproducibility, selectivity and precision. However, 
one was selected for use which, under defined conditions, gave 
reliable results. This assay (the modified NES assay) permits some 
differentiation of HIGL and LPL activities in PHP samples. Total
lipase activity is measured in low salt concentrations in the
presence of serum, and HTGL is selectively assayed in high salt con­
centrations and in the absence of serum. LPL activity is then
obtained by difference.
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Alternative differentiation procedures for LPL and HTGL have 
been suggested in the literature such as that of using SDS, which 
has been observed to inhibit HTGL in PHP selectively with only mini­
mal effect on LPL (Baginsky, 1981). This adaptation was investi­
gated with the NES assay, but was unpractical as the concentration 
of SDS required appeared to vary substantially between PHP samples 
(see Ch. 2, Section 2.3.vi).
The use of specific anti-sera against LPL, or HTGL is a 
useful alternative method if these sera are readily available.
There may be problems in raising these antibodies, however; the 
anti-serum raised from rabbits in the present work after 
challenging with enzymes purified from rat PHP were not specific 
enough for use in the assay (see Appendix III).
Assay substrates which use gum arabic as stabilizers are 
commonly employed by workers in the lipase field. This system 
(called the 'gum arabic assay in this thesis) was tried in conjunc­
tion with selective use of serum and salt (as used in the NES 
assay), but it was repeatedly found that product release was not 
linear as a function of time, especially in assays of HTGL (Ch. 2, 
Section 3.3). Satisfactory linearity has been reported for the gum 
arabic assay with use of specific antibodies against both enzymes 
(Huttenen et al., 1975) and also for measurement of LPL in the 
presence of SDS (Goldberg et al., 1983). However, no data regar­
ding linearity when measuring PHP HTGL by the salt/serum differen­
tiation have been reported, despite the widespread use of this 
assay method (Benson and Clayton-Love, 1982). Since I obtained 
poor linearity of HTGL measurements using this assay in two dif­
ferent laboratories, it is suggested that this is not a suitable
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method, although it may be satisfactory for LPL. These results 
emphasize the importance of checking all parameters when setting up 
an assay, especially when testing the activity of lipases of origin 
different from that used in the published method. For example, 
assays designed to test purified lipases will not necessarily be 
the best ones to measure the activity present in crude tissue 
extracts or in unfractionated PHPs.
Substrate preparations may differ in chemical composition,
i.e. in the source and purity of their components, which are not 
always precisely defined. This means that different types of sub­
strate preparations are not interchangeable with different assay 
methods without risk of altering the measurement of one or both of 
the enzymes. As example of this is the difference between the ccm- 
nercial TG emulsion Intralipid and TG emulsions prepared in the 
laboratory - use of the former resulted in the release of 3-5 times 
more FFA than that found with the latter substrate (also noted by 
Riley and Robinson, 1975). Whilst the composition of Intralipid is 
known (Table 8 , Ch. 2), the method of preparation has not been dis­
closed by the manufacturers. Use of this substrate however, does 
not allow inhibition of LPL with high salt concentrations. The two 
lipases have different specificities for TG and phospholipid and 
the mode of presentation' of the hydrolysable substrate in the 
preparation (including homogeneity and droplet size) may greatly 
influence the measured hydrolysis rate. Also, in the case of phos­
pholipid-emulsified radiolabelled TG preparations,the true value of 
total action of the enzyme would not be measured. Especially in 
the case of HTGL - which has better phospholipase activity than LPL 
- this would consist of measured TG hydrolysis (by release of
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^H-FFA) but also of unmeasured phospholipid hydrolysis.
8.2 Effect of Serum Factors on Lipase Measurements
Serum factors, whether present in the PHP sample to be 
assayed, or added to the substrate mixture, also affect LPL and 
HTGL differently. The modulatory apolipoproteins are probably res­
ponsible, but the lipoproteins thanselves may also ccxnpete with the 
artificial substrate. The proportion of inhibitory and stimulatory 
apoproteins may vary from sample to sample, and assessment of this 
is not easy because of the complexity of the interactions. A 
clearer view of the situation may be provided by testing the acti­
vity of purified enzymes on addition of various serum factors - 
purified apoproteins or whole lipoprotein fractions - to different 
substrates.
The unpredictable effects of serum factors provide support 
for the use of the assay method (see Ch. 1, Section 5.2.iii) which 
removes most of them by passing the PHPs to be assayed through 
heparin-Sepharose affinity columns. Lipoproteins are eluted in the 
void volume or at low salt concentrations.
8.3 The Lipase-Releasing Ability of Different Polysaccharides
A group of heparins and related polysaccharides previously 
characterized chemically and by clotting assays was investigated 
for lipase release and provided data on the structural requirements 
for this activity. Some preliminary work in vitro on release using 
preparations of isolated animal tissues was undertaken but since 
variability and non-specific release was high, no useful results 
were obtained. However, perfused tissue systems, such as that of 
the liver (Groot et al., 1983) may be worth further investigation.
The bulk of the work has been done in vivo using the rat.
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Most previous reports have either been of binding studies in vitro 
using affinity gels (Bengtsson et al., 1980) or in vivo of very 
limited scope (e.g. only 2 or 3 selected doses). In the present 
work fuller comparison of the different polysaccharides has been 
made with the dose response curves ranging from the threshold of 
release up to peak activity. Some general comments can be made. 
There were no significant differences between LPL and HTGL either 
as regards the dose of polysaccharide at which they were first 
detected, or between the doses of different polysaccharides at the 
threshold of release. The major lipase-releasing compounds tested 
fell into three main groups which had differently shaped dose- 
response curves. This makes 'ranking' of the compounds (i.e. effi­
cacy of lipase release) difficult, but based on the peak levels 
reached and the dose needed for this, the most potent were the 
heparins, followed by SSHA and SP54 then IMW heparin and HSII. The 
levels achieved by DeS and HSI were extremely low at all doses.
Comparison of the total, HTGL and LPL activity curves allows 
the tentative conclusion that the differences between the lipase 
release by different polysaccharides are primarily the result of 
variations in LPL rather than HTGL. In specific terms, it has been 
shown here that whilst heparin is more effective in releasing LPL 
than the other polysaccharides tested, it is only marginally better 
at releasing HIGL. This probably indicates a difference in the 
binding of these enzymes in situ. The finding that only the 
heparins are able to compete successfully at the endothelial sur­
face for the release of the extra 40-50% of the LPL suggests that 
at least this proportion of the population may be bound in situ to 
GAGs with a charge density approaching that of heparin.
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Time courses of lipase release by the various polysac­
charides agree with published work in that LPL is released more 
slowly and cleared more quickly than HTGL. This was particularly 
marked with the heparin analogues SSHA and SP54. The overall dif­
ference in this respect between the two enzyræs however, was not 
found to be as great as that reported by other workers (Huttenen et 
al., 1980; Krauss et al., 1974). It would be interesting to try a 
range of doses in time course studies, and also to test the plasmas 
using different assays.
No firm conclusions can be drawn on the structural require­
ments for lipase release, other than (as was previously known) that 
both MW and the degree of sulphation affect the efficacy. There 
also appears to be some effect associated with the heparin-heparan 
family of GAGs, other than that of sulphation or MW.
8.4 The Effect of Lipases on Cbaqulation
It has been suggested (Thomas et al., 1980) that lipase 
release may be indirectly responsible for all the anti-Xa activity 
present in plasma after injection of heparin analogues, and part of 
that after heparin. Use of purified lipases has produced interes­
ting but not easily explained results. HTGL, but not LPL, was 
found to have significant effects on plasma anti-Xa activity, to 
lengthen clotting times in the absence of heparin, and to shorten 
them in its presence. The HTGL action in the absence of heparin 
was especially marked in lipid-rich plasma, but absent in lipopro­
tein-free plasma, which is consistent with its proposed action via 
lipoproteins. It is suggested that this effect, v^ich progresses 
with time of incubation of HTQj with plasma, is due to the produc­
tion of LDL and certain HDL sub-fractions. If this is so, it is
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somewhat surprising that the œ-addition of LPL to the incubation 
mixture did not further augment the increase in clotting times. By 
itself, LPL affected clotting times only marginally and although 
this was tentatively explained as an effect of the presence of con­
taminating At III in the LPL sample, further work on more highly 
purified enzymes is required. Tests on the effect of purified lipo­
protein fractions on plasma anti-Xa activity in the presence and 
absence of HTGL may provide more evidence.
The above test conditions do not of course truly represent 
the position in post-injection plasmas, since the polysaccharides 
which release the lipases are absent. As mentioned, when these 
tests were performed in the presence of heparin, the effect of HTGL 
was to shorten clotting times, i.e. to reduce the normally 
heightened action of At III or other protease inhibitors. Sugges­
ted explanations for this finding are that HTGL binds loosely to 
heparin thereby preventing full potentiation of At III activity, or 
alternatively that certain lipDprotein fractions (produced by HTGL 
action) themselves neutralize heparin action. The latter is less 
likely since the observed effect was not dependent on the time of 
lipase action. Such a mechanism might be checked by testing lipo­
protein fractions from PHP and normal plasmas, possibly with the 
use of antisera to selected fractions.
The wide therapeutic use of heparin as an anticoagulant or 
antithrcxnbotic agent, with its drawbacks of risk of haanorrhage and 
osteoporosis, has led to many investigations on the use of alterna­
tive or modified preparations. In addition to their anticoagulant 
activity, there is a possible use of heparin and related conçounds 
against atherosclerosis. This has been only scantily investigated.
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but is presumably related to their ability to release lipases into 
the circulation. As stated by Morton et al. (1984), "the occur­
rence in mammalian tissues of a native polysaccharide that affects 
LPL but lacks effect on blood coagulation may have important 
physiological and therapeutic implications." In this study 
heparins, heparans and DeS were employed, together with SSHA (also 
of animal origin but chemically modified) and SP54 (a chemically 
sulphated plant polysaccharide). The previously reported finding 
(Thomas et al., 1980; Fischer et al., 1982), that the anti-Xa 
activities in vitro and ex vivo of these latter two compounds 
differ, is important - whatever its origins - since it emphasizes 
the inadequacy of in vitro tests alone. Leaving aside the effects 
of lipase, assessment of activity even of closely related (SAGs such 
as heparins and HS is not easy because of the non-parallelism of 
their dose response curves in clotting tests.
With drugs such as heparin, which display a wide spectrum of 
physiological effects, some of which are poorly understood, use of 
a number of assay procedures directed at different aspects of their 
behaviour may allow better selection of the preparation and of the 
minimum dose required.
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APPENDIX I
LIPASE ASSAY USED BY CRIN06 SpA (No. 3120/054)
146
REAGENTS
Substrate
Bovine albumin (fatty acid-free, Sigma) )
10% (w/v) in 0.05 M Tris/HCl (pH 8.15) ) Mixed 1:1 for
Intralipid (20%, KabiVitrum) ) substrate
Diluted X 9 with Tris buffer (as above) )
Extraction mixture
40 vol. Isopropanol 
1 0 vol. n-heptane 
1 vol. I N  H2SO4 
n-heptane 
002-free H2O
0.005. H2SO4 
Indicator
0.0025% brcxtothymol blue in n-heptane 
Titrant
Prepared and stored (at 4°C) as 10 N NaOH in 0 0 2 -free 
distilled water; diluted for use by 1 in 10 then 1 in 400 with 
absolute alcohol.
Fatty acid standard
1 ynole/ml stearic acid 
METHOD
1. 2 ml substrate are preincubated with shaking at 37*0 for 5 
mins. At zero time 1 ml enzyme/PHP is added to the substrate, 
For the 'test blank' 1 ml of buffer is added in place of 
enzyme.
2. 0.5 ml aliquots are sampled at zero time and after 30 mins. 
incubation, and mixed with 5 ml of the extraction mixture.
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This is left for 30 mins. at 4°C.
3. Add 3 ml n-heptane, mix and leave further 30 mins. at 4°C.
4. Add 2.5 ml 0 0 2 -free H2O, mix and leave 30 mins. at 4°0.
5. Remove the heptane (upper) phase and mix with 5.5 ml of 0.005% 
H2SO4 . Oentrifuge for 15 mins. at 3,000 g.
6 . Transfer 2.5 ml of the heptane phase into titration tubes, add 
1 ml of indicator and pass a stream of nitrogen through for 
10-15 secs.
7. Titrate this against 1/400 N NaOH, with a constant stream of
nitrogen to mix and to expel OO2 .
Standard curves and blanks
1. Add 5 ml of the extraction mixture to 0.1, 0.1, 0.4, 0.6, 0.8 
and 1.0 ml of the stearic acid solution. Leave for 30 mins. 
at 4°C.
2. Add 2.9-2.0 ml of n-heptane to give final volume of 8 mis.
For the 'standard blank' add 3 mis. of n-heptane to 5 ml of
extraction mixture. Mix and leave at 4°C for 30 mins.
3. Add 3 ml of 0 0 2 -free H2O. Mix well and leave at 4°C for 30
mins.
4. Continue as in Method from 5) onwards.
CALOJLATIGN OF ENZYMIC ACTIVITY
ymoles FFA = 6 x (test - test blank) x standard (ymoles)
ml plasma 30 mins. standard - standard blank
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APPENDIX II
METHODS USED TO TEST THE PURITY OF TRIOLEIN
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a) Gas chromatography This was done on a Perkin-Elmer 115, using 
a SGE BPl bonded phase WGOT column (25 m x 0.1 itm i.d.) with helium 
as carrier, and a flame ionization detector. Samples were prepared 
as shown in Figure 1. Methyl oleate (BEB) was also run as a 
standard. Injection of solutions was made in nonane.
b) HPLC The column used was a CDS Hypers il (Shandon Southern) of 
dimensions 150 mm x 2.2 mm (i.d.) with a mobile phase of ethanol 
(Analar, 96%) and a flow rate of 0.2 ml/min. Unlabelled triolein 
(BDH, normal grade) was dissolved in 96% ethanol to a concentration 
of 6 mg/ml, and 5 yl (30 yg of this injected. Elution was moni­
tored at 210 nm. Radioactive triolein is supplied in toluene, and 
this soient was blown off under nitrogen, and the triolein made up 
in ethanol (0.45 mg/ml, 0.25 mCi/ml). 0.25 ml fractions were 
collected off the column and the radioactivity counted with 1 0 ml 
of scintillation fluid.
The triolein was prepared for G.C. as shown in Figure 1.
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MIX 1 0 nq triolein 
5 ml methanol (Analar)
1 0 0  yl conc. sulphuric acid 
5 ml cyclohexane (Analar)
70°C/4 hours
methyl oleate and glycerol, 
methanol, etc.
Add 10 ml water
ORGANIC LAYER 
contains fatty acid methyl ester
Remove methanol by evaporation
Load onto G.C. in nonane
A2UE0ÜS LAYER 
(discard)
FIGURE 1
151
APPENDIX III
STIMULATION OF ANTI-RAT HTGL IN THE RABBIT
152
INTRODUCTION
Several methods have been described which selectively inhibit 
either LPL or HTGL in PHP samples before assaying, which then 
allows their selective measurement under their optimal assay 
conditions (Huttenen et al., 1974; Goldberg et al., 1983). Since 
there had been only partial success in selective measurements using 
chemical inhibition (NaCI and SOS) with the NES assay, it was 
decided to raise antibodies to the HTGL enzyne (from the rat, the 
animal used in most of the lipase-releasing experiments). This 
involved purification of the enzyme from PHP, injecting it in a 
concentrated form into the rabbit and testing the rabbit sera at 
intervals for an inhibitory response.
MATERIAIS
Complete Freund's Adjuvant Gibco Laboratories, New York,
USA.
Anmonium Sulphate BDH Chotiicals Ltd., Poole, Dorset, U.K.
Agarose Gel (A37) Reactifs IBF, Pharmindustrie, Clichy,
France.
Rat Albumin (Fraction V) Sigma, Poole, Dorset, U.K.
Swine Anti-Rabbit Iitinunoglobulin ( SWAR/75 ), Nordic
Iirmunological Lsiboratories, Maidenhead, Berks., U.K.
METHODS AND RESULTS
Stimulation of anti-rat hepatic lipase in the rabbit
HTGL was purified from rat PHP by heparin-Sepharose 
chromatography as described in Chapter 3. The enzyme preparation 
was mixed 1:1 (v/v) with complete Freund's adjuvant and injected 
into a New Zealand White rabbit intradermally at multiple sites, 
three times, at roughly two-week intervals. To avoid loss of
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enzymic activity by concentrating methods, two further batches of 
HTGL eluted off the affinity column were dialysed and re-bound to 
fresh heparin-Sepharose, which was then injected into the rabbit 
mixed 1:1 with 0.15 M NaCl in phosphate buffer (pH 7.4). The gel 
should allow slow release of the enzyme for stimulation of the 
antibody response.
The rabbit was bled frcxn the ear, and the blood left to clot 
in glass at 37°C for 2-3 hours then overnight at 4°C before 
spinning at 3,000 g for 15 minutes to obtain serum. Any endogenous 
lipase activity was inactivated by heating at 56°C for 30 mins.
Blood samples from an ear vein of the rabbit were taken at three- 
week intervals and tested for the presence of antibody both by 
Ouchterlony plates and by its effectiveness to inhibit HTGL in the 
lipase assay. After detection of anti-HTGL was detected by both 
techniques the immunoglobulin fraction (Ig) fraction was peirticilly 
purified from the serum. This was done to enable smaller volumes 
to be used of a more concentrated sanple, and to avoid complica­
tions that may arise from adding further serum into the assay 
system.
Preparation of partially-purified iirmunoqlobulin
Ice-cold saturated ammonium sulphate (pH 6.5) was added drop- 
wise to the rabbit serum with stirring (on ice) to give a final con­
centration of 40% of saturated. This was left to stir for 30 mins. 
then spun at 12,000 g for 10 mins. at 4°C. The pellet was washed 
with further 40% saturated ammonium sulphate and re-spun. The Ig 
pellet was extensively dialysed against phosphate buffered saline 
at 4°C, then spun at 3,000 g to remove any insoluble protein.
7
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Test of antisera by Ouchterlony immunoprécipitation
The rabbit antiserum and Ig preparation were tested by the 
Ouchterlony double immunodiffusion technique, using a 1% agarose 
gel in 0.1 M phosphate buffer pH 7.4. 25 pi of the serum or Ig
preparation were added to the centre well and 1 0 yl of antigen to 
the surrounding wells. The plates were left overnight at 37°C.
Figure 1 shows the protein precipitates from various rat 
plasma fractions by the Ig preparation. The protein present in 
samples 1-5 is probably antithrcmbin III, which is likely to be the 
major contaminant of the HTGL sample used for antibody stimulation 
(since heparin-Sepharose gel was used for purification). No 
protein is precipitated from the albumin sample. By conparing 
samples 1 , 2 and 3 , it would appear that a protein not present in 
pre-heparin plasma is precipitated from PHP and the HTGL. It is 
possible that this is the hepatic lipase. No immunoprecipitate is 
formed with the LPL.
Plates were also run using rabbit anti-human HTC5L serum, 
supplied by Dr. Olivecrona in ümeâ. The bonds of precipitated 
protein are not so clear here, since serum was used instead of Ig 
preparation (see Fig. 2 ).
Anti-HTGL activity of antiserum and Ig fraction
Rat PHP was mixed in varying proportions with neat serum or Ig 
preparation, and left 2-3 hours at 4°C before testing in the lipase 
assay. Controls of normal rabbit serum (NRS) and buffer were run 
alongside.
To aid immunoprécipitation of the HTGL-Ig complex, swine anti­
rabbit immunoglobulin (SWAR) was used. Lysophilized SWAR was made 
up in distilled water, and 1 0 yl of different concentrations added
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Fig 1 Ouchterlony immunoprécipitation using the 
Ig preparation against rat HTGL
1 Normal rat plasma
2 Rat PHP
3 Purified rat HTGL
4 Purified rat LPL
5 Heparin-binding fraction 
from normal rat PHP
6 Rat albumin
Centre well = ig prep, against rat HTGL
'V  ïpi'' ' " z -
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to 250 yl of either neat PHP or PHP/Ig (1:1) mixture. This was 
left for a further 2-3 hours or overnight at 4°C, spun in an 
Eppendorf 5412 bench centrifuge for 2 mins. at 7,500 rpm then 
assayed. The results are shown in Table 1.
Since this additional treatment appeared to aid removal of 
lipase activity without a similar effect on the control, 5 yg/ml of 
SWAR were used in subsequent incubations.
Increasing amounts of Ig preparation were incubated with rat 
EHP to determine the amount necessary for inhibition of HTGL. The 
effect on lipase activity under high salt conditions (1.0 M NaCl) 
is shown in Figure 3, with the decrease in activity appearing to be 
nearing completion. Although theoretically there should be no 
lipase measurable with anti-HTGL under high salt conditions, 
similar results were obtained in this assay system using antiHHTGL 
supplied by Dr. Olivecrona in ümeâ ( results not shown ).
However, the total lipase values appeared to be continuing to 
decrease even, at a 1:1 ratio of Ig preparation : rat PHP. This was 
confirmed using a second Ig preparation from the antiserum which, 
when used in increasing proportions effected almost total inhibi­
tion of lipase activity measured in low and high salt substrates 
(see Figs. 4 and 5). These were run against controls of Ig pre­
paration from normal rabbit serum. So, the antiserum stimulated in 
rabbit is not usable to selectively inhibit HTGL since both enzymes 
are affected, directly or indirectly. Although LPL was definitely 
excluded from the HTGL preparation by differential salt elution 
from the affinity column, it is possible that LPL cross-reacts with 
an antibody produced against HTGL. This was found to be the case 
using antiserum against HTGL prepared in chickens (Augustin et al..
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TABLE 1
Effects of SWAR on enzyme activity læasiired in lipase assay
(SWAR) in 
incubation 
mixture
Enzymic activity 
(adjusted) for dilution 
Total SEIL
214.7 73.5
Neat PHP 5 yg/1 224.4 74.4
72.4 18.3
Serum: PHP 50 yg/ml 59.8 16.6
(1 :1 ) 1 0 yg/ml 61.7 15.8
5 yg/ml 59.4 16.6
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Fig 3 Effect of Ig prep, on PHP HTGL activity
50
Buffer
40
30
Ig prep.
2 0
1 0
% Ig in PHP/Ig mixture
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Fig 4 Effect of Ig prep, on total lipase
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Fig 5 Effect of excess volumes of Ig prep, on 
PHP HTGL activity
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1978), whereas antiserum prepared in goats against the two enzyires 
selectively precipitated each activity. However, although goat 
antibodies have greater specificity, other workers have success­
fully used rabbits for stimulation of anti-rat HTGL (Jansen and 
Hiilsmann, 1974; Jensen et al., 1982). It has been found (H.
Jansen, personal communication) that injection of much enzyme 
(active and inactive) at once, results in low antibody titres, 
although the reason for this is not known. To aid slow release of 
enzyme into the bloodstream, injection into the rabbit foot pads is 
suggested.
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APPENDIX IV
PREPARATION OF HEPARIN-SEPHAROSE GELS
158
a ) Method 1
MATERIALS
Sepharose 4B (Pharmacia U.K. Ltd.)
Ethanolamine 1 M pH 8.0 
Cyanoqel bromide 
Heparin
Sodium hydroxide 10 N 
Buffers
Coupling buffer A: 0.2 M sodium bicarbonate, pH 11.0
Coupling buffer B: 0.2 M sodium bicarbonate, pH 9.0
Washing buffer A: 0.1 M sodium acetate, 1.5 M sodium
chloride, pH 4.0 
Washing buffer B: 0.2 M sodium bicarbonate, 1.5 M sodium
chloride, pH 9.0
METHOD
1. Suspend 100 ml of Sepharose 4B in an equal volume of
coupling buffer A and add 5 g of solid CNBr. Maintain the pH
at 1 1 . 0  for 2 0 mins.
2. Wash with ice-oold distilled water and add to 1.2 g 
heparin (dissolved in a small volume of coupling buffer B). 
Leave to stir overnight at room temperature.
3. Filter gel and wash with coupling buffer B then washing 
buffer B.
4. Stir for 30 mins. with 200 ml 1 M ethanolamine, then wash 
with further fresh ethanolamine.
5. Wash exhaustively with alternate volumes of washing 
buffers A and B.
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6 . Wash and leave in running buffer,
b) Method 2 
MATERIALS 
Sepharose
Ethanolamine 0.75 M (pH 8.0)
Cyanogen bromide 
Heparin
Sodium hydroxide 
Buffers
0.5 M sodium bicarbonate, 1.5 M sodium chloride, pH 9.0 
0.1 M sodium acetate, 1.5 M sodium chloride, pH 4.0 
METHOD
1. Dissolve 1 g heparin in 100 ml distilled water and add 
1 0 g cyanogen bromide.
2. Add 150 ml Sepharose and stir in an ice bath for 15 mins., 
maintaining the pH at 11.0. Leave to stir overnight at room 
temperature.
3. Wash gel with bicarbonate buffer, then stir at 37°C with 
two changes of ethanolamine.
4. Wash extensively, alternating bicarbonate and acetate 
buffers.
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APPENDIX V
PRBPmRTION OF SDS-POLYACRYLAMIDE GRTA 
FOR ELECTROPHŒŒSIS OF LIPASES
Based on the method of Weber, K. and Osborn, M. 
(J.Biol.Oiem 244, 4406-4412 (1969)
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Under gel (10%)
6.72 ml 45% (w/v) acrylamide
1.01 ml 1.6% (w/v) N, N '-methylene bisacrylamide (bis)
7.5 ml 1.5 M Tris, pH 8 . 8  
0.8 ml 4% SDS
1 2 . 6  ml distilled water
The above mixture is de-gassed and the following added:-
1 . 6 ml 1 % ammonium persulphate (freshly prepared)
40 yl TEMED (N,N,N',N'-tetramethylethylene-diamine)
Over gel (4%)
0.89 ml 45% acrylamide 
0.13 ml 1.6% bis 
0.84 ml 1.5 M Tris, pH 6 . 8  
0.27 ml 4% SDS 
7.34 ml distilled water 
De-gas and add:-
0.53 ml 1% ammonium persulphate
13.3 yl TEMED 
Electrode buffer (pH 8.3)
0.025 M Tris 
0.192 M glycine 
0.1% SDS
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APPENDIX VI
LIPASE ACTIVITIES RELEASED IN THE RAT IN VIVO 
AFTER INJECTION OF A RANGE OF SÜLPHATED POLYSACCHARIDES
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APPENDIX VII
RELEASE OF LIPASE IN MAN
164
Polysaccharides for injection
Heparin (Leo Laboratories, Princes Risborough, Bucks., U.K.), 
batch H 64578
SP54 (Benechemie, Munich, West Germany)
LMW heparin (Laboratoire Choay, Paris) (as used by Thomas,
D.P. and Merton, R.E., Thrombosis Res. 28, 343-350 (1982)). 
Procedure Six healthy volunteers were injected subcutaneously with 
SP54 (50 mg), heparin (5,000 units*) and LMW heparin (40 mg). At 
least one week was allowed between injection of the different poly­
saccharides. Blood was taken pre-injection and also 1,2, 3 and 6 
hours post-injection. Blood was mixed with 9 volumes of 3.8% 
trisodium citrate and plasma obtained by centrifugation at 48,500 g 
for 15 mins. Lipase activity was measured by the NES assay as 
described in Chapter 2.
The results from injection of SP54 and heparin have been 
published in Fischer et al., Thrombos.Haemos. 47, 109-113 (1982). 
Results
Figure 1 shows the time course of plasma lipase activity after 
SP54, heparin and LMW heparin.
Approximately 35 mg.
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Fig 1 Release of lipases In man
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ABSTRACT
The effects of hepatic triglyceride lipase (HTGL) and lipoprotein 
lipase (LPL) on the anti-Xa clotting activity of plasma were 
studied. LPL had no effect, but HTGL enhanced anti-Xa activity. 
This enhancement was shown to be due to a time-dependent action of 
HTGL on lipoproteins. These results could explain the increases in 
anti-Xa clotting activity previously observed after injection of 
heparin analogues, SSHA and SP54, v^ich are potent releasers of 
lipase enzymes.
INTRODUCTION
It is well known that injection of heparin leads to the release of lipolytic 
activity into the blood (1). This property of lipase release is shared by 
other naturally occurring glycosaminoglycans (GAGs) (2) and by analogues of 
heparin, such as the semi-synthetic heparin analogue, SSHA (3), and pentosan 
polysulphate, SP54 (4). There are two distinct enzymes released; lipoprotein 
lipase (LPL), from extrahepatic tissues, and hepatic triglyceride lipase (HTC^ L) 
from the liver (1). LPL requires apoprotein C-II for maximal activity and is
inhibited by high salt, whereas HTGL does not require an apoprotein co-factor
and is stimulated by high salt. In human post-heparin plasma, HTOL is gen­
erally present in larger amounts than LPL (5).
An interesting feature of the heparin analogues SSHA and SP54 is that both 
drugs, and especially SSHA, give rise to anti-Xa clotting activity after injec­
tion, even though they have virtually no anti-Xa activity in vitro (3,4). Evi-
Keywords; Lipase; Heparin; Anticoagulant
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dence was found that the anti-Xa activity associated with SSHA injection was 
due to release of some conponent(s) into the blood (3) and it seems possible 
that the anti-Xa activity is associated in some way with lipase release. In 
the present study, this hypothesis was tested by stu(fying the influence of purl- “ 
fied lipase enzymes on the anti-Xa clotting assay.
MATERIALS AND METHODS 
Plasma Human post-meal blood (9 vols) was collected from normal volunteers, li 
hours after a fatty neal into 3.8% trisodium citrate (1 vol.). Plasma was sep­
arated by centrifugation at 48,000 g for 10 mins. and stored at -40°C. Normal 
human plasma (anticoagulant CPD + adenine) was supplied by the North London 
Blood Transfusion Centre, Edgware, Middx, and centrifuged at 90,000 g for 90 
mins. to remove chylomicra. Lipoprotein-free plasma was prepared as described 
by Chung et al. (6), by ultracentrifugation at 200,000 g for 3 hours in a 
Sorvall TV-850 vertical rotor, using a discontinuous NaCl/KBr gradient from
1.006 to 1.33 g/ml. The protein containing fractions at the bottom of the tube 
were pooled, dialysed overnight at 4°C, and stored at -40°C. The plasma was 
checked for absence of lipoproteins by phospholipid and triglyceride analyses. 
Post-heparin plasma (PHP) was taken from male Sprague-Dawley rats by cardiac 
puncture 10 minutes after i.v. injection of 250 iu/kg heparin (sodium salt, Leo 
Laboratories, Princes Risborough, Bucks., England). The blood was mixed 9:1 
with citrate as above, and spun for 48,000 g for 10 minutes and stored at -20°C 
or used fresh.
Measurement of lipase activity Triglyceride lipase activity was measured by 
the method of Nilsson-Ehle and Schotz (7) using % - triolein stabilized with 
glycerol. Different assay conditions were used to allow selective measuronent 
of the two enzymes. Total activity was assayed in a low salt substrate contain­
ing serum (as in 7) and HTGL only in a substrate containing 1 M NaCl and with 
serum omitted. Short assay incubation times (10 minutes) and small enzyme 
volumes (10-30 yl) were used to avoid assay non-linearity.
1 mU of enzyne activity is defined as the release of 1 nanomole of oleic acid 
per minute at 37°C.
In some experiments, enzyme activity after incubation with plasma was monitored 
by plasma-free fatty acid ireasurenents, using a commercial kit (Boehringer 
Ltd., Mannheim).
Purification of lipase enzymes by affinity chromatography LPL and HTGL were 
purified on heparin-Sepharose CL-6B (Pharmacia). Solid NaCl was added to the 
PHP to a concentration of 0.35 M and mixed with the gel for 2 hours before 
packing. The column was washed with 0.35 M NaCl in 0.01 M phosphate buffer con­
taining 20% glycerol (pH 7.4) and the enzymes eluted step-wise with salt. In 
seme experiments, fresh, skimmed bovine milk was used as starting material 
instead of PHP. Highly purified milk LPL, supplied Dr. T. Olivecrona, Uneâ, 
Sweden, was also tested.
Peak fractions of the two enzymes were separately pooled and concentrated by 
overnight dialysis against ammonium sulphate (8). Precipitates were made up 
and dialysed against 0.15 M NaCl in phosphate buffer containing 50% glycerol.
All steps were carried out at 4°C.
Anti-Xa clotting assay Lipase enzymes were incubated with human plasma at 37°C 
for up to 45 minutes, to give levels similar to those achieved in man after in­
jection of heparin analogues (30-50 mU/ml). The mixture was tested by a modi-
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fied Denson and Bonnar anti-Xa clotting assay (9,10), using bovine Factor Xa 
(Diagnostic Reagents Ltd., Thane, Qxon.) and an incubation time of 2 minutes.
RESULTS
Release of lipases by heparin and related drugs The peak levels of total li­
pase released s.c. injection of heparin, the heparin analogues SSHA and SP54 
and a low molecular weight heparin fraction in human volunteers are summarised 
in Table 1. Further details of the injection experiments are given in the pub­
lished references cited in the Table. Both analogues gave considerably higher 
lipase levels than heparin or LMW heparin. The percentage of the total lipase 
activity which was due to the hepatic enzyme ranged from 55-82% (Table 1).
TABLE 1
Release of Lipase Enzymes by s.c. Heparin and Analogues in Humans
Drug Published
Reference
Lipase release
Total mU/ml % HTGL
Heparin 
(n = 6)
4 14.5 82
SSHA 
(n = 4)
3 68.7 55
SP54 
(n = 6)
4 57.7 70
M V  heparin 
(n = 6)
13 8.3 64
40-60 mg of each drug were injected subcutaneously into normal volunteers 
(numbers in brackets). Further details are given in the published references.
Purification of lipases from post-heparin plasma The fractionation of rat post­
heparin plasma on heparin-Sepharose is shown in Figure 1. The HTGL eluted at
0.7 M NaCl, with no detectable LPL contamination. The 0.8 M fraction contained 
small amounts of both enzynes and was discarded. The 2.0 M NaCl fraction con­
tained mostly LPL, with a small amount of HTGL activity (this may be due to non­
specificity of the assays). The enzymes were purified about 200 times from the 
post-heparin plasma.
HTGL
.--.LPL250
2.0M,
NaC
200 0.8M
NaCl
0.7M
NaCl
4020
Elution Volume (ml)
FIG. 1
Purification of HTGL and LPL from rat post-heparin plasma 
by chromatography on heparin Sepharose
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Effects of LPL on anti-Xa activity of plasma Neither of the two enzyme prepara­
tions from milk gave any detectable change in anti-Xa activity when incubated 
with human plasma (Table 2). Negative results were obtained with several dif­
ferent batches of milk enzyme, at concentrations up to 250 mU/ml, with differ­
ent batches of plasma, both from the Transfusion Centre and from normal indivi­
duals after a fatty meal, and also on incubation of milk LPL with whole blood.
In the initial experiments, monitoring of plasma free fatty acids showed the 
expected increase, indicating that the enzyme preparations were active. Pre­
parations of LPL from post-heparin plasma prolonged clotting times by a few 
seconds, the maximum being 3.5 seconds (Table 2). This prolongation was not 
time dependent, i.e. it was observed on immediate mixing of the lipase and 
plasma and did not change up to 45 minutes' incubation.
TABLE 2
Anti-Xa Activity of Post-Meal Plasma 4- LPL (45 mins. Incubation)
Enzyme prep. Source Concn.
mU/ml
Clotting time 
Buffer
(secs.) 
Lipase
NIBSC 1 MilK 100 31.6 30.6
Umeâ 1* Milk 35 50.0 50.3
NIBSC 2 PHP 35 52.1 55.6
* Highly purified LPL, kindly donated by Dr. T. Olivecrona, 
University of Umeâ, Sweden
Effects of HTGL on anti-Xa activity of plasma In contrast to the results with 
LPL, preparations of HTGL gave marked prolongations of clotting times in the 
anti-Xa assay. The results with three different enzyme preparations and four 
different batches of plasma are summarised in Table 3. With three batches of 
lipid-rich plasma, the average prolongation of clotting times was 12.6 seconds.
TABLE 3
Effect of HTGL (35 mU/ml) on Anti-Xa Activity of Plasma 
(45 mins. incubation)
Plasma batch Enzyme prep. Clotting time 
Buffer
(secs.) 
Lipase
1 (lipid rich) I 42.8 58.2
2 (lipid rich) II 44.3 57.6
3 (normal) II 45.2 48.2
4 (lipid rich) III 51.6 61.1
Plasma batch 3 was from the Transfusion Centre. Batches 1, 2 and 4 
were from normal subjects, taken li hours after a fatty meal.
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However, with a fourth batch of plasma, collected from the Blood Transfusion 
Centre and centrifuged to remove chylomicra, the prolongation of clotting times 
was less marked, indicating that the effect of HTGL on anti-Xa activity depen­
ded on the lipoprotein content of the plasma. This was confirmed in a separate 
experiment; vrfien the hepatic lipase was incubated with plasma from which all 
lipoproteins had been removed by ultracentrifugation, there was no increase in 
anti-Xa activity (Table 4).
TABLE 4
Involvement of Lipoproteins in Anti-Xa Activity of HTGL
Plasma Clotting time (secs.)
Buffer Lipase
Lipid-rich 51.6 61.1
Lipoprotein-f ree 51.4 51.4
Time-course of HTGL action HTGL was incubated with lipid-rich plasma for up to 
60 minutes, and anti-Xa activity measured at intervals. As shown in Figure 2, 
there was no significant effect when the plasma was tested immediately after 
addition of lipase, but subsequently there was a progressive increase in anti- 
Xa activity up to a maximum of 45 minutes' incubation. The increase in clot­
ting times observed in the buffer control after 60 minutes is due to instabi­
lity of normal plasma anti-Xa activity.
65 -
+ HTGL
/—s
CO
o
<D
CO
60 -
(D
E
^  55 -
O)
c
+ Buffer4— ' 4— '
a ^
45
0 15 30 45 60
Incubation Time (min)
FIG. 2
Time course of HTGL action. Purified HTGL (35 mU/ml) was incubated with 
human plasma and clotting times in the anti-Xa assay measured at intervals.
Quantitation of anti-Xa activity From comparisons with dilution curves of the 
Factor Xa used in the assay, the amount of Factor Xa ramaining after incubation 
with plasma + HTGL (35 mU/ml) was approximately 50% of that remaining after 
incubation with plasma + buffer. In one batch of lipid-rich plasma, the pro-
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longation of clotting times by HTGL (35 mU/ml) was compared with that given by 
in vitro addition of various amounts of heparin. The anti-Xa activity of HTGL 
was found to be equivalent to that of 0.05 iu/ml heparin.
DISCUSSION
The results of this study show that, of the two lipases released ly heparin and 
its analogues, LPL had no effect on anti-Xa activity, whereas HTGL gave a 
marked increase in anti-Xa clotting activity when incubated with plasma. The 
fact that there was a progressive increase in anti-Xa activity from 0-45 min­
utes' incubation (Fig. 2) and that lipase alone did not affect Xa clotting 
times suggests that the prolongation of clotting times is not artefactual.
Also, it is unlikely that these results can be explained by contamination with 
anti thrombin III (At III). Preliminary studies with human post-heparin plasma 
have shown that At III is mostly located in the LPL fraction (unpublished data) 
and this may be the explanation for the slight prolongation of clotting times 
with this fraction, which was not seen with the milk enzymes (Table 2) and was 
not time-dependent. The HTGL fraction contains only a small amount of At III, 
and did not prolong clotting times in plasma from which lipoproteins had been 
removed (Table 4).
It appears, therefore, that HTGL increases the anti-Xa clotting activity of 
plasma by a time-dependent interaction with lipoproteins. The exact mechanism 
is unknown, but may be related to previous studies, in which the anti-Xa clot­
ting activity of lipoproteins, particularly LDL and HDL, was markedly increased 
^  adsorption with AKOH)^ (11). The AKOH)] appeared to be acting by reveal­
ing high-affinity phospholipid binding sites for Factor Xa in the lipoproteins 
and it is possible that HTGL could be acting in the same way. The anti-Xa 
activity induced by Al(OH)g adsorption of lipoproteins is not detected by chro- 
mogenic substrates (11) and this is also the case with the activity detected ex 
vivo after injection of SSHA (3) and SP54 (4). Preliminary results indicate 
that the increase in anti-Xa activity of plasma on incubation with HTGL is also 
not shown by a chromogenic assay. It seems likely, therefore, that the inc­
rease in anti-Xa clotting activity in all three circumstances (adsorption of 
lipoproteins, heparin analogues ex vivo, and HTGL) is due to the same under­
lying mechanism. Further studies are planned, using more highly purified 
enzyme and isolated lipoprotein fractions.
The anti-Xa activity induced by HTGL was equivalent to that given by in vitro 
addition of 0.05 iu/ml heparin. This is similar to the level of heparin-like 
activity found after injection of SSHA (3,12). Such levels of anti-Xa activity 
are also found after s.c. injection of 5,000 units of heparin, and appear to be 
sufficient to prevent deep venous thrombosis (12). It seems, therefore, that 
release of hepatic lipase can not only account for the anti-Xa activity of 
heparin analogues ex vivo, but may also contribute towards their antithrombotic 
action.
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The association of apolipoprotein-CII with lipoprotein lipase in the presence and absence
of a triglyceride substrate
A N T H O N Y  R. C LAR K E, M O L L IE  LUSCOM BE and 
J. JOHN HOLBROOK
Department o f Biochemistry, University o f Bristol Medical 
School, Bristol BS8 ITD, U.K.
It  has been shown, both in vitro and in vivo, that apo-CII 
serves to enhance the activity of LPL against long-chain 
triglyceride and phospholipid substrates (for a review see 
Posner, 1982). This activation is physiologically relevant 
since apo-CII is a constituent of the surface film of very-low- 
density lipoproteins and chylomicra, and renders the core 
of these particles more susceptible to enzymic hydrolysis 
(Fitzharris et a l,  1981). Despite the numerous kinetic 
studies of LPL activation, no comprehensive description 
has emerged of the mechanism by which apo-CII achieves 
its effect.
The aim of the work reported here is to demonstrate and 
characterize the formation of an enzyme-apo-CII complex 
both in free solution and on the substrate surface, and to de­
fine the activation mechanism using a simple, globular tri­
glyceride substrate.
The binding of LPL to a fluorescently labelled apo-CII in 
the absence of a substrate was followed by measuring the 
anisotropy of the extrinsic fluorescence. These experiments 
revealed that a weak complex is formed in which a single 
apo-CII molecule associates non-co-operatively with each 
subunit of the dimeric enzyme. The for this interaction at 
0.05M-NaCl is 0.2 x IQ-^m and it is weakened markedly by 
raising the salt concentration or by the binding of heparin to 
the enzyme (Clarke et a i,  1983).
In the presence of glycerol triolate (emulsified in gum- 
arabic) the binding of apo-CII to the enzyme was monitored 
by measuring the steady-state lipolytic rate as the concen­
tration of the activator was increased. The results show that 
the higher the level of enzyme in the incubation, the more 
apo-CII is required to achieve maximal stimulation, thus 
demonstrating that activation proceeds through the forma­
tion of a protein-protein complex rather than through 
‘substrate-activation’ (Fielding &  Fielding, 1980). The data 
also show that, while the stoichiometry of the complex is 
preserved, the apo-C II-LPL interaction is much tighter 
than that in the absence of substrate (the apparent being 
15-20 X  10“^M at a substrate concentration of 4.2m M ) .
Additionally, it was observed that the complex formed 
under these conditions was not disrupted by heparin and 
was relatively insensitive to the concentration of salt.
The mechanism of activation was investigated further by 
an analysis of the first order pre-steady-state kinetics. The 
observed rate at which the system attained the steady-state 
on the addition of apo-CII was recorded as a function of the 
concentration of substrate, activator and enzyme. Plots of 
the observed rate constant versus concentration were 
hyperbolic with respect to substrate, linear with respect to
Abbreviations used: apo-CII, apolipoprotein-CII; LPL, lipo­
protein lipase.
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Fig. 1. The effect o f substrate and apo-CII concentrations on 
the pre-steady-state reaction
(a) The observed rate constant (/:obs.) describing the 
approach of the reaction to the steady-state was determined 
as a function of the concentration of glycerol trioleate. The 
medium contained 0.05M-NaCl and 4nM-enzyme, and the 
activation was started by the addition of 40nM-apo-CII. (b) 
o^bs. was also determined at varying levels of apo-CII. The 
medium contained 1.8M-substrate, 0.05M-NaCl and 4nM- 
enzyme.
apo-CII and the level of LPL had no influence (see Fig. 1). 
The simplest explanation of this kinetic pattern is that the 
enzyme and substrate combine in a rapid equilibrium, 
which is shifted by the preferential association of apo-CII 
with the form of the enzyme that is bound to the substrate. 
The mechanism can be represented as follows:
E + S E-S C -E -S
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where E =  free enzyme, S == triglyceride substrate, E-S 
=  lipid-bound enzyme, C =  apo-CII and C -E -S  =  activated 
ternary complex.
The observed rate constant (/Cobs.) for the approach of this 
reaction to the steady-state upon addition of apo-CII is 
described by the equation:
[S]k,[C] ,
^obs. ~ K,+ [S]
From the kinetic plots of vs [S] and [C] the following
constants were derived: =  3 - 4 m M ,  A:] =  3 .0 - 3.5 x
lO^M"' s"', k_2 =  2 .5- 3.5 X  10"^s~‘ .
The steady-state rate equation describing this reaction 
scheme is:
V =
where Kf is the rate of product formation by the unactivated 
enzyme (E-S) and K f '■ by the activated enzyme (C-E-S), 
and Kç is the true dissociation constant {k .ifk i)  describing 
the binding of apo-CII to substrate-bound LPL.
Further steady-state experiments m which substrate and 
apo-CII concentrations were varied gave results which were 
predicted accurately by the above equation and, addition­
ally, revealed that Kp'- is approximately 1.4 times greater 
than Ff.
In conclusion, the study shows that apo-CII achieves 
activation in this system by associating preferentially with 
the form of the enzyme which is bound to the substrate 
(Kd =  7-12 n M )  rather than to the free species (Æj =  2 0 0 nM), 
thus reducing the apparent K .^ Activated LPL forms 
products at a rate which is only slightly greater than that of 
the unactivated enzyme.
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Effects of lipase enzymes on procoagulant and anticoagulant activities of lipoproteins
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Phospholipids are essential for several reactions in the 
blood coagulation pathway, providing an active surface 
which binds the clotting factors and effectively reduces 
their K^ (Jackson, 1981). Although plasma lipoproteins 
contain large amounts of phospholipid, this is normally 
inactive in the coagulation system, probably because it does 
not have the optimal structure for clotting factor binding 
(Vijayagopal & Ardlie, 1978).
Our previous studies indicated two areas in which 
lipoproteins can become more involved with the coagula­
tion system. It was found that lipid peroxides, prepared by 
autoxidation of arachidonic acid, stimulated the generation 
of thrombin in platelet-free plasma (Barrowcliffe et a i ,  
1975), and subsequent studies showed that this proco­
agulant activity was due to interaction of the peroxides with 
triglyceride-rich lipoproteins (Barrowcliffe et a i ,  1984). 
Studies on the inhibition of the enzyme Factor Xa showed 
that part of the plasma ‘anti-Xa’ activity is due to 
lipoproteins, especially L D L  and H D L  (Barrowcliffe et a i,  
1982).
In the present study, we have examined the effects of 
various lipase enzymes on these interactions with a view to 
increasing our understanding of the mechanisms involved.
LPL and H T G L  were separated and partially purified 
from human or rat PHP by chromatography on heparin- 
Sepharose. The lipase enzymes were assayed with a tritiated 
triolein substrate as described by Nilsson-Ehle & Schotz
(1976); for H TG L, serum was omitted from the incubation 
mixture and the NaCl content was increased to 1m . 
Purification was estimated at 200 times from PHP. LPL was
Abbreviations used: LDL, low-density lipoprotein; HDL, high- 
density lipoprotein; LPL, lipoprotein lipase; HTGL, hepatic 
triglyceride lipase; PHP, post-heparin plasma; PLAi, phospho- 
lipase Ai.
also prepared by the same method from bovine milk. PLA,, 
highly purified from Vipera berus, was a gift from Dr. M . C. 
Boffa (Paris). The remaining phospholipase enzymes used 
were purchased from Sigma Ltd.
The effects of lipase release on lipid peroxide-induced 
thrombin generation in vivo were studied by subcutaneous 
injection of a lipase-releasing drug, SP54, into six volun­
teers. The peak total lipase level averaged 57.7 munits/ml, of 
which 70% was due to H TG L. The total amount of 
thrombin generated on addition of lipid peroxides to the 
post-infusion plasmas was only 50% of that generated in the 
pre-infusion plasmas.
Thrombin generation induced by lipid peroxides was 
measured after incubation of fatty plasma with various 
lipases in vitro, as shown in Table 1. H T G L  reduced the 
peak thrombin level to 30% of that in the buffer control, 
whereas LPL had little effect, suggesting that the reduction 
of thrombin generation in the experiments in vivo was 
largely due to release of H TG L. All except one of the 
phospholipase enzymes gave a similar reduction of throm­
bin generation to H TG L, indicating that the action of 
H T G L  may be due to its phospholipase activity. The lack of 
activity of PLA 2 from Naja naja is in keeping with the fact
Table 1. Ejj'ects o f lipase enzymes on lipid peroxide-induced 
generation o f thrombin in chylomicra-rich plasma
Enzymes were incubated with plasma at 37°C for 1 h at 
concentrations of 30-50munits/ml (LPL and H T G L ) or 1-4 
/ig/ml (PLAi and PLC). Peak thrombin generated was 
measured as a percentage of that in the buffer control.
Fnzyme Source Peak thrombin (%)
FLA, V. berus 30
PLAi Pancreas 29
FLA. Naja naja 100
FLC Bacillus cereus 7
LFL Rat PHP 83
HTGL Rat PHP 23
HTGL Human PHP 29
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that this enzyme, unlike PL A 2 from V. berus, is known to be 
a poor anticoagulant (Boffa et al., 1980).
The anti-Xa activity of plasma was measured by a 
clotting assay after incubation with LPL or H TG L. LPL, 
purified from milk or PHP, had virtually no effect, but 
H T G L  produced a marked increase in activity. The 
enhancement of activity increased on incubation of H T G L  
with plasma from 0 to 45 min, and was not apparent in plas­
ma from which lipoproteins had been removed by ultra­
centrifugation. These results indicate that H T G L  increases 
anti-Xa activity by a time-dependent action on lipoproteins.
Overall, it appears that release of lipase enzymes, 
especially H TG L, into plasma increases its anticoagulant 
potential, and this could be an important contribution to the 
antithrombic properties of heparin and other lipase- 
releasing drugs.
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Turnover of lipoprotein lipase in rat adipose tissue
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There is a considerable amount of evidence that adipose 
tissue lipoprotein lipase has an exceptionally high rate of 
turnover (Wing et al., 1967; Wing &  Robinson, 1968; 
Patten, 1970). This evidence is, however, based largely on 
changes in the activity of the enzyme and the role of 
proteolytic degradation in this process has, as yet, received 
little attention.
Indirect evidence for the degradation of lipoprotein 
lipase is provided by the time-course of incorporation of 
[^HJleucine into the enzyme during incubation of rat 
epididymal fat-bodies in vitro in the presence of insulin 
(2m.i.u./ml). The incubation conditions and the method for 
the isolation of ^H-labelled lipoprotein lipase are described 
by Speake et al. (1985). Whereas the incorporation of label 
into total fat-body protein is linear with time for at least 4 h, 
the radioactivity associated with lipoprotein lipase shows a 
linear increase only during the initial l-2 h  of incubation, 
and thereafter remains at an approximately constant level.
Additional experiments have indicated that the observed 
cessation of net incorporation of label into lipoprotein lipase 
which occurs between 1 and 2h of incubation is due neither 
to secretion of labelled enzyme into the medium, nor to an 
inability to maintain the synthesis of the enzyme under 
these conditions. A possible explanation for these results is 
that lipoprotein lipase is degraded, presumably at a site 
distal to the site of its synthesis, and that the steady-state 
level of radiolabelled enzyme which prevails after the initial 
l-2 h  of incorporation represents a balance between the 
synthesis and the degradation of the enzyme.
In order to investigate this possibility, the degradation of 
lipoprotein lipase was measured by using pulse-chase 
incubations of epididymal fat-bodies in vitro. Groups of fat- 
bodies were incubated in the presence of [^HJleucine for 1 h. 
At the end of this ‘pulse’ period, the fat-bodies were washed 
free of exogenous radioactivity and the incubation was 
continued for a further 3h. Insulin (2m-i.u./ml) was present 
throughout. Approx. 50% of the label incorporated into 
lipoprotein lipase during the ‘pulse’ period was lost during
the subsequent 3h decay period. Little or no degradation of 
total fat-body protein was observed under these conditions.
The extensive degradation of adipose tissue lipoprotein 
lipase thus described, provides a possible explanation for 
the rapid turnover of lipoprotein lipase activity which has 
been reported to occur both in vivo (Wing et al., 1967) and in 
vitro (Wing & Robinson, 1968; Patten, 1970). An important 
consequence of this high turnover rate is that the level of the 
enzyme will change rapidly in response to variations in the 
rate of enzyme synthesis (Schimke, 1970). Thus the 
stimulation of lipoprotein lipase synthesis induced by 
insulin and glucocorticoids, as described by Speake et al. 
(1985), will result in a rapid increase in the amount of the en­
zyme to a new steady state level.
The degradation of lipoprotein lipase may itself be 
subject to regulation. In the presence of adrenaline (10/xm), 
the rate of degradation of the enzyme was increased by 
approx. 1.5-fold. This observation is consistent with the 
evidence that adrenaline reduces the activity of adipose 
tissue lipoprotein lipase by a post-translational mechanism 
(Ashby et al., 1978).
The site and mechanism of the gradation of lipoprotein 
lipase have not yet been ascertained, although the report 
that a number of cell types have the ability to degrade 
‘ “^I-labelled lipoprotein lipase after endocytotic uptake 
(Friedman et al., 1982) may be of significance.
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Regulation of the synthesis of lipoprotein lipase in rat adipose tissue
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Studies involving the incubation of rat epididymal fat- 
bodies in vitro have shown that insulin and glucocorticoids 
can promote a protein-synthesis-dependent increase in the 
activity of lipoprotein lipase in the tissue, and it has been 
proposed that these hormones are responsible for the 
increase in the activity of the enzyme which occurs in vivo 
after the onset of feeding (Ashby & Robinson, 1980).
In order to investigate the mechanism of these hormonal 
effects, we have devised a novel method for measuring the 
synthesis of lipoprotein lipase in rat adipose tissue. 
Epididymal fat-bodies from 24h-starved rats were incu­
bated for I h at 37°C in Krebs-Henseleit bicarbonate buffer 
solution, supplemented with amino acids at the concentra­
tions defined by Eagle (1955), glucose (lOmM), casein (2% 
w/v) and L-[4,5-^H]leucine (lO^Ci/ml). At the end of the 
incubation period, groups of four fat-bodies were removed 
from the incubation flasks, and homogenized in 10 ml of 2% 
(w/v) casein, pH 7.2. The homogenate was delipidated by 
extraction with acetone and diethyl ether as previously 
described (Ashby et al., 1978). Each delipidated tissue 
residue was homogenized in 15 ml of 5 mM-sodium barbital, 
pH 7.5, containing 20% (w/v) glycerol, 0.1% Triton X-100 
and 50mM-NaCl, and the suspension was centrifuged at 
60000^ for 30 min. Lipoprotein lipase was isolated from the 
resultant supernatant in a single step by affinity chromato­
graphy on heparin-Sepharose as described by Parkin et al. 
(1982). Sodium dodecyl sulphate/polyacrylamide-gel 
electrophoresis of this ^H-labelled lipoprotein lipase pre­
paration revealed a single sharp peak of radioactivity 
corresponding to a polypeptide of Mr 56000. This poly­
peptide has previously been identified as lipoprotein lipase 
(Parkin et al., 1982). No other peaks of radioactivity were 
detected on the gel and losses of lipoprotein lipase during 
this procedure were minimal. Thus the ^H-labelled enzyme 
can be rapidly and quantitatively isolated free from other 
radioactive adipose tissue proteins.
In the presence of insulin (2m-i.u./ml), the incorporation 
of [^HJleucine into total adipose tissue protein and into
lipoprotein lipase was increased by 1.3 ±0 .2  fold and
2.6 ±0 .6  fold respectively (mean±s.D., n =  l) , compared 
with controls. Thus the insulin-induced stimulation of 
lipoprotein lipase synthesis is partly due to a general 
increase in total protein synthesis in addition to a specific 
effect on the synthesis of the enzyme. Similar results have 
been reported by Vydelingum et al. (1983).
The regulation of lipoprotein lipase by glucocorticoids 
was investigated by preincubating fat-bodies in the pres­
ence or absence of dexamethasone (400 nM) for 3h before 
the addition of [^H]leucine, in order to allow for any lag in 
the glucocorticoid-induced effects. PHjLeucine (10/xCi/ml) 
was then added and the incubation was continued for a 
further 1 h. Insulin (2m-i.u./ml) was present in all the 
incubations. The rate of synthesis of lipoprotein lipase was 
increased by 1.99 ±0.72 (mean±s.D., n =  5) fold in the 
presence of dexamethasone plus insulin, compared with 
insulin alone. This effect represents a specific induction of 
lipoprotein lipase synthesis since total protein synthesis was 
not affected by dexamethasone.
These observed effects of insulin and glucocorticoids on 
the synthesis of lipoprotein lipase are consistent with the 
changes in enzyme activity which occur under these 
hormonal conditions. It  thus seems likely that both 
hormones regulate the activity of lipoprotein lipase at the 
level of enzyme synthesis. Although the effect of insulin is 
partly explained by a non-specific increase in general 
protein synthesis, the effect of glucocorticoids apparently 
represents a specific induction of the enzyme.
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Role of apoproteins B and E in the receptor-mediated uptake of very-Iow-density 
lipoprotein remnants by the perfused rat liver
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Two distinct receptors are concerned in the binding and 
removal of remnants of plasma triglyceride-rich lipo­
proteins by the liver. The ‘LD L  receptor’ is believed to be 
primarily concerned with the removal of V L D L  remnant 
lipoproteins of hepatic origin containing apoprotein B^ oo 
whereas the ‘chylomicron remnant receptor’ appears to be 
specific for apoprotein B^g-containing remnant particles, 
which may originate either from the intestine or the liver
Abbreviations used: LDL, low-density lipoprotein; VLDL, 
very-low-density lipoprotein; HDL, high-density lipoprotein; 
CHD, 1,2-cyciohexanedione.
(Brown &  Goldstein, 1983). The apoprotein specificity of 
the two hepatic receptors remains, however, an area of 
much interest since all the remnant populations also contain 
additional apoproteins.
HDLc, an apoprotein E-enriched lipoprotein, binds to the 
LD L receptor’ with a 20-fold greater affinity than a pre­
dominantly apoprotein BioQ-containing particle such as 
LD L (Innerarity et al., 1980). Moreover, HDLc will compete 
with ^^^I-labelled chylomicron remnants for removal by the 
perfused liver (Sherrill et a l , 1980). These findings have led 
Mahley and his co-workers to suggest that apoprotein E is 
the major mediator of the hepatic removal of all the 
remnant classes (Mahley &  Innerarity, 1983). However, the 
observed differences between the metabolism of apoprotein 
Bioo and apoprotein B^ g remnants cannot be reconciled on 
the assumption that the receptor-interaction of these 
particles is mediated through apoprotein E alone (Brown &
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